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1.1 Function of vitamin D endocrine system
The Vitamin D endocrine system, consisting of the metabolites of vitamin D 
protein (involved in their synthesis and metabolism) and the vitamin D receptor 
(VDR) as well as its cofactors, plays an essential role in calcium and phosphate 
homeostasis and skeletal metabolism. This classical biological action includes intes-
tinal calcium and phosphate absorption, bone modeling and remodeling, and renal 
calcium and phosphate reabsorption. The neoclassical actions of the system have 
an important role in hematopoietic, immune, nervous and endocrine systems1,2. 1 
α, 25-dihydroxyvitamin D3 (1,25(OH)2D3, the active form of vitamin D) suppresses 
proliferation and induces differentiation of mouse myeloid leukemia cells into mac-
rophages3, and induces differentiation of human promyelocytic leukemia cell into 
macrophages4. The immunosuppressive actions of 1,25(OH)2D3 have been applied 
to control autoimmune diseases such as rheumatoid arthritis, systemic lupus ery-
thematosus, type I diabetes, and transplant rejection. Vitamin D also contributes to 
hair growth and skin development, and 1,25(OH)2D3 or its analogs have potential 
therapeutic effects on psoriasis5,6, alopecia7 and cancer8,9. In this thesis, we will only 
focus on the classical action of the system: skeletal and calcium metabolism.
The vitamin D receptor (VDR) mediates the pleiotropic effects of the vitamin 
D endocrine system. Inter-individual differences in aspects of the vitamin D endo-
crine system have been well documented. For example, circulating vitamin D levels 
vary by the season and latitude but also vary between individuals10,11. Furthermore, 
it is known that subjects respond differently when vitamin D analogs are adminis-
tered12-14. Such inter-individual variability can also contribute to the differences in 
risk for diseases in which vitamin D plays an important role. They could be caused 
by genetic differences in important proteins in the vitamin D endocrine system, 
such as the VDR. The VDR mediates most effects of its ligand, 1,25(OH)2D3 (see 
Fig. 1). Thus, one approach to understand inter-individual differences in the vitamin 
D endocrine system is to study the infl uence of variations in the DNA sequence 
of important proteins of this system. For example, Mutations in the VDR gene, 
such as in the DNA binding domain15, the ligand-bind domain16, or in splice sites17, 
cause the hereditary vitamin D-resistant rickets (HVDRR), which is characterized 
by growth retardation and small body size. More subtle sequence variations are 
“polymorphisms” that are defi ned as sequence variations that occur at a frequency 
of > 1% in the population. Their infl uence on the vitamin D endocrine system is 
currently under scrutiny in relation to a number of so-called complex diseases and 
traits, such as aspects of bone health and osteoporosis in particular on which we 
focus in this thesis.
1.2 Structure of the VDR gene
After the cloning of the human VDR cDNA in 1988 by Baker et al.18, it took 
almost 10 years before major parts of the genomic structure of the human VDR 
gene became clear as described by Miyamoto et al.19. Simultaneously, Croft et al.20 
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demonstrated multiple tissue-specifi c transcripts (exon 1d to 1f) that differed at the 
5’-end of VDR gene. Although much of this became known well before the Human 
Genome Project was fi nished, the data from Croft et al. is still not integrated in the 
Celera or NCBI gene databases. The size of the VDR gene and the exact location of 
the 5’-end exons were still unknown (Fig. 2). The location of the VDR gene on the 
physical map of chromosome 12 was indicated fi rst by linkage mapping by Labuda 
et al.21 and later on somewhat more refi ned by Fluorescent in Situ Hybridization 
(FISH) and radiation hybrid mapping by Taymans et al.22. However, these studies 
defi ned the position of the VDR gene in very general terms and this is insuffi cient 
for understanding the role of VDR polymorphisms in disease. The major reason to 
understand the exact gene structure and its size is coming from genetic association 
studies. Since mostly anonymous polymorphisms have been used in association 
studies, one explanation of an association observed was that not only the VDR 
gene but also another gene nearby could explain the association. It is therefore 
important to know which genes are also present in the area and how close they are 
to the VDR gene, and how likely it is that these other genes play a role in explaining 
the associations.
Figure 2 Genomic structure of the VDR gene and position of known polymorphisms before our 
study. The dashed line between exons indicates the distance between the two exons is uncertain. 
* indicates that these polymorphisms are in the coding sequence. 
1.3  VDR Polymorphisms
Studies of VDR polymorphisms were initially focused on the 3’-end of the 
gene, ever since an association of the VDR polymorphisms with bone turnover 
and bone mineral density (BMD) was reported by Morrison23,24. A partial correc-
tion of the data on the BMD association appeared a few years later in which the 
association was much diminished25. In the lower portion of Fig.2, a number of 
the VDR polymorphisms are depicted that were known before the start of this 
1f          1e             1a        1d       1b      1c      2        3          4  5    6         7 8    9 3’UTR
Haplotypes (RFLP): 1 =    b         a        T
        (bp)        G         G        T
  2 =    B  A       t
       A         B        C
 3 =  b         A        T
       G         B        T
Cdx-2
G/A
Fok I*
C/T
C/T C/T
RFLP:   Bsm I  Tru9 I       EcoR V     Apa I Taq I*
bp: G/A      G/A                     G/A          G/T    T/C
3’-UTR
variants
-/G
5’ Promoter Coding exons 3’ Regulatory
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project. In the region of intron 8 and exon 9, Apa I26, EcoR V23, Bsm I23, Taq I24 and 
Tru9 I27 restriction fragment length polymorphisms (RFLPs) were discovered and 
used in association studies. For the 3’-untranslated region (UTR) of the VDR gene, 
Morrison et al.24 sequenced two individuals, who were homozygous for the most 
frequent Bsm-Apa-Taq haplotypes: BAt-BAt and baT-baT, and reported 13 distinct 
polymorphic sites including a poly(A)-tract with a varying number of adenosines. 
Durrin et al. expanded this approach and sequenced the 3’-UTR region in eight 
subjects and identifi ed seven polymorphisms, of which four were common and 
three were rare in the eight annalysed subjects28. However, the number of subjects 
analysed in these studies is still limited and they were highly selected, so it is likely 
that more as yet uncovered polymorphisms exist in the complete 3’-UTR. 
So far only two polymorphisms were reported in the coding exons of the VDR 
gene. One is the Taq I RFLP which is located in exon 9 but does not change the 
amino acid sequence of the VDR protein. Another is the Fok I RFLP. On compari-
son of the original Baker sequence of the VDR cDNA18, two potential translation 
initiation start sites (ATG) were observed and subsequent sequence comparisons 
have shown that a T to C polymorphism exists (ATG to ACG) at the fi rst potential 
start site29,30. This polymorphism, also referred to as the Start Codon Polymorphism 
(SCP), was later on defi ned using the FokI restriction enzyme in an RFLP test31. 
Thus, two protein variants can exist corresponding to the two available start sites: 
a long version of the VDR protein (the T nucleotide allele detected as the “f” 
allele, also referred to as the M1 form, i.e., the methionine at fi rst position) and 
a protein shortened by three amino acids (the C nucleotide allele detected as the 
“F” allele, also referred to as the M4 form, i.e., the methionine at fourth position). 
This is the only known protein polymorphism in the VDR gene so far. Brown et 
al. sequenced the VDR coding region in 59 parathyroid tumors to fi nd mutations32. 
Apart from the previously reported Taq I and Fok I polymorphisms, they reported 
no polymorphism in the coding region and found two intronic polymorphisms 
near exon 2 and 8.
Another VDR polymorphism was found through sequence analysis of a targeted 
area in the promoter region of VDR gene. After Yamamoto et al. found a binding 
site for Cdx-2, an intestinal-specifi c transcription factor, in the VDR 1a promoter 
region (based on the genomic structure of VDR from Miyamoto et al.19), Arai and 
colleagues reported a G to A sequence variation in this binding site among Japanese 
women33. 
1.4 Linkage Disequilibrium and Haplotypes of VDR Gene
Linkage Disequilibrium (LD) measures describe the association (or co-oc-
currence) of alleles of adjacent polymorphisms with each other34. This means in 
practice that the genotype of one polymorphism can predict the other adjacent 
“linked” one because very little recombination has occurred between them over 
the time of evolution and population history. High levels of LD in a certain area 
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will coincide with a limited number of “haplotypes” in that area. Haplotypes are 
blocks of linked alleles of adjacent polymorphisms, whereby the length of such a 
block coincides with the strength of LD aross the area. In practice, this means 
that relatively few polymorphisms have to be genotyped to “cover” the variance 
in a certain area. Therefore, a massive effort is currently under way to determine a 
haplotype map of the human genome34,35.
It follows that the LD (or haplotype) structure of a certain candidate gene, such as 
the VDR, is important for association analyses to understand how the polymorphic 
variation in such a gene can contribute to risk of disease and population variance of 
certain phenotypes of interest. When a certain allele of one polymorphism has been 
found to be associated with “risk” of fracture (e.g.), it follows that this association 
might be explained by the effect of a particular allele, or by one (or more) other 
alleles that happen to be linked to this allele within the haplotype block, because 
of LD and the haplotype structure. Once we know which haplotype carries this 
risk allele, we can determine by cell biological and molecular biological functional 
analyses which of the variants on that haplotype allele truly cause this effect.
Based on some of the known polymorphisms shown in Fig. 1, several studies 
have analyzed the extent of LD especially at the 3’-end of the VDR gene. Since 
these analyses have used only a small number of polymorphisms, accurate infor-
mation on LD and haplotypes has been very limited so far. Nevertheless, strong 
LD at this region has been observed for the Bsm I, Apa I, EcoR V, and Taq I 
RFLPs as well as the poly(A) variable number of tandem repeats (VNTR) in the 
3’-UTR23,24,28,36,37. Thus, an LD map using a high density of polymorphisms across 
the VDR gene is necessary to be determined, to use the haplotype information in 
association studies.
1.5 Osteoporosis and VDR Polymorphisms
Osteoporosis is defi ned as a systemic skeletal disease characterized by low bone 
mass and microarchitectural deterioration of bone tissue, with a consequent increase 
in bone fragility and susceptibility to fracture38. It is a complex genetic disorder, 
which involves interaction between environmental and genetic factors. Because of 
the importance of the vitamin D endocrine system for a proper bone homeostasis, 
it quickly became a target for genetic association studies. Many genetic association 
studies have since demonstrated a relationship between the polymorphisms of the 
VDR gene (depicted in Fig. 2) with decreased bone mineral density (BMD), and 
increased fracture risk, but there are also many negative studies.
BMD is one of the most important predictors of osteoporosis, especially for 
postmenopausal women. Low BMD in this population results from a low peak 
BMD or/and faster bone loss with aging, and is a strong determinant of fracture 
risk. Morrison et al. fi rst demonstrated that the Bsm I RFLP in the last intron of the 
VDR gene was related to serum osteocalcin concentration, which is an important 
biochemical marker of bone turnover23. They subsequently found the Bsm I RFLP 
Chapter 1
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to be associated with differences in BMD in a twin study and in postmenopausal 
women24. Although the initial observations on the twin study (but not those on 
postmenopausal women) have been withdrawn25, in the following years dozens of 
papers were published analyzing the same RFLP in relation to BMD. However, 
also controversial observations of the relationship between the commonly used 
RFLP and BMD were reported. Three studies39-41 summarized association studies 
between the 3’ and Fok I VDR polymorphisms and BMD, but still confl icting 
conclusions were drawn and some questions remained from those analyses.
The recently described G to A sequence variation in the Cdx-2 binding site just 
upstream of exon 1a has also been found to be associated with BMD33. This site is 
suggested to play an important role in intestinal-specifi c transcription of the VDR 
gene. As the intestine is the site where the calcium absorption predominantly takes 
place, the Cdx-2 site is thought to infl uence the vitamin D regulation of calcium 
absorption. The A-allele has been demonstrated to have higher affi nity than the G-
allele for binding to the Cdx-2 transcription factor, and thus having more transcrip-
tional activity 31. With more VDR expression in the intestine, the A-allele thereby can 
increase the transcription of VDR downstream genes, especially, calcium transport 
proteins such as TRPV5, TRPV6, calbindin-D9k, and calbindin-D28k. This could 
enhance the intestinal absorption of calcium and result in increased BMD. Indeed, 
this increased BMD has been demonstrated for Japanese postmenopausal women 
who carry the A-allele. However, because the population analysed encompassed 
only 55 postmenopausal women, the power of this study was low. In addition, this 
study did not analyse the relationship with fracture, the clinically most relevant 
endpoint in osteoporosis. The association between this polymorphism with other 
endpoints of osteoporosis such as fracture and bone geometry parameters is there-
fore interesting to be investigated in other preferably large populations, including 
those of different ethnic background than Japanese.
Fracture is an import clinical endpoint to assess in genetic studies of osteopo-
rosis but also has some drawbacks. The etiology of different types of fracture (e.g., 
vertebral fracture versus hip fracture versus wrist fracture) is likely to be different. 
For example, the mean age at which fractures occur at the hip and the wrist is 
around 80 years and 65 years, respectively42. In addition, fractures are not deter-
mined by bone strength alone. Also falling risk plays a role, as well as cognitive 
and neuromuscular fi tness contribute to the overall risk of suffering a fracture. 
Finally, the few studies that have analysed the heritability of fracture risk showed 
low heritability ranging from 20 – 45%43-45. This low heritability could be explained 
by the factors discussed above, which might also involve a large contribution of 
environmental factors. Polymorphisms in the 3’-end of the VDR gene, especially 
Bsm I and Taq I RFLPs, are most commonly used in VDR gene association stud-
ies, but they are highly linked to polymorphisms in the 3’-UTR, which is thought 
to be the potentially functional region involving the stability of VDR mRNA. 
Eighteen association studies (written in English) have so far analysed the relation-
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ship between VDR polymorphisms and fracture risk but with confl icting results. 
The reason of this controversy could be small study size, diverse study designs 
and use of different study populations, but also involve heterogeneity in types of 
fractures studied. The Fok I RFLP has been analysed in relation to fracture in two 
studies46,47, but no evidence of an association between Fok I and fracture risk was 
observed. So far, no meta-analysis has systematically reviewed the published data 
of this polymorphism.
Body height is another skeletal phenotype with a strong genetic background. 
Several twin studies indicate a heritability of up to 90%48-50. Bone size is an impor-
tant determinant of bone strength, and thus, a risk factor for osteoporosis. Vitamin 
D is known to regulate the proliferation, differentiation, and maturation of cells 
responsible for skeletal growth, bone modeling and remodeling. Hence, genetic 
variations in the VDR gene might contribute to inter-individual differences in bone 
dimensions, growth and skeletal size characteristics, expressed as differences in 
height/stature, vertebral area, or femur shaft diameter. Not only deleterious muta-
tions in the VDR gene cause HVDRR (which is characterized by growth retarda-
tion and small body size), but VDR polymorphisms also seem to be associated with 
differences in body height51-54, but not consistently55. Altogether, the data indicate 
that several polymorphisms of the VDR gene might be associated with anthropo-
metric differences. A meta-analysis is necessary to systematically review the data, 
and more polymorphisms across the VDR gene are interesting to be investigated in 
different populations to test the consistency of the association.
1.6 Functionality of VDR Polymorphisms
The interpretation of association studies using VDR polymorphisms is severely 
hindered by the fact that most of the polymorphisms used are anonymous, i.e., have 
an unknown functional effect. The likely explanation for any observed association 
is then to assume the presence of one or more truly functional sequence variations 
elsewhere in the gene which is – to a certain extent – in linkage with an allele of the 
anonymous (or marker) polymorphism used. As can be understood from the com-
plex organization of the VDR gene (Fig. 1), the identifi cation of these functional 
polymorphisms in the VDR gene is a challenging enterprise.
To identify functional sequence variations in the VDR gene most investigators 
have focused on the 3’ regulatory region because this is close to the anonymous 
markers used mostly in association studies. While the Bsm I, Apa I, and Taq I 
RFLPs are located in the 3’-end of the gene, and LD extends into the 3’-UTR which 
contains several polymorphisms24. The 3’-UTR of genes is known to be involved 
in regulation of gene expression, especially through regulation of mRNA stability. 
Morrison et al.23 earlier provided evidence of different luciferase activity in monkey 
COS-7 and rat ROS 17/2.8 cell lines for the two 3’-UTRs that are linked to the two 
most frequent haplotypes “baT” and “BAt” according to Bsm I, Apa I and Taq I 
RFLPs (see Fig. 2). Durrin et al. demonstrated that certain parts of the 3’-UTR, 
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so-called destabilizing elements, are involved in determining stability of the VDR-
mRNA28. However, the UTRs linked to the “baT” and “BAt” haplotypes were not 
found by them to differ with respect to mRNA stability. Furthermore, heterologous 
constructs (human VDR-UTR sequences coupled to a rabbit beta-globin gene) and 
cell types (mouse NIH3T3 cells) were used to test for functionality. Especially, 
since it is known that 3’-UTRs display cell type specifi c effects on mRNA stability, 
this could be important in demonstrating functionality of sequence variations in 
the UTR.
Several studies31,56-59 have been carried out to fi nd evidence for the functionality 
of the non-anonymous polymorphism, detected as an Fok I RFLP, in the initial 
coding region of the VDR gene. From those studies, it appears that the Fok I poly-
morphism seems to be functional and the 424 aa VDR variant (F-allele) is somewhat 
more active than the 427 aa variant (f-allele) in terms of its transactivation capacity 
as a transcription factor. However, no consistent association studies support those 
functionality fi ndings so far. The Cdx-2 polymorphism, which is located in the 
VDR promoter region, has been well-characterized by studies of Yamamoto et al. 
and Arai et al.33,60. Although the functionality of this polymorphism has indeed been 
convincingly demonstrated and the association of the polymorphism and BMD is 
also described in a small Japanese population, the exact mechanism whereby the 
polymorphism would relate to the risk for fracture has not been elucidated yet and 
requires further study.
1.7 Aim and scope of the study
The main purpose of this study is to characterize functional sequence variations 
across genes of the vitamin D endocrine system, in particular the VDR gene, and 
to study association of such polymorphisms to aspects of osteoporosis. To this 
end we performed studies to fi nd polymorphisms, to analyse the patterns of LD 
across the gene area, and we analysed functional aspects of several combinations 
of polymorphisms. This research involves several approaches including molecular 
genetics, genetic epidemiology, bio-statistics, bioinformatics and cell biology.
1.8 Description of Chapters
Chapter 2 Genome structure, homolog y analysis and re-sequencing of the VDR gene: In 
this chapter, we fi rst describe the updated genome structure of the human VDR 
gene according to the integrated data from publications and web resources. The 
result of homology analysis between human and mouse VDR gene genomic DNA 
is presented for the determination of potentially functional regions across the hu-
man VDR gene. We present sequence variations that we found in a re-sequencing 
study of those regions across the VDR gene.
Chapter 3 LD structure of the VDR gene: This chapter presents high resolution LD 
maps and race-specifi c tagging SNPs to describe the haplotype block structure of 
the VDR gene. This information forms the basis for furthre association studies. 
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Chapter 4 Cdx-2 polymorphism and susceptibility for fracture risk: This section dem-
onstrates an ecological study of the correlation between the Cdx-2 genotype with 
hip fracture risk for different ethnic populations, and the association of the Cdx-2 
polymorphism and fracture risk in a subset of the Rotterdam Study. 
Chapter 5 VDR haplotypes and susceptibility for fracture risk: In Section 5.1 we 
demonstrate the relationship of haplotypes across the VDR gene (according to the 
genotyping of haplotype tagging SNPs) and risk of different types of fractures in 
the complete Rotterdam Study population. Section 5.2 presents a meta-analysis 
of published data on the relationship between the VDR Bsm I polymorphism and 
fracture risk.
Chapter 6 VDR haplotypes and body height: This chapter presents association stud-
ies of VDR haplotypes and body height, and bone geometry parameters in two 
Dutch populations. A meta-analysis of published data on the relationship between 
VDR Bsm I polymorphism and body height was performed.
Chapter 7 Functionality studies of VDR polymorphisms: In this chapter we pres-
ent functionality studies of EMSA and transactivation experiments for SNPs in 
the promoter region, and studies of VDR mRNA level and stability by 3’-UTR 
haplotypes in different cell lines.
Chapter 8 Interaction of VDR and DBP haplotypes on fracture: This chapter presents 
the LD map of the DBP gene using bioinformatics. The correlation of DBP haplo-
types and serum vitamin D level, interactions between DBP haplotype with dietary 
calcium intake and VDR haplotype on fracture risk are demonstrated.
Chapter 9 General discussions and conclusions: We fi nally summarize the overall 
results of the thesis and pitfalls in the process, and the general discussion ends with 
suggestions for further research.
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ABSTRACT
Introduction: Polymorphisms of the vitamin D receptor (VDR) gene have 
been reportedly associated with several complex diseases, including osteoporosis, 
but by unknown mechanisms and with inconsistent results. Most studies have used 
anonymous polymorphisms at the 3’-end and one in the initial coding region of the 
gene. However, no functional effect of the polymorphisms has been described.
Materials and Methods: We therefore searched the complete VDR gene for 
additional polymorphisms. We fi rst corrected the genomic structure of the human 
VDR according to bioinformatics analysis of different databases. We sequenced 22 
kb in the regions displaying high homology between human and mouse genomic 
VDR sequence, including the 3.2 kb 3’-untranslated region (3’-UTR), 4.1 kb of all 
coding exons and fl anking introns and 14.7 kb of the 6 promoter exons 1a - 1f, in 
15 Caucasians.
Results: We determined the structural organisation of the VDR promoter 
region by aligning our sequencing results and the Celera database, resolved a 500 
bp gap in front of exon 1b. We identifi ed 62 polymorphisms, including 55 SNPs 
and 7 tandem repeats. 22 SNPs (40%) were new and not contained in the NCBI 
and Celera databases. In the VDR promoter region, 14 polymorphisms change the 
putative recognition sequences of transcription factors, while 4 SNPs are located in 
destabilizing elements (DE) in 3’UTR.
Conclusions: We identifi ed additional polymorphisms in potentially functional 
regions across the VDR gene. The result is a fundamental step for our next study 
of linkage disequilibrium (LD) analysis across the VDR gene.
VDR sequencing
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INTRODUCTION
The vitamin D receptor (VDR, 12q13, MIM 601769) is a steroid receptor acting 
as a transcription factor responding to the biologically active form of the secosteroid 
vitamin D hormone. The vitamin D endocrine system is pleiotropic and plays an 
important role in skeletal metabolism, including intestinal calcium absorption and 
regulation of osteoblast differentiation, but has also been shown to modulate the 
immune response, insulin secretion, the renin/angiotension system, and growth of 
cancer cells1.
Although Baker et al.2 reported the human VDR cDNA in 1988, Miyamoto et 
al.3 and Croft et al.4 described the genomic structure and multiple tissue-specifi c 
transcripts at the 5’-end of VDR gene in 1998, but the complete genomic structure 
of the VDR gene is still not correctly described. The data from Croft et al. is still 
not integrated in the Celera or NCBI gene databases. The size of the VDR gene and 
the exact location of the 5’-end exons were still unknown (see Fig. 2 of Chapter 1).
As shown in chapter 1 of the thesis, many studies have been carried out to 
investigate the association of VDR polymorphisms with complex diseases, includ-
ing osteoporosis, but confl icting results were observed. One of the reason of that is 
anonymous polymorphisms were used in most studies. To identify polymorphisms 
in potentially functional region of the VDR gene, we currently determined an accu-
rate structure of the gene, and sequenced functional region across the VDR gene.
MATERIALS AND METHODS
Subjects
We sequenced genomic DNA from 15 young Caucasian individuals encompass-
ing fi ve homozygotes for each major VDR 3’-UTR haplotype, i.e., 11, 22, and 33, as 
defi ned in a previous study5 based on Bsm I, Apa I and Taq I RFLPs. 
Homolog y analysis
Human and mouse VDR genomic sequences (>105 kb from Celera database) 
were analyzed with the Vista program6 to visualise the pair-wise percentage identity 
as calculated for every 100 bp.
Resequencing and sequence analysis
We sequenced 37 overlapping PCR fragments covering 22 kb of the VDR gene 
(shown in the upper-part of Figure 3) in 30 chromosomes including the 3.2 kb 
3’-UTR, coding exons 2 to 9 and fl anking introns (4.1 kb), and 14.7 kb promoter 
area containing 6 exons (1a-1f). PCR primers were designed according to published 
sequences ( J032582; PAC clone, AC0044663; AF080454-AF0804564,7) and the 
Celera database. Melting temperatures of primers were calculated with DNAMAN 
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(v4.0, Lynnon BioSoft). Primer sequence and PCR conditions are described in Table 
1. The 50 µl PCR contained 20-80 ng of genomic DNA, 3-5 pmol primers, and 2 
units Taq DNA polymerase (SUPER TAQ, HT Biotechnology LTD. UK, TP05c; 
or Promega, M1665) and was done 25 - 38 cycles in a Thermal Cycler 480 (Perkin 
Elmer) or a GeneAmp PCR System 9700 (Applied Biosystems, ABI). Taq PCR 
Core Kit (5 × Q-Solution from QIAGEN Ltd.) was used to amplify some GC-
rich PCR fragments in promoter regions (Table 1). Sequencing extension reaction 
system (20 µl) consists of 11 µl purifi ed PCR product, 4 µl of Terminator Mixture 
(ABI PRISM® Big-Dye Terminator cycles sequencing Ready Reaction Kit), 4 µl 
of 5 × buffer (400 mM Tris-Cl pH 9.0, 10 mM MgCl2) and 1 µl of 10 pM primer,. 
We purifi ed PCR and sequencing products by Quantum Prep® PCR Kleen Spin 
Columns and Micro Bio-spin® Chromatography Columns (BIO-RAD 732-6301 
and 732-6224). Sequencing products were analyzed on an ABI PRISM® 310, or 
3100 automated capillary Genetic Analyzer. All sequencing data was analyzed and 
aligned by Navigator (Perkin Elmer) and Sequencher (Gene Codes Corporation) 
sequence analysis software.
We used the TFSEARCH program8 from the TRANSFAC databases developed 
by GBF-Braunschweig, Germany and MatInspector9 from Genomatix software 
GmbH, to search for potential transcription factor binding sites (TFBS) around 
promoter polymorphisms.
RESULTS
Genomic structure of the VDR gene
The physical organisation of the human VDR gene region on chromosome 
12q12-14 (kbp 46950 - 47350; Fig. 1a) and the VDR gene structure (Fig. 1b) is 
based on PAC clones (PAC228P16 and PAC1057I20), two published data3,4, the 
Celera database, and our re-sequencing efforts. The VDR gene encompasses at 
least 105 kb: the large 5’-region of non-coding exons 1f to 1c is 60 kb, with exon 
1f being 35 kb upstream of exon 1e, while exon 1e is 2 kb upstream of exon 1a. 
The nearest genes are COL2A1 at 20 kb distance upstream, with a small gene-like 
structure (MGC5576) close to the COL2A1 gene, and HDAC7A at 10 kb distance 
downstream.
Homolog y analysis
The overall percentage-identity between the entire human and mouse genomic 
sequence of the VDR gene is 28.8% (Fig. 2). While coding exons are found in 
highly conserved region (from 86.5 to 92.6% identity), except for exon 5 (61.2%). 
We also observed high homology regions in intronic areas, i.e., in total 14 kb of 
regions between 1f and 1e, 5kb of regions between exon 1b and 1c, and a small 
500 bp region between exon 2 and 3. Interestingly, there is a lack of homology of 
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the human exons 1b, 1e, and 1f with the mouse gene, while 1a, 1d and 1c are well 
conserved. Overall, much of the lack of homology can be explained by presence 
of Alu-repeats in the human VDR gene. We detected 62 Alu-like sequences mostly 
located in introns and between exons 1f and 1e, while one is located in the 3’-UTR 
(data not shown).
Resequencing of the VDR gene
We found 62 polymorphisms (Table 2 and Fig. 3) including 57 SNPs and 5 vari-
able number tandem repeat (VNTR) polymorphisms, of which 18 polymorphisms 
(15 SNPs) were not present in the Celera database (chromosome 12, location from 
47033000 to 47139000, April 2005 freeze/ NCBI Human Genome Build 35.1), 
NCBI dbSNP (dbSNP build 123), the Human Gene Mutation Database (HGMD), 
the HGBASE database and/or in publications. Nine (out of 62) polymorphisms 
locate in highly conserved non-coding regions (identity rate > 70%) in the 3’-UTR 
and in the promoter region. The average frequency of variation across 22 kb was 
1/355 bp, which ranged from 1/247 bp (13/3.2 kb) in the 3’-UTR, 1/315 (13/4.1 kb) 
in exons (2 - 9) and surrounding introns, to 1/408 (36/14.7 kb) across the promoter 
region. 50 SNPs, with a minor allele frequency (MAF) ≥ 5% in the 15 subjects, were 
identifi ed as “informative SNPs”.
Three informative polymorphisms were located in the so-called “destabilizing 
elements (DE; described before10) in the 3’-UTR of the VDR gene (Fig. 3.). Four 
informative SNPs were observed in coding exons 2-9: a previously known C to 
T substitution (E2-C4T; detected as a FokI RFLP), E2-C59T and E8-C2T are 
synonymous substitutions; and a previously known synonymous SNP (E9-T32C; 
detected as a Taq I RFLP). In the promoter region exons 1a-1f, we found 36 
sequence variations, including 5 VNTRs and 31 SNPs. One SNP in exon 1b (1b-
C25A) would change the predicted amino acid sequence by threonine to lysine 
(1b-Thr8Lys). TRANSFAC analysis of the 5’ upstream regions of promoter exons 
1a-1f indicated that 14 polymorphisms change the core recognition sequence of 
potential transcription factors (Table 2).
DISCUSSION
The VDR gene is an important candidate gene of osteoporosis, and it has been 
studied for more than 17 years in genetic association analyses. However, the ge-
nomic structure of the gene described in the NCBI and the Celera databases still 
does not cover the whole length of the gene. In our current study, we determined a 
more accurate genomic structure of the human VDR gene, especially at the 5’-end 
of the gene. The length of the gene by our data is one third longer as compared to 
other databases. The borders of the VDR gene seem indicated by the homology and 
linkage analyses.
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Since the human VDR gene is a complex (with six extra exons in 5’-end) and 
large gene (at least 105 kb), it was a time and money consuming design to sequence 
the complete VDR gene for functional variations. Especially in the beginning of 
this study, no high-throughput sequencing equipment was available. The homology 
analysis was therefore used to identify potentially functional regions of the VDR 
gene, we therefore sequenced in total 22 kb (instead of 105 kb) of the VDR gene. 
Those fragments covered most potentially functional region: all coding exons, the 
complete 3’-UTR and 2 kb promoter region of all extra exons in 5’-end.
One limitation of our homology analysis is we only compared the VDR se-
quence between human and mouse, because in the beginning of our study (1999), 
only human and mouse VDR sequences were available. Now more species genomic 
sequences are available for the homology analysis to identify commonly conserved 
fragments among those species.
The analyses in this chapter (determining the VDR structure, homology analy-
sis and sequencing analysis) are time-consuming (cost 2.5 years) but they are the 
fundamental steps for our following studies.
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ABSTRACT
Introduction: After 62 polymorphisms across the VDR gene were detected, 
the next questions were: a. what is the allelic association between them [i.e., link-
age disequilibrium (LD)], b. how many functional polymorphisms were among 
them, and c. how to identify them. Haplotype and LD analysis is a powerful tool 
to examine the relationship between polymorphisms in a gene. This analysis can 
cluster polymorphisms as haplotype blocks according to linkage level, and deter-
mine haplotype tagging polymorphisms for association and functionality studies to 
identify potentially functional regions or polymorphisms in a gene.
Materials and Methods: We genotyped 47 single nucleotide polymorphisms 
(SNPs) in 234 Caucasians, 107 Asians and 58 African Americans. We analysed 
several databases and determined the race-specifi c haplotype structure and hap-
lotype tagging SNPs (htSNPs) across the whole VDR gene for different ethnic 
population.
Results: LD analysis of common SNPs (frequency ≥ 5 %) revealed 4 – 8 high 
linkage haplotype blocks (D’ > 0.8) which are conserved among Caucasians and 
Asians, but more fragmented in Africans. The haplotype frequencies differ ex-
tensively among the ethnic groups. Fifteen htSNPs are diagnostic for the VDR 
haplotype blocks for large-scale association studies in Caucasians, 10 htSNPs for 
studies in Asians and 28 for studies in Africans.
Conclusions: These htSNPs can be used for further studies to investigate the 
relationship between VDR haplotypes and clinical outcomes in different ethnic 
populations.
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INTRODUCTION
The interpretation of polymorphic variations in the VDR gene is severely hin-
dered by the fact that until now only few polymorphisms in this large gene have been 
studied, and that most of these are anonymous (non-functional) polymorphisms. 
To explain the associations observed with complex diseases they should be in link-
age disequilibrium (LD) with truly functional polymorphisms. Haplotype-based 
methods offer a powerful approach to study association of genetic variation with 
complex disease1. Following a recent comprehensive study of VDR polymorphisms2 
we here present a detailed description of the genomic organisation of the VDR 
gene region, the identifi cation of 62 polymorphisms across relevant areas of the 
gene, and analysis of LD and haplotype diversity of VDR variations in different 
ethnic groups. We also compared our haplotype data with data from Nejentsev et 
al. and data in several databases including Perlegen, HapMap and SNPbrowser.
MATERIALS AND METHODS
Subjects
We studied LD in 234 random blood Caucasian bank donors, and in DNA from 
107 Asian and 58 African individuals (the Coriell Institute, Camden, NJ. USA: 
90 Chinese Han (HD100), 9 Chinese (HD02), 8 Japanese (HD07), 47 African 
Americans [HD04 and HD50) and 9 Africans from south of the Sahara (HD12)].
Genotyping
We genotyped 47 SNPs (Table 1) in 3 ethnic groups with the high throughput 
TaqMan allelic discrimination assays. The Assay Mixes (including unlabelled PCR 
primers, FAMTM and VIC® dye-labelled TaqMan MGB probes) of three Assays-
on-DemandSM and 36 Assays-by-DesignTM were designed and provided by ABI. 
The reaction system contained 1 - 5 ng of dried genomic DNA, 2.5 μl of TaqMan® 
Universal PCR Master Mix, No AmpErase® UNG (2 ×), 0.125 μl (40 ×) or 0.0625 
μl (80 ×) of Assay Mix, and adjusted with Milli-Q H2O to a total volume of 5 
μl. The genotyping results were analyzed with an endpoint reading in the ABI 
Prism® 7900HT independently by two operators, and 5% random samples were 
independently repeated to confi rm genotyping results.
Linkage disequilibrium (LD) and haplotype analyzes
We fi rst analyzed LD among all 62 polymorphisms based on the 15 sequenced 
Caucasian samples to select 37 SNPs, and also nine additional SNPs (A to I in Table 
1) from the Celera database, which are fl anking the VDR gene, and the E8-G+284A 
(Bsm I RFLP3). Selection criteria for VDR SNPs in the LD analysis is based on: 
A. Minor allele frequency (MAF) > 10 % (3/30 alleles) from our sequence analysis; 
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Table 1 Allele frequencies of 47 SNPs in different ethnic groups
Code I SNPs ID II
                  Minor allele frequency (%) III
Allele Caucasian(# chr = 468)
Asian
(# chr = 214)
African
(# chr = 116)
Intergenic region of COL 2A1 - VDR (5 SNPs)
A hCV2615323 (G/A) A 10 38 4
B hCV8724908 (G/C) C 44 15 27
C hCV2626648 (G/A) A 11 33 4
D hCV8724903 (C/G) G 7 1 5
E hCV8724902 (C/T) T 12 34 28
Promoter (24 SNPs)
1 1f-G-1904A A 46 5 10
3 1f-C-1570T T 27 78 66*
5 1f-G-1344A A 46* 5* 10*
6 1f-T-1198G G 28* 17* 12*
7 1f-G-777A A 13* 29* 23*
F 1e-T-3743C C 17 48 76
10 1e-C-2090T T 43 3 6*
12 1e-G-1739A (Cdx-2) A 17* 49* 75*
15 1e-C-577A A 42 3 10*
17 1a-G-1521C C 43 3 6
18 1a-A-1012G (GATA) G 43* 3 6*
22 1b-T-2746C C 34 3 13*
23 1b-G-2528A A 28 66 75*
24 1b-C-2481A A 10* 0.0 3
25 1b-A-2225G G 27 64 74
26 1b-T-1748A A 38 31 10
28 1b-G-886A A 25* 44 9*
29 1b-C-673T T 10* 0 2
30 1b-T-391C C 39 31* 10*
31 1b-C25A (Thr/Lys) A 32* 3 12*
33 1c-T-1930C C 40 34 14
34 1c-G-1633C C 28* 20* 30*
35 1c-C-1453T T 41* 33* 51*
36 1c-G-1156A A 29 17 11*
Coding (8 SNPs)
38 E2-C4T (Fok I) T 34* 51* 21*
41 E4-A-62G G 42 75 35*
44 E7-D+75G G 2 1 22*
# E8-G+284A (Bsm I) A 42 6 36*
46 E9-G-111C C 13 17 10
47 E9-G-94A A 2 1 14*
48 E9-T-48G (Apa I) G 44 76 26
49 E9-T32C (Taq I) C 43 8 31*
UTR (7 SNPs)
50 U-A311C C 45* 76* 31*
51 U-C440G G 2 0.5 1
52 U-G464T T 13* 17* 10*
53 U-D796T T 44 24 59*
57 U-A1909C C 44 75 29*
61 U-G2795A A 2 1 16*
62 U-A2978T T 2* 0.5 1
Intergenic region of VDR HDAC7A (3 SNPs)
G hCV3290614 (A/T) T 35 75 23
H hCV3290610 (T/C) C 46 64 42
I hCV16253844 (T/C) T 46 36 33
I: The SNP codes from A to I indicate SNPs which are selected from the Celera database, SNP A is a mis-sense mutation in 
exon 53 of COL 2α1; # indicates the RFLP SNP, E8-G+284A (Bsm I)3. The number is according to Table 2 in chapter 2.
II: The SNP ID is according to the Celera database and the resequencing result in Table 2 in chapter 2.
III: Minor alleles are based on the frequency in the Caucasian population.
*: VDR Tagging SNPs for association study in different ethnic groups
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B. In potential promoter TFBS or destabilising element in 3’-UTR; C. in a highly 
conserved region; D. a tagging SNP (based on the 15 sequenced subjects).
We then genotyped 47 SNPs in Caucasians, Han-Chinese and African-Americans 
to calculate allele frequencies (Table 1). We determined the race-specifi c SNPs, 
whose MAF is > 3% in either of the ethnic study populations, and identifi ed 42 
SNPs for Caucasian, 33 for Asian and 41 for African American. We constructed 
haplotype structure by the PHASE program4, then used PHASE outcome to calcu-
late the pair- wise standardized disequilibrium coeffi cient (D’) with the “haploxt”5 
to estimate the linkage magnitude between two SNPs, and depicted the graphic 
overviews of LD by the GOLD program6. We identifi ed haplotype blocks and 
calculated haplotype frequency in each block by HaploBlockFinder program7. 
Selection of the htSNPs in each ethnic group was based on: A. the minimal com-
bination of htSNPs in each haplotype block to represent ≥ 95% of the haplotypes; 
B. potential functionality in 3’-UTR or promoter; C. SNP is unlinked to any block 
e.g., E2-C4T (Fok I).
LD data comparison
We compared our data with the data from Nejentsev et al.2 (including 68 SNPs for 
Caucasians), and data from Perlegen8 (including 48 SNPs for European American), 
HapMap9 (Haploview version 3.0, including 33 SNPs) and SNPbrowser10 (version 
3.0, including 11 SNPs)
RESULTS
Linkage disequilibrium (LD) and haplotype analyzes
Genomic structure and polymorphisms of the VDR gene were presented in 
Figure 1a. In Caucasians, we identifi ed 5 blocks with high LD (coded 1 to 5 in Fig. 
1b and 2a) which range in size from 2 - 17 kb. SNPs in such a block are in strong LD 
with the other SNPs inside the block but show very little LD with SNPs outside the 
block. Four blocks (1-4) were found in the promoter region, while the largest block 
5 is encompassing 17 kb and includes exons 4-9 and the 3’-UTR. Block 2 and 3, 
encompassing the 1b-1e promoter region, could not be considered as one LD block 
in our analyses even when D’ > 0.50 is taken as cut-off to defi ne a block. There are 
also clear areas of very low (or absent) LD, i.e., between exons 1e and 1f (block 1 
and 2), between exons 2 and 3 (block 4 and 5), and at the end of the VDR gene (3’ 
of block 5). The E2-C4T SNP (detected as a Fok I RFLP) has no LD with any of 
the other SNPs and cannot be assigned to any of the blocks. The most distal 3’ hap-
lotype block 5 shows no LD with SNPs after the VDR gene and the most proximal 
5’ block 1 shows only weak LD with more 5’ SNPs near and in the COL2A1 gene. 
At least 7 blocks can be identifi ed when we compared different sources on VDR 
LD block structures (Fig. 2b). It is diffi cult to defi ne the exact boundaries of these 
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low LD areas because not all studies analyzed a high density of SNPs across the 
VDR gene. Interestingly, we observed LINE-1 repetitive elements to be localized 
between the boundaries of the LD blocks of the VDR gene (Fig. 2b).
The LD map of Han Chinese is similar to that of Caucasians (Fig. 1b and 3a), 
but with only 4 haplotype blocks and with areas of low LD co-localizing with those 
in Caucasians. For Asians we observed a large haplotype block in the promoter 
region (from 1e-T-3743C to 1b-T-391C) which corresponds to the combined Block 
2 and 3 in Caucasians. This larger promoter block was also observed in Caucasians 
when we used SNPs with MAF ≤ 5% (data not shown). The LD map of African-
Americans is more fragmented and substantially different compared with that of 
Caucasians and Asians (Fig. 1b and 3b). There are eight small haplotype blocks and 
seven unlinked SNPs. Again, the E2-C4T SNP (the Fok I RFLP) was found to be 
independent of any other haplotype block. Some areas of low LD are co-localizing 
in all three ethnic groups, indicated as A in Figure. 1b (separating exon 1f from 
the upstream region into COL2A1), B (separating exon 1e-1b from exon 1f), D 
(separating exon 1c from 1e-1b), E (separating exon 2 from exon 3-9/3’-UTR), and 
F (separating the exon 4 - 3’-UTR from the area downstream of VDR), while C 
(separating exon 1f from exon 1e-1b) is shared between Caucasians and African-
Americans, but is absent in Han Chinese. In African-Americans two additional 
areas of low LD (C1 and C2) can be distinguished.
We reconstructed haplotype alleles and analyzed diversity and frequencies 
across ethnic groups (Fig. 1b; only haplotypes with MAF > 3% are shown). The 
number of haplotype alleles in each of the LD blocks increases from Han Chinese to 
Caucasians and is the greatest in African Americans. Only for relatively “conserved” 
LD blocks across ethnic groups comparison is possible and this shows substantial 
differences in haplotype allele frequencies. For example, in block 1 (around exon 
1f) the most common allele in Caucasians has a frequency of 44.6% but this same 
allele is 4.7% in Han Chinese and 10.3% in African-Americans. Similarly, the most 
common allele in block 4 (around exon 1c) is 40.2% in Caucasians, 32.3% in Han 
Chinese, and 13.8% in African Americans.
While for Caucasians 15 tagging SNPs (14 htSNPs and E2-C4T) are required 
to cover the common genetic diversity across the VDR gene, this number is only 
10 for Han Chinese but increases to 28 for African Americans. When only the tag-
ging SNPs were used to genotype a population (6,148 subjects form the Rotterdam 
Study), a similar LD pattern was obtained compared to using the 34 original SNPs 
with MAF > 5% in the smaller sample of 234 bloodbank donors, indicating that 
the tagging SNPs are effectively predicting the other SNPs within the blocks.
We observed that the haplotypes constructed from the well-known Bsm I, Apa 
I, and Taq I RFLPs, as described previously by our group11, could correctly predict 
all the common haplotypes at the 3’-UTR region in Caucasians as defi ned using the 
9 SNPs with MAF > 5% (Fig. 1b). For Han Chinese such correspondence is lower 
due to the U-D796T polymorphism which has changed phase, while for African 
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Americans the haplotype structure of this area is much different.
DISCUSSION
We recently identifi ed 62 polymorphisms in potentially functional areas of the 
VDR gene (chapter 2), and now characterised the LD structures across the whole 
VDR gene for three different ethnic populations. For Caucasian population we 
identifi ed 15 tagging SNPs to represent the common haplotypes of these blocks 
in potentially functional areas of the VDR gene, we also combined several studies 
and databases2,8-10,12 to conclude that there are 7 haplotype blocks across the VDR 
gene in Caucasians.
We analysed the LD and haplotype structure of the VDR gene using 49 SNPs 
with MAF > 5% in 234 subjects, and identifi ed 5 haplotype blocks across the gene 
for Caucasian population (Fig 1b), haplotype pattern does not change when we 
selected 50 random subjects in the same analysis. Nejentsev et al.2, analysed 68 
SNPs with MAF > 10% in 916 subjects. Their analysis has the similar LD map of 
the gene in Caucasians, although they described three haplotype block including 
subset blocks. However, they missed one block structure around exon 1b, because 
only one SNP was selected in the region; and since not analysing the intron2 and 
3, we missed the block(s) in that region. Perlegen8 database defi nes three blocks 
with high density SNPs (1 kb per SNP on average) in 23 Caucasians. HapMap9 
and SNPbrowser10 databases show some small haplotype fragments in the gene, 
partially describe the LD map of the VDR gene. Combining all data together, we 
conclude that there are seven haplotype blocks across the VDR gene. To determine 
the reliable haplotype structure for the association study, one has to analyse high 
density of informative SNPs (1 – 2 kb per SNP and MAF > 5%) in the relatively 
big study population (> 50).
Using the D’ threshold of 0.8, we gained fi ve clear border blocks with a few 
common haplotypes (MAF > 5%) which cover > 95% haplotypes in the associa-
tion population. Using a few common haplotypes in association study, we limited 
the number of analysis against the multiple testing.
We constructed the LD map and identifi ed htSNPs of the VDR gene for three 
major ethnic populations. There are several further approaches to identify the (set 
of) responsible functional SNPs in the LD areas where we identifi ed risk haplotype 
alleles. Since African Americans have in general smaller LD blocks, replicating 
the associations in African Americans could “zoom in” on a smaller region with 
concomitantly less SNPs to test functionally. Subsequently, the functionality test 
we will show (Fig. 2 and 5 in chapter 7) can be repeated but now with constructs of 
promoter and 3’-UTR variants that differ at less and down to only 1 position.
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Figure 2 The linkage disequilibrium (LD) structure of the VDR gene in Caucasians. A color version of this fi gure 
is presented at the front fl ap page. 2a Blocks with pair-wise D’-values with D’>0.8 are numbered 1-5. The analyzed 
SNPs (Table 1) include: fi ve SNPs in the COL2 α 1 and VDR intergenic region (IGR VDR & COL 2A1), 39 VDR 
SNPs and three SNPs in the VDR and HDAC7A intergenic region (IGR HDAC7A & VDR). SNP ID is based on 
Table 1 in Chapter 2; Figure 1a and Table 1 in the chapter. The red boxes on the X and Y-axes indicate the high LD 
blocks used to defi ne haplotype alleles. Physical organization of the VDR gene is represented with vertical lines on 
the Y-axis (Fig. 2a, 3a and 3b). 2b Aligned LD analyzes from different sources and estimated consensus LD structure 
of the VDR gene. Total number of SNPs analyzed in each study is indicated between brackets. Thick lines indicate 
haplotype blocks with the number of analyzed SNPs below the line and the name of the block above the line.
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3a
3b
Figure 3 LD map of the VDR gene in different ethnic groups. A color version of this fi gure is 
presented at the front fl ap page. 3a LD map of 33 SNPs in 107 Asians (214 chromosomes). 3b LD 
map of 41 SNPs in 58 African-Americans (116 chromosomes). 
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ABSTRACT
Introduction: A single nucleotide polymorphism (SNP) within a binding site 
of the intestinal-specifi c transcription factor Cdx-2 in the promoter region of the 
human Vitamin D Receptor (VDR) gene was previously reported. It was found to 
modulate the transcription of the hVDR gene and to be associated with decreased 
BMD in a small group of postmenopausal Japanese women. In this study we inves-
tigated the relationship between the VDR Cdx-2 genotype and risk of fracture.
Materials and Methods: We fi rst determined the location of this SNP in the 
VDR gene by sequencing analysis, and developed an allele-specifi c multiplex PCR 
test to determine the Cdx-2 genotype. We then performed an ecological study in 8 
ethnic groups and an association analysis in a large epidemiological cohort of 2848 
Dutch Caucasian men and women, aged 55 years or older.
Results: The location of the G to A substitution was found in the promoter 
region of exon 1e (1e-G1760A) of the VDR gene. By comparing the frequency of 
the A-allele in eight different ethnic groups, we observed a negative correlation 
between prevalence of the A-allele and published hip fracture incidence rates in 
these ethnic groups (p = 0.006 for men and p = 0.02 for women), suggesting a 
protective effect of this allele on fracture risk. Subsequently, in the association 
study the A-allele (population frequency 19%) was observed to have a protective 
effect on occurrence of osteoporotic fractures, especially for non-vertebral fracture 
in women (Relative Risk of AA vs. GG genotype is 0.2, 95%CI is 0.05-0.8). This 
effect remained after adjustment for age, weight and bone mineral density (BMD). 
Conclusions: The A-allele of the VDR Cdx-2 polymorphism is present in 
Caucasians, albeit at low frequency, and has a protective effect on risk of fracture.
Keywords: osteoporosis, ethnic groups, genetics, allele-specifi c multiplex PCR
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INTRODUCTION
Polymorphisms of the vitamin D receptor (VDR) gene have been found to be 
associated with many clinical endpoints, such as osteoporotic fracture1, osteoar-
thritis2, diabetes3, breast cancer4, prostate cancer5 and low BMD6. Most of these 
studies involved the analysis of polymorphisms which are located at the 3’ end 
of the VDR gene, such as the Bsm I, Apa I and Taq I restriction fragment length 
polymorphisms (RFLPs) or poly (A) repeat. However, these polymorphisms are not 
likely to be functional by themselves, either because they are in an intron or they 
do not change the sequence of amino acids, while the potential functional effect 
of poly (A) repeat polymorphism is still unclear. Another commonly studied poly-
morphism in the VDR gene is the Fok I RFLP which detects a translation initiation 
codon polymorphism7. Although it changes the structure of the VDR protein and is 
a potential functional polymorphism8, so far there is no strong evidence of associa-
tion of this polymorphism with any clinical endpoint including fracture9,10.
Recently, Yamamoto et al.11 described a functional binding site for the intes-
tinal-specifi c transcription factor Cdx-2 in the 1a promoter region of VDR gene. 
Subsequently, Arai et al.12 described a G to A substitution polymorphism at this 
Cdx-2 site which was found to modulate the intestine-specifi c transcription of the 
VDR gene. Functional differences between these two alleles could be demonstrated 
whereby the A-allele had increased binding to the Cdx-2 protein in vitro and showed 
in the human colonic carcinoma cell line Caco-2, increased transcription activity 
of the VDR promoter compared with the G-allele. Furthermore, in a small group 
of Japanese postmenopausal women (n = 55) these authors found the A-allele to be 
associated with increased bone mineral density (BMD). Together, these data sug-
gest the Cdx-2 polymorphism to be a functional polymorphism in the VDR gene. 
However, data on the occurrence of this polymorphism in other ethnic groups 
and from large genetic epidemiological study-cohorts are currently not available. 
The Cdx-2 polymorphism is a single nucleotide polymorphism (SNP) which was 
detected by direct sequencing12. However, this technique is too laborious and time 
consuming for screening purposes in large populations. In this study we therefore 
developed a so-called allele-specifi c multiplex PCR (ASM-PCR), to detect the Cdx-
2 polymorphism. We fi rst analysed this polymorphism in a panel of several ethnic 
groups. In addition, we performed a large-scale association study in a prospective 
cohort study of Caucasian men and women, aged 55 years and older. We analysed 
this polymorphism in relation to fracture and BMD.
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MATERIALS AND METHODS
SUBJECTS
Panel of ethnic groups
We genotyped a panel of DNA from 88 subjects of different ethnicity. The 
panel was obtained from the Coriell Institute (Camden, New Jersey, USA). It 
consists of DNA from 10 African Americans (HD04), 9 Africans from south of 
the Sahara (HD12); 10 Chinese (HD02), 10 Japanese (HD07), 10 Southeast Asians 
(excluding Chinese and Japanese, HD13); 10 Northern Europeans (HD01), 9 Indo 
Pakistanis (HD03), 10 Middle Easterns (HD05) and 10 Mexicans (HD08). We 
grouped these 88 subjects into three major human race groups defi ned as: African 
(19 subjects, HD04 and HD 12), Mongoloid (30 subjects, HD02, HD07 and HD13) 
and Caucasian (39 subjects, HD01, HD03, HD05 and HD08)
Data on the incidence rates of hip fracture in different ethnic groups were col-
lected from published studies13-25, and are presented in Table 1. To enable compari-
sons among different published studies, we standardised the age-adjusted incidence 
of hip fracture in men and women aged ≥ 55 years according to the US population 
distribution in 199026,27. The direct standardisation method was used, every age-
specifi c rate was multiplied by the corresponding US population in the same age 
category to get the number of hip fractures for each age category. The sum of 
fractures was then divided by the total US population to get age-adjusted incidence 
of hip fracture. For each ethnic group, we computed the average incidence rates, 
which were weighted by the size of the study population, to compare incidence 
rates of hip fracture among these eight ethnic groups.
Study population
The study population sample of Caucasian elderly was derived from the 
Rotterdam Study (the source population), a single centre prospective population-
Table 1 Overview of studies used to determine the age-adjusted* incidence of hip fracture in men 
and women of age 50 years or older
Ethnicity Source population Author (ref.) Incidence (per 100 000)
Men Women
Chinese Chinese Lau et al.13, Koh et al.14, 118 158
Schwartz et al.15, Xu et al.16,
Yan et al.17, Zhang et al.18.
African African American Bauer et al.19 16 182
Mexican Mexican American Bauer et al.19 95 183
Japanese Japanese Hashimoto et al.20, Iga et al.21. 144 254
Southeast Asian Singapore, Lau et al.13, Koh et al.14 111 284
Malaysia, Thailand
Middle Eastern Kuwait i Memon et al.22 200 295
Indo Pakistani Singapore Indian Koh et al.14 128 361
Northern European Norwegian Schwartz et al.15, Lofthus et al.23, 243 419
Luthje et al.24, Flach at el.25
*: Adjusted according to the US population distribution in 1985 or 199026,27
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based cohort study including 7983 individuals with 3105 men (38.9%) and 4878 
women (61.1%) to analyse determinants and prognosis of chronic and disabling 
diseases in the elderly28. The baseline measurements were performed between 1990 
and 1993. The third follow-up examination phase took place from 1997 to 1999; 
the mean follow-up period was 6.6 years (range 5.3-10.2). Baseline measurements 
of BMD were available for 5931 independently living subjects from the study. For 
the current study 1453 of these were excluded on the basis of age (>80), use of a 
walking aid, diabetes mellitus or use of estrogen, thyroid hormone or cytostatic 
drug therapy. From the 4478 remaining subjects, a random sample of 2848 subjects 
(the study population) with 1131 men (39.7%) and 1717 women (60.3%) was drawn 
at baseline, comprising independently living participants aged 55 to 80 years. All 
subjects have records of incident non-vertebral fracture, while 1915 subjects (67.2% 
of study population) survived and had follow-up radiograph records to assess 
incident vertebral fracture. Data on dietary intake was available for 2536 subjects 
(90.0% of study population).
MEASUREMENTS
Anthropometric variables
Information about medical history, dietary habits, age at menopause and smok-
ing was obtained with a computerized questionnaire during a home interview. 
Intakes of calcium and total energy were calculated by food frequency questionair 
(based on all food and drinks consumed in one month) with the use of Dutch food 
composition tables. Dietary calcium intake was adjusted for total energy intake. 
Anthropometric measurements of participants were obtained at the research centre. 
Body Mass Index (BMI) was calculated as weight (kg) divided by the height square 
(m2). Bone mineral density (BMD in g/cm2) was determined by dual energy X-ray 
absorptiometry (Lunar DPX-L densitometer, Lunar Corp., Madison, WI, USA) at 
the femoral neck and lumbar spine (vertebral L2-L4) as described before29.
Defi nition of fracture
Non-vertebral fractures (including hip, wrist and other fractures, but excluding 
head, foot, hand and pathological fracture) were recorded by general practitioners 
(GPs) who covered 80% of the population. Research physicians confi rmed fol-
low-up information by checking GPs’ patient records and collected the data of 
the remaining 20% of the population. Discharge reports and letters from medical 
specialists were additionally used to verify the hospitalized non-vertebral fracture 
patients. All fractures were coded independently by two research physicians ac-
cording to the International Classifi cation of Diseases, 10th revision (ICD-10). If 
there was disagreement, consensus was reached in a separate session. A medical 
expert in the fi eld reviewed all coded events for a fi nal classifi cation. The incidence 
of non-vertebral fracture was defi ned as all new cases occurring during the follow-
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up period.
To assess presence of vertebral fracture, lateral radiographs of the spine from 
the fourth thoracic to the fi fth lumbar vertebrae were obtained and analysed mor-
phometrically by McCloskey-Kanis method as described previously30. All vertebral 
fractures were confi rmed through visual interpretation by an expert in the fi eld. 
When a vertebra was determined to be normal at baseline and any of the three 
vertebral heights (anterior, central or posterior) showed a minimum decrease of at 
least 4.6 mm and 15% in absolute height of the later fi lm, then it was considered an 
incident vertebral fracture. The incidence of vertebral fracture was defi ned as all 
new cases occurring during the follow-up period.
Genotyping
Genomic DNA was isolated form peripheral venous blood samples according 
to standard proteinase K digestion and phenol-chloroform extraction. The position 
of the Cdx-2 (also denoted 1e-G1760A) polymorphism is based on our sequence 
analysis of the 1e promoter region of the VDR gene (manuscript in preparation). 
Two sets of primers were designed for the ASM-PCR test:
 G-For: 5’-AGGATAGAGAAAATAATAGAAAACATT-3’
 G-Rev: 5’-AACCCATAATAAGAAATAAGTTTTTAC-3’
 A-For: 5’-TCCTGAGTAAACTAGGTCACAA-3’
 A-Rev: 5’-ACGTTAAGTTCAGAAAGATTAATTC-3’
A schematic representation of the method and localization of the allele-specifi c 
primer sets is shown in Figure 1a. G-Rev and A-For are allele-specifi c primers. The 
primer A-For is designed from 5’ to 3’ of the sense strand (+ strand), and the last 
base is “A” at the site of the polymorphism. The primer G-Rev is from 5’ to 3’ of 
the antisense strand (- strand), and stops at “C” (the complement base of “G”) at 
the polymorphic site. These four primers generate three PCR fragments: primer 
set G-For and G-Rev specifi cally amplifi es the G-allele with a size of 110 basepair 
(bp), A-For and A-Rev specifi cally amplify the A-allele with a size of 235 bp, the 
out-primer pair (G-For and A-Rev) amplifi es the internal control PCR fragment 
with a size of 297 bp. A schematic representation of the gel electrophoresis pattern 
is shown in Figure 1b. To verify the fi rst result of genotype calls, a random set of 
5% of the samples were genotyped again.
PCR and gel electrophoresis
The PCR amplifi cation was carried out in a GeneAmp PCR system 9700 
(Applied Biosystems) with MicroAmp Optical 96-well Reaction Plate (Applied 
Biosystems) and in a PTC-225 DNA Engine Tetrad (MJ research) with polypropyl-
ene 96-well and 384-well thin wall microplates. 10 µl of the PCR reaction system 
consisted of 1.0 µl 10× PCR Buffer (1× Buffer = 10 mM Tris-Cl, pH 8.3; 50 mM 
KCl; 1.25 mM MgCl2), 1.0 µl 10× dNTPs (2mM), 0.4 pmol G-For, 0.6 pmol G-Rev, 
0.6 pmol A-For, 0.4 pmol A-Rev, 0.5 units Super Taq (HT Biotechnology LTD) and 
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10 ng genomic DNA. PCR was performed with an initial denaturation at 96°C for 
5 minutes, followed by 28 cycles of denaturation at 94°C for 45 seconds, annealing 
at 56°C for 45 seconds and extension at 72°C for 45 seconds. The fi nal extension 
was at 72°C for 5 minutes. PCR products were size-separated on a 2.5% agarose gel 
at 125 volts for one hour. The 100-bp DNA ladder of GIBCOBRLTM was used to 
determine the size of fragments.
Figure 1 (A) Schematic representation of ASM-PCR for detecting the G to A SNP at the Cdx-2 
binding site in the VDR 1e promoter region (1e-G1760A). Primers A-For and G-Rev are located 
fl anking the SNP in opposite directions. The last base is at the SNP site, the last base of A-For is “A” 
to match the A-allele and the last base of G-Rev is “C” (complement of “G”) to match the G-allele. 
Primer set G-For and G-Rev generates a 110 bp fragment when the G-allele is present. Primer set 
A-For and A-Rev generates a 235-bp fragment when the A-allele is present. The primer set G-For 
and A-Rev generates a 297-bp fragment which is an internal control and independent of the presence 
of either the G or A-allele. (B) Schematic representation of the gel pattern obtained with the ASM 
PCR test for Cdx-2 genotyping. The largest PCR fragment (297 bp) is the internal control fragment 
which can be seen in any successful PCR. The 235-bp fragment is the A-allele specifi c PCR product, 
and the 110-bp fragment is the G-allele specifi c fragment.
1A
Cdx-binding site
---TCACAATAAAAACTTATTTCTT---
G
-1760 1e       1a
+ STRAND   5’ 3’
G-Rev A-Rev
G-For A-For
- STRAND   3’ 5’
G/A polymorphism
Internal control (297 bp)
A-allele (235 bp)
G-allele (110 bp)
1B
AA AG GG
Control fragment (297 bp)
A-allele (235 bp)
G-allele (110 bp)
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Sequencing
We sequenced the entire region of 6.5 kilo base pairs (kb) before the exon 
1a of VDR gene in DNA from 15 young female Caucasians as a part of our 
sequence analysis of the VDR gene31. To sequence the region around the Cdx-2 
polymorphism, the 297-bp PCR product, which was amplifi ed with the out-primer 
set of G-For and A-Rev, was purifi ed by using Quantum Prep PCR Kleen Spin 
Columns (BIO-RAD). We performed direct sequence analysis of PCR products 
by cycle sequencing using an ABI PRISM bigdye kit from Applied Biosystems. 
The sequencing reaction (20 µl) included 4 µl of 5× buffer (400 mM Tris-Cl pH 
9.0, 10 mM MgCl2), 1.0 nM of G-For or A-Rev, 4 µl of Terminator Ready Reaction 
Mixture (containing BigDye, Applied Biosystems) and 11 µl of PCR product. The 
sequencing reaction was performed in GeneAmp PCR system 9700 (Applied 
Biosystems) with the following 25 cycles: 96°C for 10 seconds, 50°C for 5 seconds 
and 60°C for 4 minutes. The sequencing product was purifi ed by using Micro Bio-
Spin chromatography Columns (BIO-RAD). Forward and reverse sequences of 
PCR products were produced with an ABI PRISM 310 or 3100 Genetic Analyzer 
(Applied Biosystems).
Statistical Analysis
For the ecological study Spearman’s Correlation test was used to test for cor-
relation between VDR Cdx-2 genotype distribution and the eight ethnic groups 
ranked by gender-specifi c hip fracture incidence. To compare the differences of the 
major anthropometric characteristics and clinical endpoints between the source 
population and the study population for the epidemiological study, we performed 
independent sample t-tests for continuous variables and the Pearson chi-square 
analysis for categorical variables. Hardy-Weinberg equilibrium was tested for the 
Cdx-2 genotype by a chi-square goodness of fi t test. We grouped subjects by their 
genotype for the Cdx-2 polymorphism as GG, GA and AA. The GG genotype was 
defi ned as reference group because it was the most frequent genotype in our study 
group. Differences in anthropometric characteristics by genotype were evaluated 
by analysis of variance (ANOVA) for continuous variables and Pearson chi-square 
p-value for categorical variables. Three possible genetic models were allowed to 
explain differences between groups, i.e., an allele dose effect, a dominant effect 
or a recessive effect. Allele dose was defi ned as the number of copies of a certain 
allele in the genotype, and genotype was treated as a continuous variable. For the 
A-allele the genotype is expressed as a numeric variable with 0 = GG, 1 = GA 
and 2 = AA. In case of a consistent trend refl ected as an allele dose effect, a linear 
regression analysis was performed and a “trend” p-value was calculated to quantify 
the association. In case of a recessive or dominant effect of the test allele, a two 
by two chi-square test or an independent sample T-test was performed to test 
for differences between two genotype groups. For recessive effects homozygous 
subjects for the test group (e.g., AA) were compared to the combined group of 
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heterozygous carriers (e.g., GA) and non-carriers (e.g., GG). For dominant alleles 
we compared the test allele carriers (e.g., GA and AA) versus non-carriers (e.g., 
GG).
We fi rst analysed risk of any fracture, which includes vertebral and non-verte-
bral fracture, by the Cdx-2 genotype. This analysis was limited to the group for 
which data on vertebral fracture was available (n=1915). We then stratifi ed the 
analysis by type of fracture for vertebral vs. non-vertebral fracture. For analysis 
of non-vertebral fracture the complete study sample (n=2848) could be included. 
84 individuals who had both vertebral and non-vertebral fracture during the fol-
low-up time were included in all analysis. Differences in the non-vertebral fracture 
frequency by genotype were compared using Pearson chi-square tests in general 
and a linear regression model for the allele-dose effect. Relative Risk (RR) and 95% 
confi dence intervals (95% CI) were calculated for the relationship between the 
Cdx-2 genotype and fracture by using Cox regression models. The same models 
were used to estimate the RR adjusted for potential confounders, such as age, 
gender, BMI and BMD.
To analyse effects of potential confounders and modifi cation by dietary calcium 
intake, we also stratifi ed by gender; percentiles and particular cut-off level (less or 
more 600 mg/day) of dietary calcium intake. Differences in BMD by genotype were 
adjusted for age and BMI by a general linear model. All statistical analyses (except 
Hardy-Weinberg equilibrium) were carried out with the SPSS software package 
(version 9.0).
RESULTS
The 1e promoter region
We determined the sequence of the promoter region of 6.5 kb in front of the 
VDR gene exon 1a using a sequence walking strategy. We used reference sequence 
information from Miyamoto et al.32, Yamamoto et al.11, NCBI (http://www.ncbi.
nlm.nih.gov/) and the Celera database. We found exon 1e (accession number of the 
NCBI genomic database is AH006427 from Crofts et al.33) was only 2 kb in front of 
exon 1a (see Figure 1A). The G to A substitution in the Cdx-2 binding site is located 
1760 basepairs in front of exon 1e. Therefore the Cdx-2 polymorphism is referred 
to as 1e-G1760A.
Genotyping
The ASM-PCR method to determine Cdx-2 genotype was applied to genotype 
88 subjects from different ethnicity and 2848 men and women from the Rotterdam 
Study. Figure 2 shows a representative gel separation pattern of ASM-PCR geno-
type analysis for 95 samples and one negative control (no genomic DNA). In order 
to confi rm the genotype result, we re-genotyped 5% random samples from those 
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subjects and found no discrepancy. In addition, 15 random DNA samples were di-
rectly sequenced after PCR to evaluate the Cdx-2 genotype. Both genotype results 
were completely identical. No other polymorphism was found in this 297-bp region 
around Cdx-2 polymorphism in the 1e promoter region of the VDR gene according 
to the sequencing result of these 15 random samples. The genotype distribution in 
the sample from the Rotterdam Study obeyed Hardy-Weinberg equilibrium (p= 
0.17). The frequency of the G-allele and A-allele in the large Dutch Caucasian 
population is 81% (4614/5696) and 19% (1082/5696), respectively. Allele frequen-
cies were not different in men and women (p = 0.93), did not vary by age in men 
(p = 0.42) nor in women (p = 0.17), and did also not vary in the different subsets 
drawn from the Rotterdam Study (p = 0.86).
Ecological study of the Cdx-2 polymorphism
The frequencies of the Cdx-2 alleles and the genotype distribution in different 
ethnic groups are presented in Table 2. Genotype distribution and allele frequency 
differed substantially among ethnic groups. When we combined individual Coriell 
panel groups into the three major races we found the A-allele to have highest 
frequency in Africans (74%, 95% CI 60-88%), intermediate in Asian (43%, 95%CI 
39-47%) and lowest in Caucasian (19%, 95% CI 18-20%). We observed an inverse 
relation between Cdx-2 A-allele frequency and the incidence rate of hip fractures, 
both for men and women (Spearman’s correlation test r = -0.87 p = 0.006 for men; 
and r = -0.79 p = 0.02 for women). In Figure 3 we plotted the age-adjusted incidence 
rates of hip fracture in women of age 50 years or older, against the frequencies of 
the VDR Cdx-2 A-allele in the eight ethnic groups. We excluded HD12 (Africans 
Figure 2 Gel electrophoretic separation pattern of ASM-PCR analysis of 93 samples of our study 
population and 3 controls for the Cdx-2 polymorphism
100 bp marker Negative control
Internal Control
A-allele
G-allele
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from south of the Sahara) in the fi gure, because no hip fracture incidence data are 
available for this group.
Association study of Cdx-2 polymorphism with fracture
We went on to analyse the relation between fracture risk and the VDR Cdx-2 
polymorphism in a large Caucasian study population of Dutch men and women. We 
fi rst  compared baseline characteristics, including age, gender, height, weight, BMI, 
age of menopause, dietary calcium intake and current smoking, between the source 
population and our study population. The subjects of our study group were 4 years 
younger, 0.6 cm shorter and had 0.2 (kg/m2) lower BMI on average than the source 
population. In our study population we observed that all fracture risk increased by 
increasing age (the linear regression p < 0.001 for all kinds of fractures) and the 
incidences of all fractures in women were signifi cantly higher than in men (chi-
square p < 0.001 for all). Baseline characteristics of men and women in the study 
population were not found to be signifi cantly different when stratifi ed by VDR 
Figure3 Age-adjusted incidence 
rates of hip fracture in women of 
different ethnic groups accord-
ing to the frequency of the VDR 
Cdx-2 A-allele. Incidence rates of 
each group were standardised ac-
cording to US population in 1985 
or 1990, and we calculated the 
female-specifi c incidence rates 
for subjects aged 50 or older.
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Table 2 The VDR 1e promoter Cdx-2 polymorphism in different ethnic groups
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Cdx-2 genotype (data not shown). The genotype distribution was not signifi cantly 
different in men and women as well as 5-year age categories.
We compared by Cdx-2 genotype the incidence of any fracture (including ver-
tebral and non-vertebral fracture), and then separately by vertebral fracture and by 
non-vertebral fracture during the 6.6 years follow-up period (Table3). We found 
subjects carrying the A-allele to have fewer fractures with evidence for an allele 
dose effect. The association was borderline signifi cant for vertebral fracture (p 
= 0.04) and any fractures (p = 0.06), while a similar trend was found for non-
vertebral fracture (p = 0.12). When stratifying the same analysis by gender, the 
protective effect of the A-allele was similar in women and men. Because of the 
higher incidence of non-vertebral fracture in women (13.6%) than in men (6.2%) 
and the low frequency of the Cdx-2 A-allele in our Caucasian population, we further 
investigated the effect of Cdx-2 genotype on non-vertebral fracture (including hip 
fracture) in women separately (Table 4). Compared to the whole study population 
we observed a similar protective effect of the Cdx-2 genotype in the women which 
was borderline signifi cant (p=0.05). When Relative Risks (RR) were calculated we 
found presence of the Cdx-2 A-allele to be associated with reduced risk for fracture 
with evidence for an allele dose effect. The RR estimate did not essentially alter 
after adjustment for age, weight as well as for femoral neck BMD. We did not 
observe the calcium intake to modify the relation between VDR Cdx-2 genotype 
and fracture (data not shown).
Association of Cdx-2 genotype with BMD
We also analysed the effect of Cdx-2 genotype on BMD but could not fi nd an 
association of Cdx-2 genotype with femoral neck BMD or lumbar spine BMD. 
Total By Cdx-2 genotype
GG GA AA p-value#
Case/total (%)
  Any fracture 381/1915 (19.9) 268/1270 (21.1) 103/567 (18.2) 10/78 (12.8) 0.06
    Vertebral fracture 217/1915 (11.3) 156/1270 (12.3) 56/567 (9.9) 5/78 (6.4) 0.04
Non-vertebral 248/2848 (8.8) 173/1894 (9.1) 70/838 (8.4) 5/116 (4.3) 0.12
    fracture
RR (95%CI) Per copy of A-allele
Any fracture Crude 1 0.8 (0.6-1.1) 0.7 (0.4-1.3) 0.8 (0.7-1.0)
Adjusted* 1 0.8 (0.6-1.1) 0.7 (0.4-1.3) 0.8 (0.7-1.0)
    Vertebral fracture Crude 1 0.8 (0.6-1.1) 0.5 (0.2-1.2) 0.8 (0.6-1.0)
Adjusted* 1 0.8 (0.6-1.1) 0.5 (0.2-1.3) 0.8 (0.6-1.0)
    Non-vertebral Crude 1 0.9 (0.7-1.3) 0.5 (0.2-1.2) 0.9 (0.7-1.1)
    fracture Adjusted* 1 0.9 (0.7-1.2) 0.5 (0.2-1.2) 0.8 (0.6-1.1)
#: Calculated by linear regression model
*: RR was adjusted for age, gender, weight and femoral neck BMD
Table 3 Risk of fracture according to the VDR Cdx-2 genotype in men and women
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Our data showed that BMD at femoral neck and lumbar spine were correlated to 
calcium intake and age (p < 0.001 for both by linear regression analysis). In general, 
individuals with a high calcium intake had higher BMD than individuals with a low 
calcium intake. The dietary calcium intake was not different by Cdx-2 genotype (p 
= 0.57, which was adjusted for age and gender). We then went on to analyse the 
infl uence of dietary calcium intake on the relation between Cdx-2 genotype and 
BMD.
In quartiles of dietary calcium intake, no difference in BMD was observed by 
VDR Cdx-2 genotype. There were only 119 subjects (4% of the study population) 
with a calcium intake less than 600 mg/day. In this group, a trend could be ob-
served towards A-allele having increased BMD but probably because we did not 
have suffi cient subjects in the group, this failed to reach signifi cance (p = 0.47 for 
femoral neck BMD and p = 0.56 for lumbar spine BMD). In the group with high 
calcium intake (>600 mg/day) we did not see differences in BMD among VDR 
Cdx-2 genotype groups.
 
DISCUSSION
Location of Cdx-2 polymorphism and genotyping method
From our analysis of the physical map of the region in front of exon 1a and 1e of 
the VDR gene, we found that exon 1e was only about 2 kb in front of exon 1a. The 
Cdx-2 polymorphism is therefore positioned in a promoter region in front of exon 
1e and not of exon 1a. Yamamoto et al.11 determined that the region around the 
Cdx-2 polymorphism is important for expression of the VDR in intestinal cell lines. 
However, the constructs used in that study contained either only exon 1a or both 1e 
and 1a. The effect of the promoter of exon 1e on the expression of the VDR gene 
was not analysed separately in that study. Crofts et al.33 analysed the tissue-specifi c 
mRNA expression of multiple promoters of the VDR gene, and found exon 1a 
Genotype Case/total (%) Crude RR (95% CI) Adjusted RR (95% CI)* Adjusted RR (95% CI)**
GG 139/1139 (12.2) 1 1 1
GA 57/505 (11.3) 1.0 (0.7-1.3) 1.0 (0.7-1.3) 1.0 (0.7-1.3)
AA 2/73 (2.7) 0.2 (0.06-0.9) 0.2 (0.05-0.8) 0.2 (0.05-0.8)
Per copy of A-allele 0.8 (0.6-1.0) 0.8 (0.6-1.0) 0.7 (0.5-1.0)
p-value 0.05
*: RR was adjusted for age and weight
**: RR was adjusted for age, weight and femoral neck BMD
Table 4 Relative Risk of non-vertebral fracture in 1717 women according to the VDR Cdx-2 
genotype
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expressed in all tissues or cell lines in that study. Transcripts containing exon 1f and 
1e were found to be expressed in kidney and two tumour cells, but exon 1e was not 
analysed separately. Cdx-2 protein is an intestine-specifi c transcription factor which 
could regulate the expression of VDR in the same tissue, and infl uence calcium 
homeostasis consequently. Therefore, to confi rm whether 1e is a tissue-specifi cally 
expressed exon, further analysis of tissue specifi c expression of VDR (especially in 
intestinal cells) is necessary to elucidate the underlying molecular mechanism of the 
association study.
We introduced the ASM-PCR genotyping method for detecting the Cdx-2 
polymorphism in our study. The Cdx-2 polymorphism does not create a natural or 
artifi cial restriction site by itself. In the ASM-PCR method we designed four prim-
ers, to generate three potential PCR fragments, which have about 100 bp difference 
in size, so they can be readily distinguished by normal agarose gel electrophoresis. 
In previous allele-specifi c PCR systems34, detection of each allele required one pair 
of primers, so two PCR reactions had to be performed for two alleles. This made 
it diffi cult to distinguish whether the relevant allele is truly absent or whether this 
is due to PCR failure. In the ASM-PCR system described here, genotypes can be 
determined in a single PCR without any additional treatment before agarose gel 
electrophoresis. The reliability of the method was proven by reproducible results 
obtained by sequencing and by repeated genotyping.
Ecological study of A-allele frequency and hip fracture incidence
The frequency of the A-allele in this Dutch Caucasian population (19%) was 
much lower than that reported previously for the Japanese population (43%12). Our 
analysis of the ethnic panel also suggests large differences in A-allele frequency 
of this polymorphism ranging from 19% in North European Caucasian to 74% 
in African subjects. The A-allele frequency in the small sample (10) Japanese sub-
jects used for the ecological study (25%) differed from that found in the relatively 
large study (261 subjects) by Arai et al. (43%), which can be due to differences in 
power between these two samples. The previously reported hip fracture incidence 
rates13-25 appeared to be highest in subjects of northern European extraction and 
lowest in those of Asian and African origin. By comparing incidence rates with 
the frequency of the A-allele among these ethnic groups, we observed an apparent 
inverse relationship between the A-allele frequency and hip fracture rate (Figure 
3). However, results from ecological studies have to be interpreted with caution 
because we cannot rule out alternative explanations for the observed relation 
(“ecological fallacy”). Yet, the protective effect on fracture of the Cdx-2 A-allele 
suggested by this comparison is in line with the results from our epidemiological 
study in the Caucasian population of elderly subjects, especially for non-vertebral 
fracture in elderly women (table 4). In the previous Japanese study12, Arai reported 
a signifi cant association between A-allele and an increased BMD in postmenopausal 
women, and this would predict the A-allele to be associated with a decreased risk 
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of fracture as observed in our current study. Nevertheless, separate epidemiological 
studies of the relation between the VDR Cdx-2 polymorphism and fracture risk 
have to be performed in the different ethic groups, to determine if the protective 
effect of the A-allele on fracture risk is true and consistent.
Epidemiological study in Caucasians
In the population-based cohort study of Caucasian elderly subjects we per-
formed a large-scale association analysis to investigate the relationship between 
the Cdx-2 polymorphism and fracture risk. The genotype distribution followed the 
Hardy-Weinberg equilibrium, suggesting absence of selection bias. The associations 
between Cdx-2 genotype and fractures were observed and independent of age, 
gender, weight and BMD. We found a trend of decreasing frequency of fracture 
by increased number of A-alleles, suggesting an allele dose effect. Because we did 
not have suffi cient statistical power, in particular for the AA genotype group, the 
associations were borderline signifi cant, which makes  it diffi cult to distinguish an 
allele-dose effect from a recessive effect.
The association of the VDR Cdx-2 A-allele with reduced fracture risk is 
consistent with the results of functional studies of this polymorphism that were 
previously reported 11,12. In these studies the A-allele was found to bind more 
effi ciently the Cdx-2 protein and showed increased transcription level of the VDR 
gene. The Cdx-2 transcription factor plays an important role in intestine-specifi c 
gene transcription35,36. As a transcription factor, Cdx-2 could mediate the tran-
scription of the VDR gene via the special cis-element in the 1e promoter region of 
the VDR gene, thereby affecting the expression of the VDR in the intestine. Thus, 
the VDR content of intestinal cells of the GA and AA genotype may be higher 
than that of the GG genotype. The VDR is a transcription factor, and regulates the 
transcription of other down stream genes in many tissues. Interestingly, by using 
VDR- knockout mice the expression of two intestinal calcium channels, epithelial 
calcium channel (ECaC) and calcium transport protein type 1 (CaT1), was shown 
to be strongly vitamin D-dependent 37. The VDR mediates the effect of vitamin 
D. It can therefore be hypothesized that VDR Cdx-2 A-allele carriers could have 
higher intestinal calcium absorption, because of the elevated expression of these 
intestinal calcium channel proteins. Increased calcium absorption in turn could 
increase the BMD, and might, thus, contribute to a decreased fracture risk.
In order to investigate the potential mechanism underlying the association be-
tween fracture and the VDR Cdx-2 genotype, we further analysed the relationship 
between BMD and Cdx-2 genotype. However, in our study of Dutch Caucasian 
elderly we could not observe VDR Cdx-2 genotype to be associated with BMD, 
which is in contrast with the results reported for the Japanese population. Arai et al. 
found the VDR Cdx-2 A-allele to be associated with increased BMD at the lumbar 
spine in a Japanese population of postmenopausal women12. However, several 
environmental factors involved in bone metabolism, could be different between 
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the Japanese and the Dutch population, including dietary calcium intake and serum 
vitamin D level. For example, the dietary calcium intake of this Dutch study popu-
lation is higher than that of the Japanese population (average intake of 1117 vs. 600 
mg/day38). We therefore went on to analyse the infl uence of dietary Ca-intake on 
the relationship between Cdx-2 genotype and BMD in our study population.
In our study group increased dietary calcium intake was associated with in-
creased BMD, but the association was independent of VDR Cdx-2 genotype. Yet, 
when we analysed subjects with a dietary calcium intake of less than 600 mg/day 
(n=119) which is the similar to that of the Japanese population, we observed a trend 
towards the A-allele being associated with increased BMD but this failed to reach 
signifi cance, probably due to low statistical power. Thus, to draw conclusions in 
this respect it is necessary to analyse VDR Cdx-2 genotype in relation to BMD and 
fracture in a population with relatively low calcium intake and, for Caucasians, in 
an even larger sample size than that of the current study population.
In conclusion, in the present study we introduced a simple and specifi c genotyp-
ing method for association analysis of the Cdx-2 polymorphism in the 1e promoter 
region of VDR gene. In an ecological study we found a strong correlation between 
frequency of Cdx-2 A-allele and the incidence rates of hip fracture from different 
ethnic groups. In an epidemiological study we demonstrated that the A-allele has a 
protective effect on the risk of fracture in Caucasian elderly, especially for women. 
The association seems not to be directly explained by differences in BMD. Our 
results prompt the further association analysis of this polymorphism in relation to 
fracture risk and environmental factors, particularly in Asian and African popula-
tions.
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ABSTRACT
Introduction: Most genetic association studies for the VDR focused on the 
analysis of individual polymorphisms of the vitamin D receptor (VDR) gene and 
complex diseases, but with confl icting results. We therefore recently determined 
sequence variation across the major relevant parts of the VDR gene, including con-
struction of linkage disequilibrium (LD) blocks and identifi cation of “haplotype 
tagging” single nucleotide polymorphisms (htSNPs).
Materials and Methods: We here analyzed Fok I, Bsm I, Apa I, Taq I RFLPs 
and 14 htSNPs in relation to 937 clinical fractures and 335 vertebral fractures 
recorded in 6,148 elderly Caucasians over a follow-up period of 7.4 years.
Results: Haplotype alleles of the 5’ 1a/1e (block 2-hap1), 1b (block 3-hap3) 
promoter region and of the 3’ untranslated region (UTR, block 5-hap1) were associ-
ated with increased fracture risk of 15% (p = 0.06), 74% (p = 0.002) and 23% (p 
= 0.004), respectively. For the 16% of subjects who had risk genotypes at all three 
regions, risk increased 48% for clinical fractures (p=0.0002), independent of age, 
gender, height, weight, and BMD. The population attributable risk varied between 
1% - 12% for each LD block, and was 4% for the combined VDR risk genotypes.
Conclusions: This comprehensive candidate gene analysis demonstrates small 
but consistent effect of risk alleles of multiple VDR LD blocks on fracture risk.
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INTRODUCTION
Rare deleterious mutations in the VDR gene cause the well known 1,25-di-
ydroxyvitamin D resistant rickets (rickets type II), a rare monogenetic disease 
characterised by osteomalacia, alopecia, and increased 1,25-(OH)2 D3 levels. 
Some isolated, more common VDR single nucleotide polymorphisms (SNPs) 
have previously been associated with several complex diseases and traits, such as 
osteoporosis1-4. Yet, most studies have used polymorphisms at the 3’end or in exon 
2, but information on other polymorphism across the VDR gene is scarce. The 
relationship between disease and haplotype alleles across the VDR gene has not 
been systematically analyzed.
We recently sequenced 22 kb genomic VDR sequence, including the 3’untrans-
lated region (3’UTR), all coding exons and the 6 promoter exons 1f – 1c (chapter 2), 
and determined linkage disequilibrium (LD; pair-wise D’) between single nucleo-
tide polymorphisms (SNPs) across and fl anking the VDR gene in different ethnic 
populations, and also identifi ed haplotype tagging SNPs (htSNPs) of the VDR gene 
(chapter 3). In the current study, we use this information in a large-scale association 
analysis of htSNPs in relation to osteoporosis in a group of 6,148 Caucasian elderly 
men and women.
MATERIALS AND METHODS
Subjects
The association of VDR genotype with fracture risk was analyzed in the 
Rotterdam Study with 7,983 subjects5, of which 6,580 DNA were collected, and 
6,148 DNA samples were available and succeeded for genotyping of all SNPs. 
Genomic DNA was isolated from blood according to standard procedures.
Genotyping
We genotyped Fok I, Bsm I, Apa I, Taq I RFLPs and 14 haplotype tagging 
SNPs (htSNPs) in 6,148 Caucasian subjects from the Rotterdam Study with the 
high throughput TaqMan allelic discrimination assays. The detail of genotyping 
assays are provided in the Materials and Methods section of chapter 3. Five percent 
random samples were independently repeated to confi rm genotyping results. The 
disagreement rate varied from 0.3-1.2 % for fi ve htSNPs, while genotype results of 
all other htSNPs were completely consistent.
Epidemiological analysis
Genotype distribution was tested for Hardy-Weinberg equilibrium. 
Anthropometric measurements, body mass index (BMI, kg/m2), BMD (g/cm2; 
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dual energy X-ray absorptiometry, Lunar DPX-L densitometer; Madison, WI, USA) 
at the femoral neck and lumbar spine (L2-L4) and other variables were measured 
as described before6,7. BMD measurements were available for 5,027 (82% of the 
cohort with genotypes) subjects. Gender-specifi c T-scores were calculated from the 
femoral neck BMD using the NHANES reference population8 of Caucasian males 
and females aged 20 to 29 years. For assessing incidence of fracture, follow-up 
ended before 1st of January 2002 (mean follow-up period of 7.4 years ± 3.3 years). 
We defi ned “clinical fracture” as all fractures confi rmed by general practitioners 
or hospitals as described before4,7, and excluded head, foot, hand and pathologi-
cal, post-procedural, skull and face fractures. Presence of vertebral fracture was 
analyzed as described previously9,10.
We applied the Pearson χ2 test, and calculated the Relative Risk and 95% 
confi dence interval (RR, 95% CI) by logistic regression models, and calculated 
Hazard Ratio (HR, 95% CI) for incidence of clinical, wrist and hip fractures by 
Cox regression model. Both logistic regression and Cox models were adjusted for 
potential confounders, such as age, gender, height, weight, BMD and bone loss. The 
population attributable risk (PAR) was calculated for genetic and other markers for 
clinical fracture risk. All statistical analyses were done with the SPSS (11.0). The 
PAR was calculated as: P × (HR-1) / [P × (HR - 1) + 1], where P is the proportion 
of the study population that is exposed to the risk factor for fracture and HR is the 
Hazard Ratio for the risk factor.
RESULTS
The 15 tagging SNPs were in Hardy-Weinberg Equilibrium. Haplotype alleles 
in block 2, 3, and 5 had consistent, albeit not always signifi cant, effects on clinical 
fractures (Fig 1), with similar effects in men vs. women and for vertebral, hip and 
wrist fractures (data not shown). Subjects homozygous for the block 2 -hap1 allele, 
or homozygous for the block 3-hap3 allele, or carrying the block 5-hap1 allele had 
an increased risk for clinical fracture of 15% (p = 0.06), 74% (p = 0.002) and 23% 
(p = 0.004), respectively (Table 1). We went on to investigate the combined effect 
of promoter and 3’-UTR risk genotypes on fracture risk, and found that subjects 
carrying two or three risk genotypes across the VDR gene have 48% increased risk 
for clinical fracture (p = 0.0002).
Baseline characteristics of 6,148 Caucasian elderly of the Rotterdam Study are 
presented in Table 2. While age was borderline signifi cantly different by combined 
VDR genotype, all associations with fracture are independent of age, gender, 
height, weight, bone loss (data not shown). We did not observe BMD to infl uence 
the association of individual or combined blocks with fracture risk.
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The population attributable risk (PAR) of the VDR genetic markers (Table 
3) was 1% (frequency of subjects homozygous for the block 3-hap3 allele = 2%), 
and 2% (frequency of subjects homozygous for the block 2-hap1 = 21%) for the 
promoter region, but increased to 12% for the 3’ region (including the 3’-UTR, 
frequency of the block 5 hap1 allele-carriers = 68%). This was higher than the 1% 
PAR of the best validated genetic marker for osteoporosis so far (COL1A1 Sp111,12 
with a frequency of 3% of subjects homozygous for the Sp1 T-allele in our study 
population), and similar to PAR’s for smoking and use of a walking aid.
DISCUSSION
A major limitation so far of association studies using VDR polymorphisms 
in relation to complex disease endpoints has been the small number of analyzed 
polymorphisms and, thus, the lack of knowledge about infl uence of and relation 
between other polymorphisms in the gene. In addition, the lack of statistical
Figure 1 Hazard Ratio (HR) for clinical fracture by VDR genotypes based on haplotype alleles in fi ve haplotype 
blocks (1-5) and the Fok I RFLP. The HR point estimate and the surrounding 95% Confi dence Interval (95% 
CI) are represented with squares and lines. The HR for one copy versus no-copy of the test allele is represented 
with open squares and grey lines, the HR for two copies versus no-copy of the allele is represented with solid 
squares and black lines. The logarithmic HR is plotted for the frequent haplotype alleles (frequency > 3%) in all 
haplotype blocks (see Fig. 1b for Caucasians in Chapter 3) and the Fok I RFLP.
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Table 1 Incidence of fractures in 6,148 men and women from the Rotterdam Study by 
VDR genotype defi ned by haplotype allele status in blocks 2, 3 and 5
Total Genotype groups* p-value
Clinical fx. by individual LD blocks:
Block 2-hap1 Non-Homozygous Homozygous
Case/total (%) 906/6148 (14.7) 695/4844 (14.3) 211/1304 (16.2) 0.06
Crude HR (95% CI)  1 1.15 (0.97-1.35) 0.06
Block 3-hap3 Non-Homozygous Homozygous
Case/total (%) 876/6019 (14.6) 30/129 (23.3) 0.006
Crude HR (95% CI) 1 1.74 (1.22-2.50) 0.002
Block 5-hap1 Non-Carrier Carrier
Case/total (%) 256/1988 (12.9) 650/4160 (15.6) 0.004
Crude HR (95% CI)  1 1.23 (1.07-1.42) 0.004
Fractures by combined LD blocks:        Number of risk genotypes in blocks 2, 3 & 5# Trend p-value
Zero One Two or Three
Case/Total (%)
  - Clinical fx. 906/6148 (14.7) 207/1586 (13.1) 516/3560 (14.5) 183/1002 (18.3) 0.001
  - Vertebral fx.** 335/3055 (11.0) 78/814 (9.6) 186/1748 (10.6) 71/493 (14.4) 0.01
  - Hip fx. 261/6148 (4.2) 61/1586 (3.8) 144/3560 (4.0) 56/1002 (5.6) 0.05
  - Wrist fx. 257/6148 (4.2) 58/1586 (3.7) 145/3560 (4.1) 54/1002 (5.4) 0.04
Crude HR (95% CI)
  - Clinical fx. 1 1.14 (0.97-1.33) 1.48 (1.21-1.80) 0.0002
  - Vertebral fx. 1 1.12 (0.85-1.48) 1.59 (1.13-2.24) 0.01
  - Hip fx. 1 1.06 (0.79-1.43) 1.49 (1.04-2.14) 0.04
  - Wrist fx. 1 1.13 (0.83-1.53) 1.53 (1.06-2.21) 0.03
*: “Non-homozygous” includes the genotype groups without the risk allele and the heterozygotes. 
“Homozygous” is the genotype group homozygous for the risk allele. “Non-Carrier” is the genotype group 
without the risk allele, “Carrier” includes genotypes heterozygous and homozygous for the risk allele
#: “Zero” indicates the “Non-Homozygous”: genotype groups for blocks 2 and 3, and the “Non-Carrier” 
genotype groups for block 5
“One” indicates either the “Homozygous” genotype group for blocks 2 or 3 or the “Carrier” genotype group for 
block 5
“Two and three” indicates two or three of the risk genotype groups, i.e., the “Homozygous” genotype group for 
blocks 2 and 3, and “Carrier” for block 5
**: Vertebral fracture was diagnosed by the X-ray
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power of most studies to detect the expected subtle effects and misconceptions 
about how such small biological effects could be translated to the risk of disease 
has led to a number of controversies in the fi eld. In our recent studies we identifi ed 
62 polymorphisms in potentially functional areas of the VDR gene, characterised 
the LD structure and identifi ed htSNPs, and used 15 tagging SNPs to represent 
Table 2 Characteristics of the study population
Characteristic* a. Total Cohort b. by combined promoter and 3’-UTR VDR genotype# p-value
0 1 2 & 3
Number (%) 6148 1586 (25.8) 3560 (57.9) 1002 (16.3)
Female (%) 3649 (59.4) 932 (58.8) 2102 (59.0) 612 (61.1) 0.49
Age (years) 69.5 ± 9.1 69.1 ± 9.1 69.5 ± 9.1 70.0 ± 9.4 0.03
Height (cm) 166.8 ± 9.5 167.0 ± 9.5 166.7 ± 9.4 166.6 ± 9.8 0.16
Weight (kg) 73.1 ± 12.0 73.3 ± 12.2 73.1 ± 12.0 72.9 ± 11.7 0.55
FN BMD (g/cm2) 0.867 ± 0.142 0.872 ± 0.143 0.864 ± 0.142 0.868 ± 0.145 0.40
LS BMD (g/cm2) 1.090 ± 0.198 1.098 ± 0.197 1.089 ± 0.198 1.082 ± 0.199 0.25
FN BMD change (10-3 g/cm2/year) -2.1 ± 9.4 -1.6 ± 8.6 -1.9 ± 9.5 -3.2 ± 10.0 0.02
*: The following adjustments were applied:
- Age: adjusted for gender
- Height: adjusted for age and gender
- Weight: adjusted for age, gender, and body height
- BMD: subset n = 5027, adjusted for age, gender, height, and weight
- BMD change: subset n = 2391, 7.4 years follow-up, adjusted for age, gender, and clinical fracture
#: Defi nition of the combined genotype is shown in Table 1.
Table 3 Population attributable risk of independent risk factors for clinical fracture in 6148 men 
and women from the Rotterdam Study
Frequency (%) 
at baseline HR (95% CI)*
PAR
(%, 95% CI)*
Age > 75 years 32 2.3 (2.1-2.6) 29 (25-34)
T-score< -2.5 16 2.7 (2.3-3.1) 21 (17-25)
Current Smoking 23 1.3 (1.1-1.5) 6 (2-10)
Use of walking aid 12 1.3 (1.1-1.6) 3 (1-4)
Genetic Markers
     ColIA1 Sp1 T-allele homozygotes 3 1.4 (1.0-1.9) 1 (0-3)
     VDR risk genotypes
         Block 2 hap 1 21 1.1 (0.9-1.3) 2 (0-5)
         Block 3 hap 3 2 1.6 (1.2-2.4) 1 (0-3)
         Block 5 hap 1 68 1.2 (1.1-1.4) 12 (4-21)
         Carrier of two or three risk genotypes 16 1.3 (1.1-1.5) 4 (2-6)
* HR = Hazard Ratio, 95% CI = 95% confi dence Interval; PAR = population attributable risk; all HR and PARs 
were adjusted for age and gender.
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the common haplotypes for fi ve of LD blocks in potentially functional areas of the 
VDR gene. We here examined the association between those VDR haplotypes and 
fracture risk in a large-scale population.
A large association study with the htSNPs in a population-based cohort (6,148 
elderly subjects) identifi ed haplotype alleles in 3 LD blocks that confer risk for frac-
ture, and we present evidence for intragenic additive effects. These relationships 
were found in both men and women and for different types of fractures (including 
vertebral, hip and wrist fractures), and were independent of age, height, weight, 
BMD and BMD change. In our study population (15% prevalence of fracture and 
6,148 subjects), we have 80% statistical power to detect a 25% increased fracture risk 
for a polymorphism/haplotype with a frequency > 10%. We analyzed haplotypes 
instead of individual SNPs, which limited the number of tests. For block 2 and 5, we 
did not adjust the signifi cant p-value by the conservative Bonferroni correction for 
multiple comparisons, because in our previous studies3,4 we observed two fracture 
risk alleles from these blocks in a subset of our current study, and we confi rmed 
the association in this study, but now for the haplotype alleles encompassing the 
previously observed risk alleles. However, we used p = 0.005 (0.05/11), based on 
a Bonferroni correction for analyzes in the other three blocks and Fok I, only the 
association between block 3-hap 3 and fracture risk remains border line signifi cant 
(p = 0.002). Thus, we cannot reject the possibility that some of the associations we 
observed are false positives, even in this very large population.
We previously reported haplotype 1 of the 3’-end variants, defi ned by only 
Bsm-Apa-Taq RFLPs, to be associated with increased fracture risk in 1004 post-
menopausal women3, which is a subgroup of the current study population. We here 
confi rm this association between Bsm-Apa-Taq haplotype 1 and fracture risk in the 
complete study population (p = 0.03, data not shown). Yet, in our more detailed 
haplotype analysis based on more SNPs we defi ned a sub-type of the Bsm-Apa-Taq 
haplotype 1, i.e., block 5-hap1 (40.2%, Fig. 1b for Caucasians in chapter 3), which 
shows a stronger and more signifi cant association with fracture risk. These subtle 
differences in exact defi nition of the risk allele could contribute to heterogeneity 
in association results observed for different studies. While we here focussed on 
the more common (haplotype) alleles in the population, we cannot exclude (many) 
less frequent risk alleles to contribute to VDR genotype-dependent fracture risk. 
Further studies will be necessary to assess their contribution. We show that ef-
fects are modest (about 20-70% increased risk) as can be expected for common 
variants in relation to complex disease. The VDR risk haplotype alleles therefore 
have a modest infl uence on individual risk of fracture but make a substantial con-
tribution at the population level (PAR = 4 – 12%) in comparison to other genetic 
markers we previously identifi ed in this population, such as COL1A1 Sp112 and 
ESR1 Pvu II and Xba I polymorphisms13. The most prominent genetic effect on 
fracture risk according to the PAR analyzes is the block 5-hap1 risk allele. Many 
previous confl icting association studies on VDR and BMD as well as fracture, 
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analyzed usually (very) small study populations and used the Bsm I, Apa I or Taq I 
polymorphisms in this block, but mostly analyzed separately. We therefore suppose 
that this controversy can partly be explained by a lack of statistical power as a 
result of small sample size, and failure to use haplotypes. In addition, population 
stratifi cation, such as mixed ethnic groups with different allele frequencies, popula-
tion-specifi c differences of some environmental factors, such as (dietary) calcium 
intake, (dietary) vitamin D intake, sunlight-exposure, and other characteristics of 
the study population pertinent to bone metabolism and fracture risk could result 
in heterogeneity of association observed across different study populations. Based 
on a meta-analysis of published data on the relationship between the VDR Bsm 
I RFLP and fracture risk we have some evidence that this could be an important 
factor (chapter 5.2). We have data on serum vitamin D and dietary calcium intake 
in a subset of our study population (n=1,312 and 4,747, respectively), but we don’t 
have reliable dietary vitamin D intake data. We note that our study population has a 
very high dietary calcium intake (1,120 mg/day). For the VDR-fracture relationship 
we repeated the analyses but now stratifi ed by the median, tertiles and quartiles of 
vitamin D level or dietary calcium intake. However, the association did not differ 
in these strata, and no interaction was observed (data not shown).
VDR as a transcription factor infl uences the expression of down-stream genes, 
such as TRPV5, TRPV6, and Calbindin, which are involved in calcium absorption, 
which could therefore impact BMD and thus fracture risk. However, we found that 
the association between VDR genotype and fracture risk was BMD-independent, 
which suggests other mechanisms (such as bone micro-architecture, bone quality 
and bone strength) to determine fracture risk. Alternatively, we can hypothesize that 
the bone tissue of the subjects carrying a risk allele is thought to have a somewhat 
lower sensitivity to vitamin D since the expression of VDR is lower. Therefore, 
the osteoblast activity could be lower, and the bone formation rate (in the bone 
remodelling balance) could be decreased. The age-related expansion of the outer 
diameter of long bone is associated with a marked increment of bone strength. We 
recently have observed that the fracture risk haplotype alleles were also associated 
with decreased bone size (chapter 6) in the same population. This genotype-related 
bone geometry difference refl ects that the bone gain resulting in outer bone di-
ameters expanding is smaller than the bone loss resulting in inner bone diameter 
expanding. This bone geometry difference leads to a decrease in bone strength for 
the risk allele carriers, possibly increasing the fracture risk.
In conclusion, basing on our recent sequencing and LD analysis of the VDR 
gene, we demonstrated polymorphisms in the 5’ promoter region and the 3’-UTR 
of the VDR gene to contribute to fracture risk in a large population. This “whole 
gene” analysis demonstrates intragenic interaction of VDR polymorphisms in the 
promoter region and in the 3’UTR to signifi cantly contribute to fracture risk. Our 
fi nding suggests these risk alleles to encode a “less-sensitive” VDR, probably by 
encoding lower numbers of VDRs on target cells.
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ABSTRACT
Introduction: Fracture is the major clinical outcome of osteoporosis. The 
vitamin D receptor (VDR) gene is thought to be a candidate gene for osteoporosis. 
Many genetic studies have suggested an association of VDR polymorphisms and 
osteoporosis, but evidence remains confl icting.
Materials and Methods: We searched published studies from 1996 to September 
2005 through PubMed, and evaluated the genetic effect of Bsm I polymorphism of 
VDR on fracture risk in a meta-analysis. Thirteen studies with a total of 20 eligible 
comparisons (1,632 fracture cases and 5,203 controls) were analyzed with fi xed and 
random effects models.
Results: No evidence of relationship between VDR Bsm I polymorphism and 
fracture risk was observed with any genetic model. The odds ratio (95% confi dence 
interval) of b-allele versus B-allele was 0.98 (0.86 – 1.12) with random effects cal-
culations. There was signifi cant between-study heterogeneity. Small studies did not 
differ signifi cantly from larger ones.
Conclusions: No relationship of VDR Bsm I polymorphism and fracture risk 
was found in the meta-analysis of published data.
Keywords: VDR; Bsm I genotype; fracture; meta-anlaysis
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INTRODUCTION
Osteoporosis is a common complex genetic disease, characterized by decreased 
bone mineral density (BMD), increased bone fragility and fracture risk. Vitamin D 
plays a crucial role in calcium and phosphate homeostasis and skeletal metabolism. 
The vitamin D receptor gene (VDR) mediates the action of its ligand, and results 
in normal bone mineralization and remodeling, therefore VDR has been con-
sidered an important candidate gene of osteoporosis. Since 1994 when Morrison 
et al.1 reported the relationship between VDR polymorphisms and BMD, about 
a hundred subsequent studies have been carried out on the association between 
VDR polymorphisms and diverse outcomes of osteoporosis, including BMD and 
fracture. At least three systematic reviews2-4 have tried to summarize association 
studies between VDR polymorphisms and BMD. However, analyzing the associa-
tion between VDR polymorphisms and BMD may be not suffi cient to estimate 
the role of VDR in osteoporosis. Bone fragility also depends on the morphology, 
micro-architecture, and remodeling of bone. Some studies5,6 also showed that the 
relationship of VDR polymorphisms and fracture risk was independent of BMD.
Fracture is a relevant clinical outcome to assess in genetic studies of osteopo-
rosis. Polymorphisms in the 3’-end of the VDR gene, especially Bsm I and Taq I 
RFLPs, have most commonly been used in association studies to date. These are 
highly linked to polymorphisms in 3’-UTR, which is thought to be the potential 
functional region involving the stability of VDR mRNA. Several association studies 
have shown confl icting results of the relationship between VDR polymorphisms 
and fracture risk. The reason of the controversy could be due to small study size, 
diverse study design and different populations. So far, no meta-analysis has sys-
tematically reviewed the published data of on VDR polymorphisms and the risk 
of osteoporotic fracture. In the current study, we performed a meta-analysis of all 
studies relating Bsm I or Taq I polymorphisms of VDR gene with fracture risk.
MATERIALS AND METHODS
Identifi cation of studies
We searched publications on PubMed (1996 to September 2005) with the com-
bination of keywords: VDR AND (polymorphism OR genotype) AND fracture. 
References from retrieved publications were checked for additional studies. This 
search tracked 40 studies, of which 18 studies (all in English) addressed the as-
sociation between fractures and VDR genotype. Others were reviews (n = 4), or 
association and meta-analysis studies of VDR polymorphisms with other outcomes 
such as BMD, bone turnover, muscle strength, hormone therapy and vitamin D 
supplementation (n = 18), but no original fracture data per VDR genotype were 
available. We also reviewed 108 references from three meta-analysis studies2-4 of 
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VDR polymorphisms and BMD, including a meta-analysis on other bone phe-
notypes (Gong et al.3). These 108 references included 59 published original as-
sociation studies, and 49 abstracts. Five references contained fracture data by VDR 
genotypes, but they were already included in the 18 studies of fractures.
Of the 18 potentially eligible studies, further scrutiny suggested that 14 could 
be included in the meta-analysis. This included eight studies for Bsm I restric-
tion fragment length polymorphisms (RFLPs)7-14, one for Taq I RFLP15, two for 
Bsm-Apa-Taq (B-A-T) haplotype5,16, and three studies investigated more than one 
polymorphisms (Fok I, Bsm I, Apa I, Taq I or B-A-T haplotype) of the VDR for 
fracture risk17-19. Conversely, we excluded from the meta-analysis two studies that 
investigated the Cdx-26 and Fok I20 polymorphisms in relation to fracture risk, 
respectively, and two ecological studies21,22 of Bsm I and Taq I. Of the 14 remain-
ing reports, two reports presented overlapping data from the same population5,16, 
and we retained for the meta-analysis only the study with the most extensive data. 
Thus, 13 studies were fi nally included in our meta-analysis (Table 1). The study of 
Ramalho et al.9,14 had two control groups, which we combined in one.
Data Extraction
Data were extracted according to agreement of two reviewers (Y. Fang and F. 
Rivadeneira), and the third investigator (A. Uitterlinden) arbitrated the disagree-
ment by discussion and consensus. We extracted information on authors, published 
year, country of origin, study design, mean or range of age, gender, site of fracture 
(e.g. vertebral, non-vertebral, hip, forearm, low-energy and any fracture), number of 
cases or controls and frequency of B-allele in cases, controls, and the whole popula-
tion for each study (Table 1). We also examined whether the genotype distributions 
of study populations followed Hardy-Weinberg equilibrium (HWE) proportions 
using a χ2-test23.
Data Analysis
Three polymorphisms, Bsm I, Apa I and Taq I, have been commonly analyzed 
in published association studies, and Bsm I is most consistently reported. They 
are highly linked to each other with pair-wise D’s from 0.95 to 0.98, according to 
our recent study of 6,500 subjects24. With a direct haplotyping test, the “B”-allele 
of Bsm I has been shown to be 99% linked to the “t”-allele of Taq I, but only 
41% linked to the “A”-allele of Apa I in a large-scale Caucasian population25. We 
therefore considered Bsm I and Taq I as interchangeable genetic markers of the 
VDR gene (at least in the Caucasian population). In the current study, we focused 
on analyzing the relationship of Bsm I and fracture. When Bsm I genotype was 
absent, Taq I genotype was used to infer the Bsm I genotype.
For the meta-analyses we used the Cochrane Review Manager (RevMan 
Version4.2 program, the Cochrane Collaboration, Oxford, UK). The association 
between the Bsm I polymorphism and fracture was assessed under the following 
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genetic models, which were treated as a dichotomous variable: (a) b-allele versus B-
allele for the allele level comparison; (b) bb versus Bb + BB for recessive model of 
b-allele, (c) bb + Bb versus BB for dominant model of b-allele, and (d) bb versus BB 
for extreme genotypes. The study of Ensrud et al. only presented fracture data by b 
or B alleles, but not by genotype in the original report, hence it was only included in 
the analysis of model (a). We calculated fracture type-specifi c and overall odds ratios 
(ORs) and 95% confi dence intervals (95% CIs) for all pair-wise comparisons. The 
p-value cutoff level, adjusted for multiple comparison, was considered signifi cant 
when lower than 0.0125 (Bonferroni corrected: p = 0.05/4, to consider pair-wise 
comparisons in the four genetic models).
Assessment of heterogeneity and bias diagnostics
Between-study heterogeneity for difference of fracture risk was tested using 
the χ2 – distributed Q statistic (with p-value considered signifi cant at a level of 
0.1026), and the inconsistency index I2 (suggesting inconsistency among the studies’ 
results with values of 50%, or higher and large heterogeneity for values of 75% or 
higher27 estimated by the RevMan program. ORs (95% CIs) were estimated by both 
fi xed effect and random effects models. Fixed effects assume that the genetic factor 
shows a similar effect on fracture across all investigated study groups, and the 
observed variation among study groups is caused by chance alone. Random effects 
assume that there may be substantial diversity among different study groups, and 
assesses both within-study sampling error and between-study variance. When there 
is no heterogeneity between study groups, the two models are similar; otherwise, 
random effects model usually give wider CIs than the fi xed effect model. Random 
effects are preferable in the presence of signifi cant between-study heterogeneity. In 
order to clarify the source of potential heterogeneity, we also performed subgroup 
analyses by type of fracture (vertebral, hip, any fractures), type of study (cohort and 
case-control studies) design and gender.
We also evaluated whether smaller studies gave different results from larger 
studies and using: the Begg-Mazumdar test28, which is based on the Kendall’s tau 
rank correlation coeffi cient between the natural logarithm of OR [ln(OR)] and 
its variance; and its regression equivalent29, which is a linear regression of ln(OR) 
on its standard error (SE). We also performed recursive cumulative meta-analysis 
to evaluate whether the summary odds ratio changed in the same direction over 
time and appraised whether the fi rst published study gave different results from 
subsequent ones30-32.
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RESULTS
Eligible data
The 13 eligible studies included 1,632 fracture cases and 5,203 controls with 
genotype data (Table 1). Some studies considered separate data for different types 
of fractures or different gender, thus there were 20 comparisons available. Two 
comparisons from the Feskanich et al.10 study (for hip and forearm fractures, re-
spectively) have no overlap in case and control groups, since fi rst-reported fractures 
were defi ned as cases and independent controls for hip and forearm fractures were 
selected. However, there is some overlap in the control groups of Ensrud et al.17 
who studied different type of fractures, because control groups were selected from 
the same pool of a cohort. Two comparisons (vertebral vs. non-vertebral) from the 
Garnero et al.14 study used the same cohort, and cases could suffer more than two 
times (or types) of a fracture. We cannot clarify the exact extent of overlap accord-
ing to the original data of these studies14,17. The mean age for each study was 51 – 89 
years. Eleven of the comparisons originated from cohort studies and nine from 
case-control designs, and sample size per comparison varied from 49 to 1,002. The 
frequency of the B-allele in the entire population of cohort studies or control group 
of case-control studies ranged from 34 – 52%, and we observed highly signifi cant 
differences across all study groups (p < 0.001). All populations were of Caucasian 
descent and most of them were peri- or postmenopausal women. Three studies11,18,19 
contained separate data for men (mean age from 51 – 67 years), and one study9,14 did 
not show separate data by gender. The genotype frequencies of all studies did not 
deviate signifi cantly from HWE proportions.
Data synthesis-main analysis
We fi rst compared the b-allele frequency difference in fracture cases and controls 
(Fig. 1). There was signifi cant between-study heterogeneity when all comparisons 
were considered (Q statistic χ2-test p = 0.003, I2 = 54%). No relationship between 
the b-allele and different types of fracture was observed in any analyses. The 
summary OR (95%CI) was 0.98 (0.86-1.12) for random effects model. Summary 
ORs (95%CI) of fi xed and random effects models with various genetic models are 
shown in Table 2. The study of Ensrud et al., which only presented fracture data 
by b-allele versus B-allele, but not by Bsm I genotype from the original study, was 
only included in the analysis by allele. There was no evidence for the effect of Bsm 
I polymorphism of the VDR gene and fracture risk in any of the genetic models.
Subgroup analyses
When we stratifi ed fracture as vertebral, hip and any type of fractures [non-
vertebral fracture data from Garnero et al.14 was included in the analysis of any 
fracture] according to the original report, no evidence of heterogeneity was found 
for vertebral fracture, but modest heterogeneity still remained in hip and any type 
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of fracture sub-group analyses.
When we stratifi ed the analyses by type of fracture in women, similar results 
were observed in each sub-group (Table 3) as compared to the results presented 
in Figure 1. No signifi cant heterogeneity was found in men, which only contained 
three study groups. We also stratifi ed the meta-analysis by cohort and case-control 
designs. Eleven comparisons containing 4,857 subjects (with 932 fractures) were 
derived from cohort association studies, and signifi cant heterogeneity was observed 
among those studies (p = 0.005, I2 = 62%). Nine comparisons containing 1,978 
subjects (with 700 fracture cases) were derived from case-control studies, and some 
Figure 1 Meta-analysis of relationship between the b-allele of the VDR Bsm RFLP and fracture 
risk stratifi ed by type of fractures. Point estimates and 95% confi dence intervals (CI) are shown for 
the odds ratio (OR) in each study group. Summary estimates of OR and their 95% CI (diamonds), 
test for heterogeneity and effect are given by random effects models by vertebral, hip and any 
fractures, as well as for the overall database.
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heterogeneity was found also among those studies (p = 0.09, I2 = 44%). 
Other bias and heterogeneity diagnostics
In our meta-analysis of allele model, there is no evidence of signifi cant differ-
ences in the genetic effects of large versus small studies based on tests of rank cor-
relation (p = 0.78) and regression on the SE (p = 0.86). Two studies, Uitterlinden et 
al. and Garnero et al. showed statistically signifi cant effects on their own, but these 
were in the opposite direction (Figure 1). We then carried out a cumulative meta-
analysis (Figure 2). Starting with the fi rst study 7, we added stepwise the subsequent 
studies, and observed that no cumulative step showed statistical signifi cance until 
the end of the meta-analyses and the summary effect changes were rather small at 
all steps.
Table 2 Summary odds and 95% confi dence intervals for various comparisons
Contrast Study groups Sample size Summary OR (95% CI) Heterogeneity
(n) (n) Fixed effect Random effects p-value I2 (%)
b vs. B (alleles) 18 13670 1.01 (0.93-1.10) 0.98 (0.86-1.12) 0.003 54
bb vs. Bb + BB* 15 4761 0.98 (0.84- 1.14) 0.97 (0.79-1.20) 0.03 45
bb + Bb vs. BB* 15 4761 0.90 (0.75-1.08) 0.86 (0.66-1.11) 0.03 45
bb vs. BB* 15 1934 0.91 (0.74-1.11) 0.87 (0.62-1.21) 0.003 57
*: The data of Ensrud et al. was not included (no fracture data by Bsm I genotype were available). 
Table 3 Subgroup analyses for “b” vs. “B” comparison
Strata Comparisons Sample size Summary OR (95% CI) Heterogeneity
(n) (n) Fixed effect Random effects p-value I2 (%)
Type of fracture for women*
  Vertebral 4 2720 1.07 (0.88-1.31) 1.07 (0.88-1.31) 0.99 0
  Hip 5 4515 0.97 (0.85- 1.12) 0.94 (0.72-1.22) 0.02 65
  Any 7 6111 1.04 (0.92-1.19) 1.01 (0.78-1.32) 0.002 72
  Summary 16 13346 1.04 (0.95-1.13) 1.00 (0.88-1.15) 0.005 55
All fracture for men* 3 820 0.92 (0.66-1.30) 0.92 (0.58-1.44) 0.18 41
Type of study
  Cohort 11 9714 1.04 (0.94-1.16) 1.02 (0.85-1.22) 0.005 62
  Case-contol 9 3956 0.96 (0.84-1.10) 0.94 (0.78-1.13) 0.09 44
In the analysis by gender stratifi cation, Ramalho et al. was excluded (data could not be separated by gender)
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DISCUSSION
Association studies are a powerful tool to identify genetic factors conferring 
susceptibility to common disorders like osteoporosis33. Yet, most reported asso-
ciation studies are underpowered to detect the modest genetic effects underlying 
the genetic susceptibility to develop common diseases34. This has resulted in the 
continuous reporting of inconsistent fi ndings in the literature that could be due 
to false positive studies, false negative studies or true variability in associations 
among different populations34. A systematic meta-analytic approach may permit 
the estimation of population-wide effects and the identifi cation of sources of vari-
ability of genetic risk factors in human disease 31. In the current study, we combined 
the data of 6,835 subjects from published studies to evaluate the genetic association 
of the most commonly used polymorphism of the VDR gene, Bsm I, to fracture 
Figure 2 Cumulative meta-analysis. By each study, the cumulative odds ratio point estimates and 
the surrounding 95% CI for fracture by “b” allele of Bsm I of the VDR gene are represented with 
squares and lines. The cumulative estimate is calculated with random effects model.
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risk. The results of our meta-analyses show there is no evidence supporting an 
association between the VDR Bsm I polymorphism and the risk of osteoporotic 
fracture. Moreover, the tight CIs exclude a 15% increase or decrease in the relative 
risk of fractures.
We have found considerable between-study heterogeneity which is highlighted 
by the fact that two studies have provided signifi cant associations in the opposite 
direction35. The defi nition of osteoporotic fracture is diffi cult to standardize and 
the defi nition can be infl uenced in several different ways depending on diagnosis 
(clinical versus X-ray confi rmed), type of trauma (low-energy versus high-impact), 
history of fracture (prevalent versus incident) and location (vertebral, non-vertebral, 
fragility, hip or wrist). However, most studies included in our meta-analysis did 
not provide suffi cient information to address all those issues. When we stratifi ed 
our meta-analyses by type of fracture, we observed that heterogeneity was more 
prominent for the studies of hip and any fractures, while data on vertebral fracture 
were more consistent across studies.
Another potential source of heterogeneity is differences in study design. 
However, there was no strong evidence that cohort studies had less or more 
heterogeneity than case-control studies. Also, we did not fi nd strong evidence to 
conclude that gender is a source of heterogeneity in our meta-analysis: there was no 
observed association in either gender. Nevertheless, the number of studies in men 
was limited. Other possible sources of heterogeneity are differences in the study 
population characteristics including differences in age, ethnicity, serum vitamin D 
level, Ca++-intake, smoking and physical activity among others.
Thakkinstrian et al.4 had indicated that differences in the study setting (popula-
tion-based and non-population-based) might be an important source of heterogene-
ity affecting the strength of the detected association between Bsm I polymorphism 
and BMD. However, full dissection of heterogeneity would require both large-scale 
evidence and detailed data on individual subjects. The GENOMOS consortium36, 
the largest case collection yet reported for osteoporosis, is an example of a col-
laborative effort where such reliable answers in this fi eld may be pursued37.
Genetic heterogeneity in the form of differences in allele frequencies of analyzed 
polymorphisms and the presence of admixture within the study populations could 
also be a source of heterogeneity infl uencing the conclusion of our meta-analysis. 
Another potential explanation for differences in allele frequency is genotyping er-
ror, caused by one SNP present in the reverse primer sequence of Bsm I genotyping 
PCR38. This could have contributed to the modest variation in allele frequencies we 
observed across studies.
The VDR gene is a large and complex gene extending a size of 105 kilo base 
pairs, encompassing more than 120 single nucleotide polymorphisms (SNPs) 
according to Celera and NCBI databases, and seven haplotype blocks across the 
gene have been determined24. Thus the Bsm I polymorphism might not completely 
represent the genetic effect of the whole VDR gene on fracture risk. The genetic 
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effect of “whole gene” haplotype tagging SNPs on fracture need to be carried out 
in large-scale populations24 or consortia36.
Previous meta-analyses have focused on analyzing the genetic effect of the 
Bsm I polymorphism on BMD. Three studies2-4 have summarized the relation-
ship, but confl icting conclusions were drawn and some questions have remained 
from those analyses. Cooper et al.2 reported that the BB genotype of the Bsm I 
was associated with low BMD only at the hip, and that younger women with BB 
genotype had borderline signifi cant lower BMD compared to women with the bb 
genotype. Nevertheless, this effect disappeared after excluding the data with clearly 
documented genotyping error1. That study only analyzed one pair-wise compari-
son, BB versus bb, but did not involve other genetic models. A model of comparing 
extreme genotypes perhaps has insuffi cient statistical power to estimate a small 
genetic effect in relatively small study populations. In addition, different ethnic 
groups were mixed in the analysis, and frequencies of the B-allele and BB genotype 
differed across studies (1.4 – 31.3% of BB). Furthermore, three included small stud-
ies of northern Europe Caucasian population had low BB genotype frequencies 
(7.1-12.2%), while, in our current meta-analysis the frequencies of the BB genotype 
from the same region have been between 18.0 – 26.1% across studies7,13,18.
The meta-analysis of Gong et al.3 summarized 75 studies on the association 
between Bsm I, Apa I, Taq I and Fok I RFLPs of VDR gene with BMD as well as 
other related skeletal phenotypes. The authors grouped all studies as “positive” and 
“non-positive”, where the “positive” study was defi ned as studies with association 
between either one of the b, a, T, or F alleles and increased BMD or other pheno-
types (see below). This approach has some drawbacks. It simply counts the “positive 
rate”, but it ignores the study size and magnitude of the genotype effect on BMD. 
Furthermore, the inclusion of all polymorphisms cannot be justifi ed based on cur-
rent knowledge. According to our recent data24, Fok I RFLP is clearly not linked to 
Bsm I, Apa I and Taq I polymorphisms. The latter three polymorphisms are in the 
same haplotype block of the VDR gene. Bsm I and Taq I are highly linked to each 
other, but Apa I has relatively low linkage to the other two. Therefore, association 
studies of Bsm I and Taq I can be merged as one genotype group, but studies on 
Fok I and Apa I polymorphisms should be analyzed as different genotype groups, 
or employ Bsm-Apa-Taq haplotype in the association analyses. Some phenotypes in 
the study of Gong et al. were not always in line with BMD, such as, bone geometry 
variables, response to vitamin D treatment, bone turnover and fracture, and they 
should not be considered as the same phenotype group as BMD.
In another study, Thankkinstian et al.4 observed that the BB genotype had lower 
spine BMD than Bb + bb genotypes but only in studies of postmenopausal women 
with a big range of B-allele frequency (29 – 53%). Moreover, there was considerable 
heterogeneity in this analysis. So far, almost one hundred association studies and 
meta-analyses, which adjusted for or stratifi ed by age, gender, menopausal status, 
different measured instruments and different locations, show that Bsm I genotype 
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is not consistently associated with BMD, and more recent studies39,40 on genome-
wide linkage scans of BMD have not found the VDR locus (12q12) linked to BMD. 
Alltogether, this indicates that there is also no clear evidence of a genetic effect of 
Bsm I RFLP on BMD either.
In the current meta-analysis, we only included published English-language as-
sociation studies of Bsm I and fracture. Perhaps we missed some studies, especially 
with negative results, or studies on BMD but that did not report on fracture data. 
Missing studies with negative results, however, would probably not change our 
conclusions. Such data would most likely reinforce our observations about the lack 
of an effect.
In conclusion, no evidence of a relationship between VDR Bsm I polymorphism 
and fracture risk was observed in the meta-analysis of published data. Further 
research should examine the effect of other haplotype tagging SNPs in large-scale 
populations or consortia.
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ABSTRACT
Introduction: Adult stature is a complex genetic trait. We studied whether vita-
min D receptor (VDR) gene variants contribute to the genetic variation in height. 
Recently, we resolved the linkage disequilibrium (LD) structure of the VDR gene, 
and identifi ed promoter and 3’-UTR haplotype alleles in LD blocks 2, 3 and 5 
respectively that infl uence VDR expression.
Materials and Methods: We studied VDR haplotype alleles and body height 
in two independent populations (total n = 7,198). In a subsequent meta-analysis 
(including 11,378 subjects from 19 studies and our current data) we evaluated the 
effect of a polymorphism in block 5 (Bsm I) which was studied previously.
Results: Haplotypes of LD block 3 and block 5 were associated with body 
height differences with evidence for additive effects in the Rotterdam study (p = 
0.00002) and the LASA study (p = 0.001). Height differences between the extreme 
genotypes were 1.4 cm and 2.7 cm, respectively. The relationship was independent 
of age, gender, presence of vertebral fractures and age-related height loss. In the 
Rotterdam population we found the combined genotype to be associated with 
decreased vertebral area (p = 0.03), and femoral narrow neck width (p = 0.002). In 
the meta-analysis, subjects with the “BB” genotype were 0.6 cm (95% CI, 0.5 – 1.4 
cm) taller than those with “bb” genotype (p = 0.006).
Conclusions: Alleles of the VDR gene are associated with differences in body 
height, as evidenced by our study and by a meta-analysis. The underlying mecha-
nism of the association might involve slightly lower copy numbers of VDR protein 
in cells important for determining bone size.
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INTRODUCTION
Human adult stature is one of the most heritable human traits (heritability 
up to 90%), as demonstrated in twin studies1,2 and family studies3,4, while also 
ethnicity infl uences body height. On the other hand, environmental changes (e.g., 
improved nutrition) have progressively increased height (as a secular trend) during 
the 20th century. Adult stature has been reported to be inversely associated with 
a number of common complex genetic diseases, such as cardiovascular diseases, 
diabetes, pulmonary diseases, cancer and osteoporosis, as well as disease-specifi c 
mortalities in different populations5-11. Short stature also seems to share some risk 
factors with these diseases, such as serum low density lipoprotein cholesterol level, 
blood pressure and socio-economic position12,13. The genetic contribution of the 
relationship between height and those risk factors has been described previously. In 
a case-control study14, students with a paternal history of myocardial infarction had 
lower body height as compared to age- and gender- matched controls. In addition, 
a family study12 showed familial clustering and negative correlation between height 
and low density lipoprotein cholesterol and triglycerides. Therefore, stature appears 
to be an interesting model complex trait because the understanding of the underly-
ing genetic causes of height determination, may provide insight into mechanisms 
of other related diseases.
The vitamin D endocrine system has been shown to have pleiotropic effects on 
a number of endocrine pathways, e.g., related to immune-modulation, regulation 
of cell proliferation and differentiation, and on skeletal metabolism15. Long term 
vitamin D defi ciency results in rickets in children and osteomalacia in adults. The 
vitamin D receptor (VDR) gene is a central regulator in this endocrine system and 
therefore, it is an interesting candidate gene for genetic studies of stature. Mutations 
in the VDR gene, such as in the DNA binding domain16, the ligand-bind domain17, 
or in splice sites18, cause hereditary vitamin D-resistant rickets (HVDRR). Like other 
rickets, HVDRR is commonly associated with clinical manifestations of impaired 
longitudinal growth resulting in short stature and/or regular bone deformities. 
Adult height was found to be correlated with severeness in 13 HVDRR patients19, 
while growth retardation nearly invariably accompanies vitamin D resistant rickets20. 
Also a deletion of the DNA binding domain VDR null mice show growth retar-
dation, in addition to rickets, secondary hyperparathyroidism and alopecia21. The 
phenotype of rickets or osteomalacia in both human and animal models show the 
same skeletal abnormalities associated with defective mineralization in the growing 
skeleton, small body size and weaker bones. Recent genome-wide linkage analy-
ses22,23 showed evidence of linkage between stature and a region on chromosome 
12 (12p11.2-q14), where the VDR gene is located. Therefore, sequence variation 
of the VDR gene might infl uence body height differences in normal population. 
Although several association studies have investigated the relationship between 
VDR polymorphisms and body height in the past, confl icting results were found, 
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possibly because of small sample sizes, variations in study design, heterogeneous 
populations, and because mostly anonymous VDR polymorphisms were used so 
far.
Recently, we and others have resolved the linkage disequilibrium (LD) struc-
ture of the VDR gene24,25. Haplotypes consisting of several polymorphisms might 
provide more power over individual polymorphisms in genetic association studies. 
However, evolutionary structure exists in the haplotype variation on either side of 
the recombinational hotspot26. Recombination events decrease the linkage between 
polymorphisms, and markedly damage the power of study. So-called cladistic 
analysis provides a way to estimate evolutionary history of the haplotype variation 
in a statistical design for an association study26. Haplotype alleles within clusters of 
the cladistic analysis are expected to share more-common ancestry than haplotypes 
between clusters. Therefore, the combination of cladistic and haplotype analysis 
can further increase power for an association study.
In functional studies we have identifi ed promoter and 3’-UTR haplotype alleles 
in block 2 and 5, respectively, that infl uence VDR expression24. In a subsequent 
association study we observed these risk alleles in block 2, block 3 and block 5 to be 
associated with increased risk to develop an osteoporostic fracture. The hypothesis 
of the current study was that the VDR fracture risk alleles might be associated with 
weak bone possibly due to small bone size, and subsequently with a decreased body 
height. We investigated the relationship of haplotypes (including the fracture risk 
haplotypes and others) across the VDR gene with height as well as bone geometry in 
a population-based population (the Rotterdam Study27), and replicated the analysis 
of height-related haplotypes in another independent populations, the LASA study. 
Finally, we compared our results with those of previous studies on VDR polymor-
phisms and height in a meta-analysis of published data. These studies focused on 
the anonymous Bsm I and /or Taq I polymorphisms in the 3’-end of the VDR gene. 
We have, however, demonstrated that these SNPs can be used to identify the most 
common haplotypes in that area24,25,28. Thus, we assessed the genetic effect of VDR 
Bsm I or Taq I polymorphism on body height with a meta-analysis of published 
literature and including our current studies.
MATERIALS AND METHODS
Subjects
The Rotterdam Study population: The Rotterdam Study is a single center 
prospective population-based cohort study, and includes 7,983 individuals, with 
3,105 men (38.9%) and 4,878 women (61.1%), designed to analyse determinants and 
prognosis of chronic and disabling diseases in the elderly (> 55 years) Caucasians27. 
The baseline measurements were performed between 1990 and 1993. The latest 
follow-up period ended 1st of January 2002, and the mean follow-up period was 
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7.4 years for clinical fracture. For the current study, 6,580 DNA samples (82.4% 
of the whole cohort population) were available and 6,031 DNAs were successfully 
genotyped. For the association analysis, we included 5,931 subjects with baseline 
measurement data of BMD, 5,933 subjects with clinical data of vertebral fracture, 
3,114 subjects with X-ray confi rmed data of vertebral fracture data, 5,165 subjects 
with vertebral area data, and 4,230 subjects with hip bone geometry data.
LASA population: The Longitudinal Aging Study Amsterdam (LASA) is an 
ongoing cohort study of older persons aged 55-85 years. The sampling and data col-
lection procedures have been described in detail elsewhere29. In summary, a random 
sample stratifi ed by age, sex, and expected 5-years mortality rate was drawn from 
the population registers of 11 municipalities in three regions of the Netherlands. 
In total, 3,107 persons were enrolled in the baseline examination in 1992-1993. 
For the current study, persons who participated in the medical interview, and were 
born in or before 1930 (aged 65 years and older as of January 1, 1996), were selected 
(n=1509).  Of these, 1,352 blood samples were obtained, and 911 DNAs were suc-
cessfully genotyped for all SNPs.
DNA isolation and genotyping
Genomic DNA was isolated from peripheral venous blood specimens according 
to standard protocols. We genotyped 14 haplotype tagging single nucleotide poly-
morphisms (htSNPs) according to our recent haplotype analysis across the entire 
VDR gene24 and the Fok I polymorphism in 6,580 Caucasian subjects from the 
Rotterdam Study with the high throughput TaqMan allelic discrimination assays. We 
successfully genotyped 6,031 DNA samples for all 15 SNPs. The genotype results 
were analysed independently by two operators. 332 (5%) random samples from the 
Rotterdam Study were independently repeated to confi rm the genotyping results 
for all SNPs, the disagreement rate of the genotype results were 0.3-1.2 % for fi ve 
htSNPs, and the genotype results of other htSNPs were completely consistent. The 
Assay Mixes (including unlabelled PCR primers, FAMTM and VIC® dye-labelled 
TaqMan MGB probes) of three Assays-on-DemandSM and 36 Assays-by-DesignTM 
were designed and supported by ABI. The reaction system contained 2 ng of dried 
genomic DNA, 2.5 μl of TaqMan® Universal PCR Master Mix, No AmpErase® 
UNG (2 ×), 0.125 μl (40 ×) or 0.0625 μl (80 ×) of Assay Mix, and adjusted Milli-Q 
H2O in a total volume of 2 μl. The reaction conditions consisted of an initial step 
at 95 °C for 10 minutes, followed by 40 cycles with 92 °C for 15 seconds and 60 °C 
for 60 seconds in a 384-well plate using the PCR machines, ABI Prism® 7900HT, or 
ABI GeneAmp® PCR system 9700 (ABI), or PTC-225 Peltier Thermal Cycler (MJ 
Research, INC.). The genotyping results were analysed with an endpoint reading in 
the ABI Prism® 7900HT.
Linkage disequilibrium (LD) haplotype analyses and cladogram construction
Our recent LD and haplotype analyses were based on 47 SNPs (identifi ed by re-
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sequencing) across the VDR gene and indicated that the whole VDR gene contains 
seven haplotype blocks24. In this study, we combined the nested cladistic method, 
pair-wise LD measurement and LD block defi nition together, constructed clado-
gram and haplotypes within LD blocks. We included nine SNPs from block 3 and 
ten SNPs from block 5 for LD and haplotype analyses with the PHASE program30. 
PHASE output was used to calculate the pair-wise standardized disequilibrium 
coeffi cient (D’) with the “haploxt”31 to estimate the linkage magnitude between 
two SNPs. We represent haplotype diversity by means of a cladogram, that was 
generated with a PHASE output linked to the “hapdist” program32, and depicted 
the graphic overviews of the cladogram for each LD block with CLadogramer33.
Clinical examination of association study
Anthropometric measurements of participants were obtained at the research 
center. Height and weight were measured in standing position wearing indoor 
clothing without shoes, and all height measurements were attained by a research 
assistant using a standard wall-mounted stadimeter. Height loss was calculated as 
the difference of height between the baseline and the ending of follow-up measure-
ments. Body mass index (BMI) was calculated as weight (kg) divided by height 
squared (m2). BMD (g/cm2) was determined by dual energy X-ray absorptiometry 
(DXA, Lunar DPX-L densitometer, Lunar Radiation Corporation, Madison, WI, 
USA) at the femoral neck and lumbar spine (vertebral L2 - L4) as described before 
34. Vertebral body area (cm2) was measured over L2 – L4 by postero-anterior scan-
ning using the same DXA instrument. Hip structure analysis, such as the section 
modulus (Z, an index of bending strength), the buckling ratio (BR, in index of bone 
instability), were calculated as described in previous reports35,36. The narrow-neck 
(NN) width (cm) of the hip is across the narrowest point of the femoral neck. 
Clinical vertebral fracture was diagnosed according to a previous description37, 
X-ray confi rmed vertebral fractures at baseline were determined by the McCloskey-
Kanis method37,38. The incidence of vertebral fracture was considered as new cases 
diagnosed during the follow-up period.
Statistical and association analysis
We applied one-way analysis of variance (ANOVA) to investigate the relationship 
between genotypes and age, height, bone geometry variables and other continuous 
outcomes. All genotyping results were tested for Hardy-Weinberg equilibrium. 
To clarify the possible confounding effect of potential factors on the association 
between VDR genotypes with height and bone geometry data, we employed ad-
justed analysis of covariance (ANCOVA) for age, gender and BMI, and we also 
stratifi ed the analyses by gender, clinical or X-ray confi rmed vertebral fracture. To 
test the association between three fracture risk haplotypes in block 2, 3 and 5 with 
height, normal signifi cance cut-off p-value (0.05) was used, since we had a clear 
up-front test hypothesis for those three haplotypes. We adjusted the signifi cance 
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cut-off p-value using the Bonferroni correction in the association analyses of other 
seven common haplotypes (MAF > 5%) from LD block 1 and 4, as well as Fok I 
polymorphism. This resulted in a cut-off p-value at 0.006 (0.05/8), considering that 
eight independent tests were performed.
Three possible genetic models were allowed to explain differences between 
genotype groups, i.e., an allele dose effect, a dominant effect or a recessive effect. 
Allele dose was defi ned as the number of copies of a certain allele in the genotype, 
and genotype was treated as a continuous variable. For a certain haplotype or 
combined genotype allele, the genotype is expressed as a numeric variable with 0 
= non-carrier, 1 = heterozygous (one copy of the allele) and 2 = homozygous (two 
copies of the allele). In case of a consistent trend refl ected as an allele dose effect, 
a linear regression analysis was performed and a “trend” p-value was calculated 
to quantify the association. In case of a recessive or dominant effect of the test 
allele, a two by two chi-square test for binary outcomes or an independent sample 
T-test for continuous outcomes was performed to test for differences between two 
genotype groups. For dominant alleles we compared the test group of “Carrier” 
(e.g., heterozygous and homozygous of block 3-hap 3) versus “Non-Carrier” (e.g., 
subjects without block 3-hap 3 allele). For recessive effects homozygous subjects 
for the test allele (e.g. homozygous block 3-hap 3), were compared to the combined 
group of heterozygous (e.g. heterozygous block 3-hap 3) and non-carriers (e.g. 
subjects without b_hp 3). The intragenic effect of combined VDR polymorphisms 
was defi ned as the combined genotypes of haplotype 3 (block 3-hap 3) from block 
3 in the exon 1b promoter region, and haplotype 2 (block 5-hap 2) from block 5 
in the 3’-untranslated region (UTR). According to the genetic model of individual 
haplotypes in our study populations, we combined genotype of the VDR gene with 
a dominant model for block 3-hap 3 and an allele dose model for block 5-hap 2. 
“Zero” indicates the “Non-Carrier” of block 3-hap 3, and the homozygous block 
5-hap 2; “One” indicates either the “Carrier” of block 3-hap 3 and homozygous 
block 5-hap 2, or the “Non-carrier” of block 3-hap 3 and the heterozygous block 
5-hap 2; “Two” indicates the “Non-carrier” of block 3-hap 3 and the non-carrier 
of block 5-hap 2, as well as the “Carrier” of block 3-hap 3 and the heterozygous of 
block 5-hap 2; “Three” indicates the “Carrier” of block 3-hap 3 and the non-car-
rier of block 5-hap 2.
All statistical analyses of the association study were carried out with the SPSS 
software package (version 11.0).
Meta-analysis
Identifi cation of studies: We fi rst searched publications on PubMed with a 
combination of keywords: [vitamin D receptor] and [polymorphism or genotype] 
and [height]. References from retrieved publications were checked for additional 
studies. In addition, we also reviewed 108 references from three meta-analysis 
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studies39-41 of VDR polymorphisms and different bone phenotypes to detect data 
of height distribution by VDR genotypes. In total, we identifi ed 27 studies42-68 with 
genotyping of Bsm I or Taq I or Bsm-Apa-Taq haplotyping and body height from 
1995 to May 2005. We also included our current association results in the meta-
analysis. Of studies from the same population, we retained for the meta-analysis 
only the study with the most extensive data. We extracted information on authors, 
published year, country of origin, ethnicity, study design, mean or range of age, 
gender, number of subjects and frequency of the B-allele in the control or the 
complete follow-up population for each study (Table 5). We also examined whether 
the genotype distribution frequencies of the studies followed Hardy-Weinberg 
equilibrium (HWE) proportions.
Data Analysis: Three polymorphisms, Bsm I, Apa I and Taq I – restriction 
fragment length polymorphisms (RFLPs), are commonly analysed in association 
studies, and Bsm I is the most consistently reported. Bsm I, Taq I and haplotypes in 
block 5 (in current association study) are highly linked with each other with a pair-
wise D’ = (0.88 – 1.0) according to our recent study24, “B” of Bsm I is linked to “t” 
of Taq I, and block 5-hap 2 in block 5. In the meta-analysis, we focused on analyzing 
relationship of Bsm I and height, when Bsm I genotype was absent, Taq I and block 
5-hap 2 genotype were used to predict Bsm I genotype. We analysed the reliable data 
using the RevMan 4.2 program from the Cochrane Collaboration (www.cochrane.
dk). According to our cross-sectional analysis, the relationship between VDR Bsm 
I genotype and height followed an allele-dose effect genetic model. We therefore 
only evaluated the comparison between homozygous genotypes, BB versus bb, in 
the meta-analysis. BB genotype group was absent or only one individual had BB 
genotype three studies from Asian population54,57,65, we extracted height data by Bb 
versus bb. One study67 only presented height data by B-carrier versus bb, we also 
used data by BB+Bb versus bb.
Sensitivity of meta-analysis: Between-study heterogeneity was evaluated by 
the chi-square distributed Q statistic with a cut-off p-value level at 0.10, and the 
inconsistency index I2 (suggesting inconsistency among studies’ results with values 
of 50% or higher, and larger heterogeneity for values of 75% or higher) as esti-
mated from the RevMan program. The standardized mean difference (SMD) and 
its confi dence interval (95% CI) were estimated by both fi xed effect and random 
effects models. The fi xed effect model assumes that the genetic factor shows a 
similar effect on height across all investigated comparisons, and the observed 
variation among comparisons is caused by chance alone. The random effects model 
assumes that there may be substantial diversity among different comparisons, and 
assesses both within-study sampling error and between-study variance. When 
there is no heterogeneity between comparisons, the outcomes of the two models 
are similar. Otherwise, the random effects model will give a wider CI than the 
fi xed effect model. We also stratifi ed studies by ethnicity and by age to attempt to 
clarify potential between-study heterogeneity. We carried out sensitivity analyses by 
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excluding one study with the largest sample size, or/and excluding studies deviating 
from HWE proportions. We also performed recursive cumulative meta-analysis to 
evaluate whether the summary SMD changed in the same direction over time and 
appraised whether the fi rst published study gave different results from subsequent 
ones69-71.
RESULTS
Cladogram of VDR haplotype blocks
Nine SNPs around exon 1b and ten SNPs from exon 4 to the end of 3’-UTR of 
the VDR gene were found to be highly linked in block 3 (D’ is 0.93 – 1.00) and 5 
(D’ is 0.88 – 1.00), respectively (Fig. 1). Twelve haplotype alleles were predicted by 
PHASE in block 3, and 18 in block 5 for these Caucasian populations. The cladogram 
graphs showed that these haplotypes could be categorized as three main clusters 
(labled as I, II and III in Fig. 1) in the blocks with one or two common haplotype 
alleles (frequency > 10%). Some SNPs (with arrow below the fi gure) are specifi c 
for certain clusters, e.g. 1b-G-2528A and 1b-G-886A for cluster III in LD block 3; 
E9-T-48G, U-A311C and U-D796T for cluster I in LD block 5. We combined this 
feature with the potential functional background (possible transcriptional factor 
binding site) and a reliable genotyping method together to determine haplotype 
tagging SNPs (htSNPs24). We identifi ed four and three htSNPs which can represent 
most (93 – 95%) of the estimated fi ve common haplotype alleles (frequency > 3%) 
in block 3 (4 htSNPs) and 5 (3 htSNPs), respectively. Therefore these htSNPs were 
used in our association study.
VDR haplotypes and body height
We genotyped seven htSNPs for block 3 and 5 in the Rotterdam and LASA 
population. The genotype distribution of all htSNPs followed HWE proportion. 
The baseline characteristics of each study population are shown in Table 1. Data 
from the Rotterdam and LASA populations are presented by the combined VDR 
genotype (based on the block 3-hap 3 allele and the block 5-hap 2 allele, as de-
scribed in the Materials and Methods section). No signifi cant differences in baseline 
characteristics were found according to VDR genotype. The allele frequencies of 
block 3-hap 3 and block 5-hap 2 were similar between the Rotterdam and LASA 
populations.
We fi rst investigated the relationship of body height in the Rotterdam popula-
tion with the haplotype risk alleles for fracture (Table 2). Block 3-hap 3 carriers 
were found to have a 0.3 – 0.7% decreased body height, and the block 5-hap 2 
homozygotes were found to have a 0.4 – 0.8% increased body height, with evidence 
for an allele-dose effect. The combined genotype of block 3-hap 3 and block 5-hap 
2 had an additive effect on body height. The height difference between two 
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extreme genotype groups was 1.4 cm [0.8%; p = 0.00002, corresponding to 0.15 
standard deviations (SD.)]. This effect was replicated in the LASA population (1.6% 
difference; p = 0.001) using the same genetic model. We observed that the VDR 
genotype dependent height difference by block 5-hap 2 genotype increased with 
increasing mean age of the study population. This increase was 0.9 cm (0.09SD.) 
with mean age 70 years in the Rotterdam Study and 1.4 cm (0.15SD.) with mean age 
76 years in LASA. 
An inverse correlation between body height and age was observed for both men 
and women in the Rotterdam Study (r = -0.31, p < 0.001) and the LASA cohort 
(r = -0.21, p < 0.001). We then analysed the relationship between VDR genotypes 
and body height by 5-year age strata to investigate the contribution of the VDR 
genotypes to age-related genotype dependent height differences (secular trends). In 
all the age categories of the two populations, VDR genotype was associated with 
increased body height. In addition, we analysed “height loss” longitudinally during 
a 7.4 years follow-up in the Rotterdam Study. Height loss was not signifi cantly dif-
ferent by VDR genotype. We also examined the relationship between body height 
and VDR haplotype alleles from other LD blocks, but no other LD blocks showed 
evidence of association (data not shown).
Vertebral fracture is known to be an important confounder to infl uence associa-
tions regarding body height in elderly subjects. In the Rotterdam population, there 
were 98 cases (out of 6,031 analysed) with incident clinical vertebral fracture during 
the follow-up period, and 232 X-ray confi rmed vertebral fractures (out of 3,114 
screened) at baseline. In the LASA cohort, seven cases (out of 902 analysed) of 
incident clinical vertebral fracture were reported during the follow-up time. When 
Table 1 Characteristics by VDR genotype in different study populations
Total Combined VDR genotype# p-value##
Zero One Two Three
Rotterdam population
Number (%)* 6276 881 (14.0) 2416 (38.5) 2323 (37.0) 656 (10.5) -
Female (%)* 3732 (59.5) 531 (14.2) 1409 (37.8) 1387 (37.2) 405 (10.9) -
Age (year)** 69.5 ± 9.1 69.2 ± 8.9 69.5 ± 9.1 69.6 ± 9.2 69.3 ± 9.2 0.70
BMI (kg/m2)** 26.3 ± 3.7 26.4 ± 3.8 26.2 ± 3.6 26.3 ± 3.8 26.4 ± 3.7 0.49
LASA population
Number (%)* 911 133 (14.6) 361 (39.6) 334 (36.7) 83 (9.1)
Female (%)* 467 (51.3) 66 (14.1) 189 (40.5) 167 (35.8) 45 (9.6)
Age (year) 75.6 ± 6.6 75.2 ± 6.8 75.3 ± 6.6 76.0 ± 6.5 76.2 ± 6.3 0.10
BMI (kg/m2) 26.9 ± 4.2 27.2 ± 4.2 26.9 ± 4.3 26.9 ± 4.0 26.2 ± 4.4 0.19
#: Combined VDR genotype for risk genotypes in haplotype blocks 3 and 5 (see materials and methods)
##: ANOVA p-value is presented
*: Number (proportion in %)
**: Age was adjusted for gender, BMI was adjusted for age and/or gender
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we only analysed subjects without clinical or X-ray confi rmed vertebral fracture, 
the association of VDR genotype with height remained essentially the same (Table 
3).
We also analysed bone geometry parameters available in the Rotterdam study 
(Table 4). The combined VDR genotype was associated with decreased vertebral 
area of L2 – L4, and decreased femoral size parameters (external and internal 
diameters) at the narrow-neck and at the shaft, and lower section modulus (index 
of bending strength) of femoral neck. Associations remained when we adjusted 
for age, gender, vertebral fracture, height and weight. We did not see the cortical 
thickness difference by the VDR genotype. 
Meta-analysis of VDR genotype and body height
We identifi ed 27 eligible published studies and the two current studies, in total 
reporting data from 35 different comparisons, which together included 14,157 
subjects from Caucasian, Asian and African American populations (Table 5). Study 
design contained cohort, case-control, normal subject-based and hospital-based 
cross-section studies. The mean age for each study was 2 – 75 years for both male 
and female. The sample size of studies varied from 24 – 6,154. Twenty one com-
parisons presented Bsm I and height data, four comparisons had Taq I genotype 
data, while six studies had Bsm I and Apa I and Taq I, or Bsm-Apa-Taq haplotype 
data. Because of the high linkage disequilibrium, we assumed the “t”-allele (or the 
C nucleotide) of Taq I, the haplotype 2 allele of Bsm-Apa-Taq56, or the block 5-hap 
2 allele (in the current study) to represent the “B”-allele (or the A nucleotide) of 
Bsm I. The frequency of the B-allele ranged from 3 – 49%.
In our current association analysis, an allele-dose genetic model was observed 
for the block 5-hap 2 allele. In the meta-analysis, we therefore compared the ex-
treme genotype groups, BB (2,447 subjects) versus bb (5,329 subjects), based on an 
allele dose genetic model. A signifi cant between-study heterogeneity was observed 
(p = 0.0002, 52%). The random effects model was used to test the overall genetic 
effect of Bsm I genotype on body height from all comparisons (in the bottom of 
Fig. 2). Subjects with BB genotype were found to be 0.63 cm (95% CI: 0.17 to 1.08) 
higher compared to bb genotype carriers (p = 0.006).
To investigate the source of the heterogeneity, we fi rst stratifi ed the analyses 
in the Table 6 by age (< 20 years or > 20 years). Body height changes remarkably 
during puberty and the age of puberty differs between individuals. Evidence of 
strong heterogeneity was found in the young (< 20 years) group (p = 0.002, I2 
= 76%, in the upper of Fig. 2), and no association was found. In the adult (> 
20years) group, a signifi cant but mild heterogeneity was found (p = 0.003, I2 = 
47%), and a signifi cant and strong association was observed (p = 0.002, height 
difference: 0.75 [0.34, 1.15]) compared to overall effect. Five comparisons for Asian 
populations53,54,57,65, which had a signifi cantly lower B-allele frequency (3-9%, p < 
0.001), showed modest heterogeneity. Other studies with a similar higher B-allele 
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frequency (27-49%, including one study62 of African Americans with a B-allele fre-
quency of 36%) showed a borderline signifi cant heterogeneity (p = 0.05, I2 = 34%). 
The point estimates of the height difference by genotype were similar between the 
random effects model and the fi xed effect model, and the genetic effect of Bsm I 
genotype on height remained. After stratifying for gender, status of menopause 
(pre- vs. post-menopausal) and study design, we still could see heterogeneity in all 
strata (data not shown).
To test the sensitivity of the meta-analysis, we replaced the study with the largest 
sample size, the current complete Rotterdam Study population, with the previous 
published data56 using a subset (1,004 subjects) of the same population. This did not 
impact on the conclusion of association and heterogeneity, but height difference by 
genotype became smaller [p = 0.03; mean difference (95% CI), 0.57 (0.04 – 1.09) 
cm in the random effects model]. When we excluded two studies which deviated 
from HWE (Garnero et al. 1996 and Laaksonen et al.), the association remained 
the same.
Table 6. Mean difference of body height in body height between BB versus bb genotype of Bsm I in the meta-analysis
Studies Study Subjects Mean (95% CI) Heterogeneity# Effect#
group (n) (n) Random effects Fixed effect p-value I2 (%) p-value
Overall 35 14157 0.63 (0.17, 1.08) 0.85 (0.64, 1.06) 0.0002 52 0.006
Young (< 20 yrs) 5 550 -0.42 (-2.91, 2.08) 0.14 (-0.84, 1.13) 0.002 76 0.95
Adult (> 20 yrs) 30 13607 0.75 (0.34, 1.15) 0.88 (0.67, 1.10) 0.003 47 0.002
  Low B-allele freq.* 5 893 0.99 (-0.08, 2.26) 0.97 (-0.06, 2.23) 0.04 61 0.10
  High B-allele freq.* 25 12714 0.70 (0.16, 1.24) 0.71 (0.36, 1.06) 0.05 34 0.01
*: Low B-allele freq. indicates the frequency of B-allele is from 3 to 9%, and high B-allele freq. is from 31 to 49% in Table 5;
#: Heterogeneity and effect were tested by the Random effects model.
Chapter 6
108
Figure 2. Meta-analysis of the relationship between BB versus bb genotypes of VDR Bsm I RFLP 
and body height. Point estimates of the standardized mean difference (SMD) of height between the 
genotypes and 95% confi dence intervals (CI) are presented for each study group. Summary estimates 
of SMD and their 95% CI (diamonds) are given by random effects models in “young” (< 20 years) 
and “adult” (> 20 years) strata, as well as in the overall database. 
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DISCUSSION
Although several polymorphisms of the VDR gene have been assessed in the 
association analyses of body height47,48,50,72,73, confl icting results were reported. One 
reason for this might be that non-functional or non-causal polymorphisms were 
used in the studies. Recently, we systematically analysed the linkage disequilibrium 
(LD) across the whole VDR gene, and determined fi ve haplotype blocks and 15 
htSNPs to represent all common haplotypes in each block24. The cladogram, enables 
inference of evolutionary history patterns and identifi es recombination events74. 
“Old” alleles tend strongly to be common alleles, recombination is common but 
concentrates into a hotspot and recurrent mutations at multiple sites may have 
occurred26. We combined cladistic and haplotype analyses and identifi ed a small 
number of common haplotype alleles (frequency >10%) in LD blocks, which con-
tain polymorphisms after recombination. In an LD block, haplotype alleles within 
the clusters of the cladogram are more similar than haplotypes between clusters. 
According to the common disease/common variation hypothesis75, a common risk-
allele accounts for more contribution to disease in a population. In the association 
study we therefore, only focus on common haplotype alleles in each block. The 
homozygous block 3-hap 3 genotype and the block 5-hap 2 carriers were found to 
be associated with 74% increased and 23% decreased fracture risk, respectively. In 
the consequent functionality analysis, we found that in vitro assays of block 5-hap 
2 showed a 15% higher VDR mRNA level compared to the block 5-hap 1 in fi ve 
different cell lines (including one osteoblast cell line). We here demonstrate an as-
sociation between these two alleles and adult body height in two independent large 
populations of elderly subjects.
Interestingly, the summarized genetic effect of Bsm I genotype on height from 
our meta-analysis was in line with our association results, although a heterogeneity 
among studies was found. The height difference between BB and bb carriers was 
0.63 cm. In the sensitivity analysis, we found that the result of the Rotterdam Study 
did not substantially infl uence the signifi cance of the association and heterogeneity 
in the meta-analysis, although the magnitude of the height difference decreased 
when we remove our current study from the meta-analysis. Taken together, this 
indicates that the VDR polymorphisms have a modest and constant genetic effect 
on the progressing and accumulated height different through lifetime to infl uence 
the body height.
To investigate the source of the between-study heterogeneity, we fi rst stratifi ed 
the analysis by age in young (< 20 years) or adult (> 20 years) groups. In young 
populations, large heterogeneity was found, because the direction of the effects is 
different between studies. Childhood and adolescence is the period of most rapid 
skeletal growth in an individual’s lifetime. After this period, the stature tends to be 
relatively stable, and is more suitable for investigation of the relationship between 
adult body height and genetic effects of VDR genotypes. However, in the adult 
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group we still observed signifi cant but mild heterogeneity. Further stratifi cation by 
B-allele frequency was carried out in the adult group. In the low B-allele frequency 
group (freq. = 3-9%), a modest heterogeneity resulted from a different magnitude 
of genetic effects between studies, although a similar direction of the effect was 
found between studies. This probably is because of insuffi cient statistical power 
to detect the genetic effect in the small number of BB homozygote at this low 
allele frequency. In the high B-allele frequency group (freq. = 27-49%), a borderline 
signifi cant heterogeneity was found, and other factors of heterogeneity need to be 
further analysed in this group. We did not stratify the analysis by ethnic groups, 
because according to our previous study24, only Asian populations have a lower 
B-allele frequency (5%) compared to Caucasian and African populations (39% and 
36%, respectively). Therefore, age and B-allele frequency variation both infl uence 
heterogeneity of this meta-analysis. Although heterogeneity between studies was 
observed, the genetic effect of Bsm I genotype on body height still exists, especially 
in the adult population.
As we demonstrated, adult body height (this study) and fracture risk24 are two 
complex skeletal phenotypes related to the variations of the VDR gene. We dem-
onstrated fracture risk alleles of the VDR gene to be associated with decreased 
body height, decreased bone size (e.g., vertebral area, femoral external and internal 
diameters) and lower bending strength (section modulus) at femoral neck. The ef-
fect we observed of VDR genotype on vertebral area could contribute to the VDR 
genotype effect we observed on stature. Hence, the correlations of VDR genotype 
with body height and bone size are in line with each other. Therefore, our study 
indicates the genetic effect of VDR genotype on related bone phenotypes, e.g., 
fracture risk, short stature and small bone size.
Another fracture-risk haplotype allele found in the Rotterdam Study popula-
tion24, block 2-hap1, was not found to be related to height difference in our elder 
and high calcium intake (1,117 mg/day) populations: the Rotterdam Study and the 
LASA. However, this haplotype was found to be associated with decreased body 
height in young and low calcium-intake (< 865 mg/day) French adolescent girls76, 
and this haplotype also associated with decreased serum 25(OH)D3 and decreased 
serum IGF-1 level in the same population. Since Cdx-2 polymorphism is one of 
the htSNPs which involve calcium absorption through intestine77, the interaction 
between block 2-hap 1 with calcium-intake and/or serum vitamin D level on bone 
phenotype is interesting to be further investigated in other young and old popula-
tions.
In our functionality study of VDR alleles we observed the block 5-hap 2 allele 
to result in 15% higher mRNA level and stability compared to the block 5-hap 
1 in several cell lines including an osteoblast cell line24. A possible underlying 
mechanism might be that for individuals with block 5-hap 2 haplotype, bone tissue 
(especially osteoblast cells) has a higher sensitivity to vitamin D ligands because of 
higher expression of VDR, and higher osteoblast activity. As a result, block 5-hap 
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2 carriers might have relatively higher bone formation to make bigger and stronger 
bones more resistant to fracture.
In addition, the intervertebral disc height and toughness might infl uence the 
body height especially in the elderly populations. The “t” allele of the Taq I poly-
morphism of the VDR gene was reported to be associated with decreased quantita-
tive signal intensity (more degeneration) of thoracic and lumbar disc78, increased 
risk of disc bulges79, disc degeneration and herniation80 in different populations. In 
our study population we don’t have data on intervertebral disc to investigate disc 
changes by VDR genotype. The relationship between VDR polymorphisms and 
spine phenotypes is certainly interesting to be investigated in further studies.
In conclusion, we observed haplotype alleles in the promoter region and the 
3’-end LD block of the VDR gene to be associated with decreased body height 
in two elderly populations. This association was independent of age, gender and 
presence of vertebral fracture. A meta-analysis of published data confi rmed the 
relationship between the same allele in the 3’-end of the VDR gene and decreased 
“adult” height. The underlying mechanism of the association might involve slightly 
lower copy numbers of VDR protein (in carriers of this risk haplotype) in cells 
important for determining bone size and strength.
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ABSTRACT
Introduction: Vitamin D receptor (VDR) gene polymorphisms are associated 
with complex diseases, including osteoporosis, but with inconsistent results. We 
previously analysed LD haplotype blocks in Caucasians across the VDR gene, 
and found haplotype alleles of the promoter and 3’untranslated region (UTR) 
associated with increased fracture risk and decreased body height. To investigate 
the underlying mechanism, we performed functional experiments for individual 
polymorphisms and haplotypes in both the VDR promoter and 3’UTR areas.
Material and Methods: To examine VDR promoter SNPs electrophoretic gel 
mobility shift assay (EMSA) were done using HEK293 or CaCo2 nuclear extracts, 
and luciferase reporter constructs were assayed in HEK293. We measured VDR 
mRNA level for the 3’-UTR variations by transfecting constructs with VDR cDNA 
and the entire 3’UTR of either the block 5-hap1 (risk) allele or the block 5-hap2 
(protective) allele in osteoblast cell lines MG63 and SV-HFO, and in HEK293, 
CaCo2 and COS1. mRNA stability was determined in MG63 at 0-8-24 h after 
inhibiting transcription.
Results: For the 1e/1a promoter, we found that the “G” weaker binding (by 
EMSA) alleles at a known Cdx-2 site (1e-G-1739A) and a novel GATA binding 
site (1a-A-1012G) are both on the promoter risk block 2-hap1 haplotype allele. 
We transfected reporter constructs containing 2 kb 1a-promoter sequence, and 
observed 53% lower expression of the risk block 2-hap1 allele vs. block 2-hap2 or 3 
(p=5×10-7, n = 51 exp.). For the 3’UTR variants the normalized VDR mRNA level 
of block 5-hap1 was 15% lower for all cell lines combined with similar patterns in 
all individual cell lines (p=2×10-6, n = 53). We observed a 30% faster mRNA decay 
of block 5-hap1 vs. block 5-hap2 in the MG63 (p=0.02, n = 9).
Conclusions: We demonstrate in vitro that risk haplotypes in both the VDR 
promoter and the 3’-UTR cause a reduction in mRNA level in potential target 
cells. We postulate these subtle functional effects to underlie the associations we 
reported for fracture and height, by resulting in a reduced sensitivity for vitamin 
D signalling.
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INTRODUCTION
Vitamin D receptor (VDR) gene polymorphisms are associated with complex 
diseases, including osteoporosis, but with inconsistent results. One reason for the 
confl icting results might be the fact that non-functional polymorphisms were used 
in most of association studies. To explain the associations of those polymorphisms 
with complex diseases, linkage disequilibrium (LD) is assumed to truly functional 
polymorphisms. Functionality studies of some VDR polymorphisms have been 
performed but also with inconsistent results (see chapter 1.6). Reasons for this 
inconsistency could involve the use of non-functional polymorphisms, the use of 
different cell lines (from different species and different tissues), and the use of 
heterologous constructs.
We previously analysed sequence variations (chapter 2) and LD haplotype 
blocks (chapter 3) in Caucasians across the VDR gene. According to our sequence 
analysis, we observed 14 out of 35 polymorphisms to change the putative recogni-
tion sequences of transcription factors in the promoter region, while four out of 13 
polymorphisms are located in destabilizing elements (DE) in the 3’-untranslated 
region (UTR) of the VDR gene. In our association studies, we found haplotype 
alleles of the promoter and 3’-UTR to be associated with increased fracture risk 
and decreased body height. We therefore carried out functionality experiments, 
especially for polymorphisms in the promoter region and in the 3’-UTR, which 
regulate the mRNA level to help understand the underlying mechanism of the 
associations we observed.
MATERIALS AND METHODS
Electrophoretic gel mobility shift assay (EMSA) and transactivation assay for promoter polymor-
phisms
Cell nuclear extracts from Caco2 (human colonic adenocarcinoma) and HEK293 
(human embryonic kidney) were prepared as described previously1. Annealed oli-
gonucleotides (Table 1) were [γ−32P] ATP end-labeled (Amersham Biosciences) by 
the T3-polynucleotide kinase (Invitrogen Life Technologies) and purifi ed on a non-
denaturing 10% polyacrylamide gel prior to gel shift studies. Nuclear extracts (20 
µg) were incubated at 4 °C for 30 min in the presence of 1 µg of double strand poly 
[dI-dC]-poly [dI-dC] (Amersham Biosciences) and 10 fmoles of purifi ed labeled 
oligonucleotide in a fi nal buffer containing 10 % glycerol, 5 mM Tris (pH 7.5) and 
150 mM KCl. Samples were resolved on a 4% non-denaturing polyacrylamide gel 
in a low salt buffer (pH7.5) of Tris (6.7 mM), acetate (3.3 mM) and EDTA (1 mM). 
Supershift experiments were done similarly except for a 1 h incubation at 4 °C in 
the presence of 1 µl of monoclonal anti Cdx-2 antibody (MU392-UC, Biogenex, 
San Ramon, California, USA) prior to the addition of the oligonucleotide probe.
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Three reporter constructs containing 2 kb 1a-promoter sequence with 2 SNPs 
(1a-G-1521C and 1a-A-1012G) were created. Site-directed mutagenesis at the SNP 
locations in the hVDRp was performed using the Gene Editor TM system (Promega 
Corp., Madison, WI, USA). The mutated oligonucleotides used were 5’-AGG CGA 
ATA GCA ATG TCT TCC CTG GCT AA-3’for -1012 SNP and 5’-GCT AGC 
TTT CCC ACC ATG CTT TGG GCA AG-3’ for -1521 SNP (the mutated base is 
underlined). Each site-directed mutant was confi rmed by sequencing.
Cells were in 6 seeded-well plates (2x105 cells/well) and grown in 2 ml medium 
for 24 h. Then, a mixture of 1 µg of plasmid DNA, containing 50 ng of pCMV-β 
plasmid (Clontech), 950 ng of luciferase reporter vector and 2 µl of Fugene-6® 
(Roche) was added (maintaining the presence of serum and antibiotics). No change 
of medium occurred during 72 h culture. Cells were grown for a further 48 h 
and harvested with 200 µl of 1x reporter lysis buffer (Promega Corp.). Luciferase 
activities were measured in 10 µl of cell extract with a LG Berthold Lumat LB 9507 
and corrected over β-galactosidase activity determined by a standard colorimetric 
procedure using o-nitrophenyl-β-D-galactopyranoside (ONPG) as substrate.
2-D structure of RNA analysis and functionality experiments for 3’-UTR polymorphisms
RNA secondary structure of VDR 3’-UTR was predicted by the RNAfold 
Table 1 Oligonucleotides for EMSA
Name Sequence
Cdx-2
1e-2090-C sense 5’-AAGTACTGGGATTACAGGCCTGAGCCACT-3’
1e-2090-C antisense 5’-AGTGGCTCAGGCCTGTAATCCCAGTACTT-3’
1e-2090-T sense 5’-AAGTACTGGGATTATAGGCCTGAGCCACT-3’
1e-2090-T antisense 5’-AGTGGCTCAGGCCTATAATCCCAGTACTT-3’
1e-1739-G sense 5’-TAAACTAGGTCACAGTAAAAACTTATTTC-3’
1e-1739-G antisense 5’-GAAATAAGTTTTTACTGTGACCTAGTTTA-3’
1e-1739-A sense 5’-TAAACTAGGTCACAATAAAAACTTATTTC-3’
1e-1739-A antisense 5’-GAAATAAGTTTTTATTGTGACCTAGTTTA-3’
SIF sense 5’-GAGGGTGCAATAAAACTTTATGAGTAGGT-3’
SIF antisense 5’-ACCTACTCATAAAGTTTTATTGCACCCTC-3’
GATA
1a-1012-A sense 5’-AGGCGAATAGCAATATCTTCCCTGGCTAA-3’
1a-1012-A antisense 5’-TTAGCCAGGGAAGATATTGCTATTCGCCT-3’
1a-1012-G sense 5’-AGGCGAATAGCAATGTCTTCCCTGGCTAA-3’
1a-1012-G antisense 5’-TTAGCCAGGGAAGACATTGCTATTCGCCT-3’
1a-1521-G sense 5’-GCTAGCTTTCCCACGATGCTTTGGGCAAG-3’
1a-1521-G antisense 5’-CTTGCCCAAAGCATCGTGGGAAAGCTAGC-3’
1a-1521-C sense 5’-GCTAGCTTTCCCACCATGCTTTGGGCAAG-3’
1a-1521-C antisense 5’-CTTGCCCAAAGCATGGTGGGAAAGCTAGC-3’
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server2, which offers prediction of secondary structure of RNA from a single se-
quence. The RNA secondary structure of the four most frequent haplotypes of the 
entire 3.2 kb VDR 3’-UTR were predicted based on free energy minimization3.
Constructs encompassed VDR exons 2-9, linked to the entire 3’-UTR of the 
block 5-hap1 or block 5-hap2, were cloned into a pCI-Neo mammalian expression 
vector (Promega). The accuracy of all cloning was verifi ed by direct sequencing of 
constructs.
Before transfection MG63 (human osteoblast), SV-HFO (human osteoblast), 
Caco2, HEK293 and Cos1 (Green Monkey kidney) cells were grown overnight in 
Dulbecco’s modifi ed Eagle’s medium (DMEM, Gibco), supplied with 10% fetal calf 
serum (FCS, Gibco), 50 U/ml penicillin and 50 μg/ml streptomycin (Gibco), and 
transfected using Fugene transfection reagent (Roche) at a reagent to DNA ratio of 
3:1. After 24 hours, cells were harvested and VDR mRNA level was measured. For 
the mRNA stability measurements cells were put on fresh medium with 7.5 μl/ml 
actinomycin D (Sigma), cells were harvested at time points 0, 8 and 24 hours after 
addition of actinomycin D.
Harvested cells were washed once with phosphate buffered saline (PBS), and to-
tal RNA was extracted with High pure RNA isolation kit (Roche). One microgram 
total RNA was reverse transcribed into cDNA using a cDNA synthesis kit accord-
ing to the protocol of the manufacture (MBI Fermentas, St. Leon-Rot, Germany). 
Quantitative real-time PCR was performed using an ABI PRISMTM 7700 sequence 
detector. 25 μl reaction system with qPCR core kit (Eurogentec, Seraing, Belgium) 
contained 20 ng cDNA, 5 mM MgCl2, 200 μM dNTPs and 0.025 U/μl Hot GoldStar 
enzyme.Primers and probes were designed with the Primer Express program from 
ABI (v1.5). cDNA primers: VDR For (5’-CCTCCAGTTCGTGTGAATGATG-
3’) and VDR Rev (5’-TCATGTCTGAAGAGGTGATACA-3’), NEO For (5’-
GCGCCCGGTTCTTTTTG-3’) and NEO Rev (5’-CCTCGTCCTGCAGTTCAT 
TCA-3’) were used to amplify the VDR and neomycin cDNA respectively. Neomycin 
was used as an internal control at 0 hour time point. Reaction condition of real time 
PCR was followed: 50 ºC for 2 min., 95 ºC for 10 min., 40 cycles with 95 ºC for 15 
sec. and 60 ºC for 1 min. All transfection experiments were carried out for six to 21 
times. The mRNA levels were calculated by the equation of 2(20-Ct).
RESULTS
Functionality studies for promoter polymorphisms
Among 14 polymorphisms which are located at potential transcription factor 
binding sites (TFBS) in the VDR promoter region, we performed EMSA for four 
common SNPs (MAF > 20%; 1e-C-2090T, 1e-G1739A, 1a-G1521C and 1a-A-
1012G) in the promoter region of exon 1e and 1a using Caco2 or HEK293 nuclear 
extracts (Fig. 1). We identifi ed a putative GATA-binding site for the A-allele of 
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the 1a-A-1012G SNP in exon 1a promoter region (AGATAT in reverse orienta-
tion) and, demonstrated that G-allele has markedly decreased binding to GATA 
compared with the A-allele.
Reporter constructs containing 2 kb 1a-promoter sequence with the 2 SNPs 
1a-G-1521C and 1a-A-1012G in block 2 (Fig. 2) showed that in HEK293 cells, the 
normalised luciferase activity of the block 2-hapl allele was decreased 53% and 50% 
compared to the block 2-hap 2/3, and hap 4/5 alleles (p = 5 × 10-7, and 8 × 10-7, 
respectively). This indicates that the G-allele of the htSNP, 1a-A-1012G, has a 2-
fold lower transcription compared to the A-allele. The same results were observed 
in COS-7 cells (data not shown).
Surrounding sequence analyses showed that the 1e-C-2090T and 1e-G-1739A 
SNPs locate at potential Cdx-2 binding-sites (Fig. 3a). EMSA confi rmed that the G-
allele of 1e-G-1739A and the T-allele of the 1e-C-2090T have a relatively decreased 
Figure 2 Relative luciferase activity in HEK293 cells of VDR exon 1a promoter activity including two SNPs. 
2a The three constructs containing the 2 kb 1a-promoter sequence with the SNPs: 1a-G-1521C and 1a-A-1012G. 
2b beta-Gal normalized luciferase activity for the three constructs. The block 2-hap1 allele is set at 100% as the 
reference group, p-value is calculated by independent t-test.
Figure 1 EMSA of 1a-A-1012G for GATA protein. 1a GATA 
binding assay using Caco2 cell line nuclear extract. The binding 
of GATA to the 1a-1012A was analyzed in competition experi-
ments for Caco2 nuclear extract using the well-characterized 
GATA sites of the EpoR and Lactase gene promoters14,7. These 
experiments showed similar binding characteristics of the 
complexes bound to the 1a-1012A site and to the other GATA 
sites (lanes 1 and 4 versus lane 7). In addition, the signal found 
on the 1a-1012A site was eliminated by a hundred-fold excess of 
unlabeled GATA sites of the EpoR and Lactase genes (lane 7-10). 
Inversely, a hundred-fold excess of the 1a-1012A site eliminated 
the binding of GATA on the EpoR and Lactase GATA sites 
(lanes 1 versus 2, and lanes 4 versus 5). 1b GATA binding using 
HEK293 cell line nuclear extract. Competition experiments for 
HEK293 nuclear extract using the -1012 GATA site as probe 
revealed that the 1a-1012G variant were unable to compete the 
binding of the 1a-1012A variant.
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Figure 3 Two SNPs in the 1e promoter re-
gion of the human VDR gene are at a Cdx-2 
binding site. 3a 15 well-characterized Cdx-2 
sites from mammalian gene promoters were 
lined up. Base usage was summarized in 
a table and compared to DNA sequences 
surrounding SNP 1e-C-2090T and 1e-G-
1739A. DNA bases involved in SNPs are 
underlined. 3b Double strand oligonucle-
otides either containing the Sucrose isoma-
ltase (SIF) Cdx2 binding site as control or 
sequences encompassing SNPs 1e-C-2090T 
and 1e-G-1739A have been 32P-labeled 
and purifi ed on a 10% polyacrylamide gel. 
EMSA experiments were performed using 
Caco-2 cell nuclear extracts. The competi-
tion experiments with an oligonucleotide 
containing the SIF element. Gel shift experi-
ments was performed in the absence (-) or 
the presence (+) of a hundred-fold excess of 
cold SIF probe as competitor, and resulted in 
relatively more elimination of these specifi c 
complexes for the A-allele of 1e-G-1739A 
and the T-allele of 1e-C-2090T compared 
with their counterparts. 3c The antibody 
experiments with a monoclonal anti-Cdx-2. 
EMSA was performed with nuclear extract 
alone (-) or the presence (+) of monoclonal 
anti Cdx-2 antibody. Supershift complexes 
were identifi ed by an arrow when present. 
A clear supershift was observed with SIF, 
but weakly in the 1e-1739G, and very low 
intensity of the complex was seen with 1e-
2090. Comparison of the surrounding 1e-C-
2090T and 1e-G-1739A sequences with the 
consensus Cdx-2 sequence (lower panel of 
Suppl. Fig. 3a.) evidenced the presence of a 
substitution (T/A) in the 1a-2090 sequence, 
corrupting somehow the Cdx-2 site, maybe 
explaining the lower intensity observed in 
EMSA compared to 1e-G-1739A.
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binding to Cdx-2, compared with their allelic counterparts (Fig. 3b). The risk allele 
of the GATA and Cdx-2 promoter SNPs are contained in the block 2-hap1, which 
is the risk allele for fracture.
Functionality studies of 3’-UTR polymorphisms
Thirteen polymorphisms and four common haplotypes (frequency > 3%) were 
identifi ed in the VDR 3’-UTR (see chapter 2 and 3). The block 5-hap1 allele and the 
block 5-hap2 allele in the 3’-UTR differ in only fi ve polymorphisms (Fig. 4a). These 
result in differences in the RNA secondary structure (Figure 4b).
We found that 24 hours after transfection of reporter constructs containing the 
complete 3.2 kb 3’-UTR of the block 5-hap1 or hap2, the neomycin normalized 
VDR mRNA level of the block 5-hap1 transcript was 15% lower than that of the 
block 5-hap2 transcript when results of all tested cell lines were combined (p = 2 
×10-6, n = 53) while similar patterns were observed in individual cell lines (Fig. 
5a). We then investigated the stability of VDR mRNAs transcribed from the block 
5-hap1 and hap2, and observed that the decay rate of VDR mRNA for the block 
5-hap1 was 30% faster than that for the hap2 in MG63 24 hours after inhibiting 
transcription (p = 0.02, n = 9; Fig. 5b).
DISCUSSION
According to results from our association studies of VDR SNPs and fracture 
risk, the genetic effect of the VDR polymorphisms on fracture risk is modest (15 
– 48%), which corresponds to the modest difference we observed (15%) in the 
VDR mRNA level by genotype in our functionality analysis. For comparison, in 
one previous study4, the “Ss” (or GT) genotype of COL1A1 Sp1 was found to have 
an 21% increased COL1A1/COL1A2 protein ratio compared to “SS” (or GG) as 
measured in osteoblasts. Another functional study of a 3’-UTR SNP [+1073C/T 
in the oxidised LDL receptor (OLR1) gene) that associates with increased risk for 
Alzheimer’s disease (AD) demonstrated that C-allele carriers had 41% decreased 
OLR1 mRNA level compared to “TT” homozygotes5. These examples indicate 
that genetic effects of polymorphisms on gene expression and clinical phenotypes 
are modest. 
By analysing functionality of the risk alleles in vitro, we demonstrate that the 
molecular mechanisms underlying these associations are likely to involve a lower 
expression of VDR mRNA. Some of promoter polymorphisms results in altered 
transcription factor binding for Cdx-2 and GATA. The previously reported Cdx-2 
site at 1e-G-1739A6,7 and the GATA site at 1a-A-1012G8 are encompassed in the 
block 2-hap1, the risk allele of fracture. Our and previous9 functionality experi-
ments show that both these two weak-binding alleles together result in decreased 
transcription activity of this VDR promoter. Further research is needed to establish 
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4b
Figure 4 Sequence difference between the block 5-hap1 and hap2 in the VDR 3’-UTR. 4a The VDR 
3’-UTR with sequence variations which distinguish the block 5-hap1 from the block 5-hap2. “No.” 
of SNP refers to the Table 2 in chapter 2. 4b RNA secondary structure difference between the block 
5-hap1 and hap2. Entire 3’-UTR single sequence of block 5-hap1 and hap2 were used to predict the 
RNA secondary structure. Five polymorphisms were labeled in the fi gure.
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Figure 5 VDR mRNA expression level and stability analysis by 3’-UTR haplotypes in different cell 
lines. 5a Neomycin normalized VDR mRNA expression level (mean ± SD) by VDR block 5-hap1 
vs. hap2. Hap2 is set at 100% as the reference group, p-value is calculated by independent t-test, n = 
number of experiments for each cell line. 5b Decay rate of VDR mRNA by block 5-hap1 vs. hap2 
determined in MG63. Time point at 0 hour is defi ned as 100% mRNA level for both haplotypes, 
p-value of each time point is calculated by independent t-test.
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in more detail, in which cells/tissues this promoter part is infl uencing VDR expres-
sion. While GATA is expressed in many tissues, Cdx-2 is expressed predominantly 
in the intestine. Thus, the hap1 allele might cause relatively lower VDR expression 
in target cells for vitamin D, including the intestine.
The 3’-UTR of genes is known to be involved in regulation of gene expression, 
especially through regulation of mRNA stability. The Bsm I, Apa I and Taq I SNPs 
are anonymous, and block 5 does not include polymorphisms beyond the 3’-UTR 
of the VDR gene. Therefore, SNPs in 3’-UTR are the most likely candidates for 
the truly functional sequence variations explaining the associations we observed. 
We identifi ed differences in VDR mRNA expression level and stability between 
the block 5-hap1 and hap2 alleles, which differ at only fi ve positions across the 3.2 
kb 3’-UTR. The fracture risk allele, the block 5-hap1, causes 15% lower levels of 
mRNA expression compared to the hap2 in all tested cell lines. This is in line with 
the 30% faster decay of or lower of VDR mRNA stability we observed in MG63, 
an osteoblast cell line. This observation also corresponds to other studies in vivo 
and in vitro10-13. This is likely to also result in lower numbers of VDR protein being 
present in target cells for vitamin D, giving such target cells a decreased response 
to vitamin D.
We demonstrate that polymorphisms within the promoter area and the 3’-UTR 
area of a gene are having effects that can infl uence VDR gene function in certain 
cells and/or subjects. Thus, the 5’ promoter and 3’-UTR polymorphisms together 
can determine how much of a given VDR mRNA will be expressed in a given 
target cell. The combined risk genotypes in promoter region and 3’-UTR represent 
a moderate genetic effect of the entire VDR gene on fracture risk. The vitamin D 
endocrine system has been implicated in several other complex diseases including 
osteoarthritis, diabetes, and cancer. Whether our fi ndings have relevance for these 
other diseases needs to be tested in separate association studies using the LD and 
haplotype information we here provide.
The determination of RNA structure from sequence contains two levels of 
complexity: secondary structure and tertiary structure (i.e., the three-dimensional 
shape). It may be possible to infer tertiary structure from interactions of secondary 
structure elements. It is still unclear how three-dimensional structure infl uences the 
stability of mRNA. Although we here showed that only four SNPs and one tandem 
repeat polymorphisms results in the RNA secondary structure difference of block 
5-hap1 and hap2 in the VDR 3’-UTR, the mechanism underlying the secondary 
structure difference for mRNA stability needs to be further investigated.
In conclusion, we demonstrate in vitro that risk haplotypes in both the VDR 
promoter region and the 3’-UTR cause a reduction in mRNA level in potential 
target cells. We postulate these subtle functional effects to underlie the associations 
we reported for fracture and height, by resulting in a reduced sensitivity for vitamin 
D signalling.
Chapter 7
128
ACKNOWLEDGEMENTS
We thank Drs. John Eisman and Linda Crofts for helpful sharing of unpublished 
sequence information, Dr. Mark Haussler for kindly providing VDR cDNA, and 
Marco Eijken for initial help with the RT-PCR of 3’-UTR experiments.
This project was funded by the Dutch Research Organisation (NWO 903-46-
178, 925-01-010, 014-90-001 and 911-03-012) and the European Commission under 
grant QLK6-CT-2002-02629 (“GENOMOS”).
REFERENCES
1. Dame, M.C., Pierce, E.A. & DeLuca, H.F. Identifi cation of the porcine intestinal 
1,25-dihydroxyvitamin D3 receptor on sodium dodecyl sulfate/polyacrylamide gels by 
renaturation and immunoblotting. Proc Natl Acad Sci U S A 82, 7825-9 (1985).
2. RNAfold. http://rna.tbi.univie.ac.at/cgi-bin/RNAfold.cgi.
3. Mathews, D.H., Sabina, J., Zuker, M. & Turner, D.H. Expanded sequence dependence of 
thermodynamic parameters improves prediction of RNA secondary structure. J Mol Biol 
288, 911-40 (1999).
4. Mann, V. et al. A COL1A1 Sp1 binding site polymorphism predisposes to osteoporotic 
fracture by affecting bone density and quality. J Clin Invest 107, 899-907 (2001).
5. Lambert, J.C. et al. Association of 3’-UTR polymorphisms of the oxidised LDL receptor 
1 (OLR1) gene with Alzheimer’s disease. J Med Genet 40, 424-30 (2003).
6. Yamamoto, H. et al. The caudal-related homeodomain protein Cdx-2 regulates vitamin 
D receptor gene expression in the small intestine. J Bone Miner Res 14, 240-7 (1999).
7. Fang, R., Olds, L.C., Santiago, N.A. & Sibley, E. GATA family transcription factors 
activate lactase gene promoter in intestinal Caco-2 cells. Am J Physiol Gastrointest Liver 
Physiol 280, G58-67 (2001).
8. Halsall, J.A., Osborne, J.E., Pringle, J.H. & Hutchinson, P.E. Vitamin D receptor gene 
polymorphisms, particularly the novel A-1012G promoter polymorphism, are associated 
with vitamin D3 responsiveness and non-familial susceptibility in psoriasis. Pharmacogenet 
Genomics 15, 349-55 (2005).
9. Arai, H. et al. The polymorphism in the caudal-related homeodomain protein Cdx-2 
binding element in the human vitamin D receptor gene. J Bone Miner Res 16, 1256-64 
(2001).
10. Morrison, N.A., Yeoman, R., Kelly, P.J. & Eisman, J.A. Contribution of trans-acting 
factor alleles to normal physiological variability: vitamin D receptor gene polymorphism 
and circulating osteocalcin. Proc Natl Acad Sci U S A 89, 6665-9 (1992).
11. Morrison, N.A. et al. Prediction of bone density from vitamin D receptor alleles. Nature 
367, 284-7 (1994).
12. Carling, T., Ridefelt, P., Hellman, P., Rastad, J. & Akerstrom, G. Vitamin D receptor 
polymorphisms correlate to parathyroid cell function in primary hyperparathyroidism. J 
Clin Endocrinol Metab 82, 1772-5 (1997).
13. Ogunkolade, B.W. et al. Vitamin D receptor (VDR) mRNA and VDR protein levels 
in relation to vitamin D status, insulin secretory capacity, and VDR genotype in 
Bangladeshi Asians. Diabetes 51, 2294-300 (2002).
14. Zon, L.I., Youssoufi an, H., Mather, C., Lodish, H.F. & Orkin, S.H. Activation of the 
erythropoietin receptor promoter by transcription factor GATA-1. Proc Natl Acad Sci U S 
A 88, 10638-41 (1991).
Chapter 8
Association of  Vitamin D Binding Protein (DBP) 
Gene Haplotype with Serum Vitamin D level
and Osteoporosis
Yue Fang, Pascal Arp, Joyce B. J. van Meurs, Johannes P. T. van Leeuwen, 
Albert Hofman, Huibert A. P. Pols, André G. Uitterlinden
To be submitted
Chapter 8
130
ABSTRACT
Introduction: Vitamin D binding protein (DBP) is a polymorphic and multi-
functional serum protein. DBP action is infl uenced by environmental factors since 
it binds to vitamin D and transports it to target tissues to maintain calcium homeo-
stasis. However, DBP can also be converted to DBP-macrophage activating factor 
(DBP-MAF), which mediates bone resorption by activating osteoclasts. Therefore, 
the DBP gene is a candidate gene of osteoporosis.
Materials and Methods: We summarized the haplotype structure across the 
DBP gene according to Perlegen, HapMap and SNPbrowser datasets, and proposed 
consensus haplotype structures for different ethnic populations. We genotyped 
two non-synonymous SNPs (rs7041 and rs4588) in a population-based Caucasian 
population of 6,181 elderly. Haplotypes of these SNPs correspond to protein varia-
tions Gc1s (hap1), Gc2 (hap2) and Gc1f (hap3). We analised DBP genetic variation 
in relation to BMD and fracture risk and studied interaction with dietary calcium 
intake and vitamin D receptor (VDR) genotype.
Results and Conclusions: In a subgroup of 1,312 subjects, DBP genotype was 
found to be associated with differences in serum 25-(OH)D3 for hap1 (P = 3×10
-4), 
and for hap2 (p = 3×10-6). Similar associations were observed for 1,25-(OH)2D3. 
The DBP genotype was weakly and borderline signifi cantly associated with fracture 
risk (p = 0.13) and the effect on fracture risk was likely to be independent of vita-
min D level. The hazard ratio for clinical fracture risk of DBP hap1-homozygote 
versus non-carrier was 1.47 (95% confi dence interval: 1.06–2.05) in a subgroup 
with dietary calcium intake < 1.09 g/day. In the total study population, we dem-
onstrated interaction between DBP and VDR haplotypes on fracture risk. In the 
DBP hap1-carrier group, VDR risk genotype carriers had 33% increased fracture 
risk compared to non-carriers (p = 0.005). All associations were independent of 
age and gender.
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INTRODUCTION
Osteoporosis is defi ned as a reduction in bone mass associated with disrup-
tion of bone microarchitecture, resulting in increased bone fragility and increased 
fracture risk1. It is a complex genetic disorder with interaction between environ-
mental and genetic factors. The genes involved remain ill defi ned but candidate 
gene association studies seem a powerful tool to identify causative genes2. Indeed, 
several genetic association studies have demonstrated a relationship between poly-
morphisms of candidate genes with decreased bone mineral density (BMD), and 
increased fracture risk3-8.
Vitamin D binding protein (DBP), was initially named as group-specifi c com-
ponent (Gc), and is a polymorphic serum protein with different functions. Two 
functions of DBP involve skeletal metabolism.
First, DBP binds to vitamin D metabolites such as 25-hydroxyvitamin D3 
[25(OH)D3], the major circulating metabolite, and 1,25-dihydroxyvitamin D3 
[1,25(OH)2D3], the most active form of vitamin D. Strong and positive correlations 
were found between those vitamin D metabolites and DBP levels in serum9. Vitamin 
D plays an essential role in regulating serum calcium and phosphate homeostasis 
as well as bone metabolism. A defi ciency of vitamin D results in rickets in children 
and osteomalacia in adults and increased risk of osteoporosis10. DBP transports 
vitamin D metabolites to liver, kidney, bone and other target tissues. DBP also 
plays a crucial role in storing and prolonging the half-life of the circulating vitamin 
D metabolites11.
Second, serum DBP can be converted to a DBP-macrophage activating factor 
(DBP-MAF) by deglycosylation of DBP. Though the mechanism is still unclear, 
some studies suggested that DBP-MAF upregulates oxidative metabolism in osteo-
clasts12 and potently inhibits the sensitivity of osteoclast to extracellular calcium13 
which is a powerful anti-resorptive signal14. DBP-MAF plays a role in osteoclast 
differenciation from monocytes15, and is a cytokine to mediate bone resorption by 
directly activating osteoclasts16. DBP-MAF treated osteopetrosis rats have increased 
number and activity of osteoclast, and decreased bone mass12.
Hence, the contribution of the DBP to bone metabolism can not only be 
through assisting the vitamin D endocrine system, but also through directly in-
fl uencing bone resorption. Therefore, the DBP gene, on chromosome 4q13.3, is 
a potential osteoporosis candidate gene. In addition, DBP has been observed to 
have several other functions. It is able to bind and clear gelsolin-actin (G-actin) 
from the circulation, and prevent the formation of fi lamentous actin (F-actin) and 
actin-mediated damage in the microcirculation after cellular trauma17,18. Moreover, 
DBP-MAF consequently activates macrophages19 and enhances a number of spe-
cialized immune functions such as chemotaxis, phagocytosis and destruction of 
tumor cells20.
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Three most commonly studied protein variations (Gc1f, Gc1s and Gc2) can be 
identifi ed by two DNA polymorphisms in exon 11: a G/A substitution in codon 416 
(rs7041) leading to a Glu/Asp amino acid change and a C/A substitution in codon 
420 (rs4588) leading to Thr/Lys amino acid change21. Haplotypes of the nucleotide 
changes result in the protein isoforms: Gc1f, Gc1s and Gc2 (see Fig. 2). Affi nity of 
the DBP isoforms for vitamin D metabolites was reported to be different: Gc1f > 
Gc1s > Gc222. A positive correlation was found between serum 1,25(OH)2D3 and 
DBP level23. Recently, two studies demonstrated a relationship of a DBP haplo-
type (or protein isoform: Gc1) with decreased BMD and increased fracture risk in 
Japanese and Caucasian populations24,25. However, it remains necessary to replicate 
these associations in a large-scale population-based study.
The action of these genes is under the infl uence of several environmental fac-
tors, e.g., dietary vitamin D intake and calcium intake. Furthermore, osteoclasts 
can have a different response to some environmental factors, such as dietary cal-
cium intake. The number of osteoclasts signifi cantly increases when rats were at a 
calcium defi ciency condition, and the number decreased to a similar level of control 
groups after calcium or phosphorus replenished26,27. No studies have investigated 
the interaction between DBP and dietary calcium intake on osteoporosis.
Another osteoporosis candidate gene, the vitamin D receptor (VDR) gene 
mediates the action of the vitamin D endocrine system in calcium homeostasis and 
bone metabolism. In a previous study of >6,000 elderly Dutch Caucasian subjects, 
we reported that the VDR block 5-haplotype 1 allele associated with increased frac-
ture risk. In a functionality study, this haplotype allele was found to associate with 
15% decreased VDR mRNA level comparing to the haplotype 2 allele, especially 
in osteoblast cells28. DBP stimulates the activity of osteoclasts, and infl uences the 
bone resorption12. Thus, VDR and DBP might infl uence the bone remodelling in 
two different pathways and further impact risk of osteoporosis. So far, no studies 
have addressed the interaction between VDR and DBP polymorphisms on oste-
oporosis.
In addition, it is necessary to systematically analyse the complete gene haplotype 
structure of the DBP gene in major ethnic populations to guide further genetic 
studies. In this study, we fi rst determined the haplotype structure of the whole DBP 
gene according to existing databases. Subsequently, we investigated the relationship 
between the most common polymorphisms of the DBP gene with serum vitamin 
D level and bone phenotypes in a population-based large study population, and 
fi nally we tested the interaction between DBP haplotypes with VDR haplotypes 
and dietary calcium intake on fracture risk.
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MATERIALS AND METHODS
Subjects:
The Rotterdam Study population: The Rotterdam Study is a single center pro-
spective population-based cohort study, and includes 7,983 (> 55 years) individuals 
Caucasian, with 3,105 men (38.9%) and 4,878 women (61.1%), to analyze determi-
nants and prognosis of chronic and disabling diseases in the elderly29. The baseline 
measurements were performed between 1990 and 1993. The latest follow-up period 
ended 1st of January 2002. For the current study, 6,580 DNA samples (82.4% of 
the whole cohort population) were available and 6,181 DNA was successfully geno-
typed. A subgroup with 4,747 subjects we had data on dietary calcium intake. 5,931 
subjects had baseline measurement data of bone mineral density (BMD, g/cm2). 
On baseline, for 1,317 subjects we measured serum vitamin D level data.
Panel of ethnic groups: We genotyped a panel of DNA from 107 Chinese Han 
and 68 African individuals [the Coriell Institute, Camden, NJ. USA: 98 Chinese 
Han (HD100), 9 Chinese Han (HD02), 59 African Americans (HD04 and HD50) 
and 9 Africans from south of the Sahara (HD12)].
DNA isolation and genotyping
Genomic DNA was isolated from peripheral venous blood specimens accord-
ing to standard protocols. In the DBP gene we genotyped two single nucleotide 
polymorphisms (SNPs) in exon 11, rs7041 and rs4588, which change the amino acid 
sequence at codon 416 and 420, respectively. The genotype results were detected 
using the Taqman procedure. The Assay Mixes (including unlabelled PCR prim-
ers, FAMTM and VIC® dye-labelled TaqMan MGB probes) of Assays-by-DesignTM 
were designed and supported by ABI. The reaction system contained 2 ng of dried 
genomic DNA, 2.5 μl of TaqMan® Universal PCR Master Mix, No AmpErase® 
UNG (2 ×), 0.125 μl (40 ×) or 0.0625 μl (80 ×) of Assay Mix, and adjusted Milli-Q 
H2O in a total volume of 5 μl. The reaction conditions consisted of an initial step 
at 95 °C for 10 minutes, followed by 40 cycles with 92 °C for 15 seconds and 60 °C 
for 60 seconds in a 384-well plate using PCR machines, ABI Prism® 7900HT, or 
ABI GeneAmp® PCR system 9700 (ABI), or PTC-225 Peltier Thermal Cycler (MJ 
Research, INC.). The genotyping results were analysed with an endpoint reading in 
the ABI Prism® 7900HT. The genotype results were determined independently by 
two operators and 5% random samples were re-genotyped to check for genotyping 
errors. No inconsistencies were observed.
Linkage disequilibrium (LD) and haplotype analyses
We fi rst extracted from the Perlegen database30 genotype data of 40 SNPs 
across the DBP gene and one SNP out of 3’-untranslated region (UTR) of the 
DBP gene for different ethnic groups: 24 European Americans, 24 Han Chinese 
and 23 African Americans. We selected race-specifi c SNPs with a minor allele fre-
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quency (MAF) > 10% in either of the ethnic study populations, and identifi ed 16 
SNPs for European American, 22 for Chinese Han and 25 for African American. 
These race-specifi c SNPs were used to determine haplotype structure of the DBP 
gene with the PHASE program 31. We identifi ed haplotype blocks (defi ned as, the 
standardized pair-wise disequilibrium coeffi cient between SNPs, D’ > 0.8) and cal-
culated haplotype frequency in each block by HaploBlockFinder program32. Other 
haplotype structure data of the DBP were included in the further analysis: A. the 
original Perlegen haplotype data, including 32 SNPs for European American, 31 
for Chinese Han and 33 for African American; B. HapMap data (Haploview ver-
sion3.233), including 30 trios CEPH (Utah residents with ancestry from northern 
and western Europe), 45 singletons of Han Chinese in Beijing, 30 trios YRI (Yoruba 
in Ibadan, Nigeria); C. SNPbrowser data (version 3.034), including 60 parent samples 
from 30 CEPH (Caucasian from HapMap data), 45 Han Chinese in Beijing and 45 
African American from Coriell DNA samples. The defi nition of haplotype block 
was as follows: MAF of analysed SNPs > 10% and D’ > 0.8, and haplotype block 
from original Perlegen was defi ned by the HAP program35. We extracted consensus 
race-specifi c LD maps of the DBP gene by comparing our haplotype structures 
(re-analysed Perlergen data) with other sources: Perlegen original data, HapMap, 
SNPbrowser and Ezura et al.24.
The haplotypes of rs7041 and rs4588 SNPs in the Rotterdam study population 
were generated by the PHASE program.
Clinical data for the association study
Information on medical history, dietary habits, age at menopause, and smok-
ing was obtained with a computerized questionnaire during a home interview at 
baseline. Intakes of calcium and total energy were calculated by food frequency 
questionnaire (based on all food and drinks consumed in 1 month) with the use 
of Dutch food composition tables. We calculated the total dietary energy intake 
adjusted dietary calcium intake for all individuals. Anthropometric measurements 
of participants were obtained at the research center. Height (cm) and weight (kg) 
were measured in standing position in indoor clothing without shoes, and all height 
measurements were attained by a research assistant using a standard wall-mounted 
station-meter. Body mass index (BMI) was calculated as weight (kg) divided by 
the height squared (m2). BMD (g/cm2) was determined by dual energy X-ray ab-
sorptiometry (DXA, Lunar DPX-L densitometer, Lunar Radiation Corporation, 
Madison, WI, USA) at the femoral neck and lumbar spine (vertebral L2 - L4) as 
described before36. The presence of a clinical vertebral fracture was diagnosed as 
described according to previously6,37,38. The incidence of fracture was considered as 
new cases diagnosed during the follow-up period (7.4 years ± 3.3 years).
50µl serum obtained at baseline was stored at -20 °C was used for the quantitative 
determination of 25-hydroxyvitamin D3 [25(OH)D3] and 1, 25-dihydroxyvitamin D3 
[1, 25(OH)2D3] level by using radioimmunoassay kits from IDS (Immunodianostic 
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systems limited, UK).
Statistical and association analysis
All genotyping results were tested for Hardy-Weinberg equilibrium. We applied 
one-way analysis of variance (ANOVA) to investigate the relationship between 
genotypes and age, height, weight, BMD, BMD loss, bone geometry variables, 
serum vitamin D level, dietary calcium intake, and other continuous outcomes. We 
employed the Pearson χ2 test, and calculated the Hazard Ratio and 95% confi dence 
interval (HR, 95% CI) to investigate the relationship between incidence of clinical 
fracture and haplotypes of the DBP gene by Cox regression model. Both analysis 
of covariance (ANCOVA) and Cox models were adjusted for potential confound-
ers, such as age, gender, height, weight, BMD and dietary calcium intake. We also 
stratifi ed the analyses by gender and high/low, tertiles and quartiles of dietary 
calcium intake in the study population. The interaction term of high/low calcium 
intake and DBP haplotype for facture risk was estimated in the Cox model with the 
adjustment for age and gender. All statistical analyses of the association study were 
carried out with the SPSS software package (version 11.0).
RESULTS
Haplotype structure of the DBP gene
The DBP gene structure is shown in Figure 1. It is at least 42 kb in length, 
contains 12 exons with a 4.3 kb 3’-untranslated region (UTR) and has at least 
162 SNPs according to the dbSNP database (build 12439). Three genotype data 
sources, Perlegen30, HapMap33, SNPbrowser34, and one publication24 provided the 
haplotype structure of the DBP gene in different ethnic populations. The Perlegen 
database includes genotype data of the highest number of SNPs as compared 
to other databases, and it also uses the HAP program35 to infer haplotypes. In 
order to summarise the haplotype structure of the DBP gene in Caucasian, Han 
Chinese and African American populations, we extracted genotype data from 
Perlegen, determined haplotype and LD block structure with the PHASE31 and 
HaploBlockFinder32 programs. We used the same criteria to defi ne haplotype 
blocks for the three datasets, and aligned all blocks across the gene to describe 
the linkage disequilibrium (LD) structure of the DBP gene. The distribution of 
selected SNPs in the DBP gene based on each dataset is shown in the upper panel 
of Figure 1. Seven common SNPs across the DBP gene were used in these three 
databases. Three consensus haplotype blocks across the DBP gene were observed 
in the Caucasian population (A-C), four blocks in Han Chinese and eight blocks in 
African American populations. In each ethnic population, the selected SNPs and 
the size of the study populations were different between soures, and therefore the 
LD structures of different sources were observed to be different from each other.
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Exon 11 contains two non-synonymous SNPs, rs7041 and rs4588, which are 
located in an overlapping region of the 3’-end haplotype blocks among the three 
ethnic populations (between two vertical lines in Figure 1). Because of high linkage 
between these two SNPs, only three instead of the possible four haplotypes were 
present in our population, corresponding to three Gc isoforms distinguished at 
the protein level. The allele frequency distribution of haplotypes in different study 
populations is shown in Figure 2.
Association study of DBP haplotypes
Serum vitamin D level: We measured serum vitamin D level in a sub-group (n = 
1,317) of the study population. The vitamin D level in our study population [mean 
and standard deviation (SD)] of serum 25(OH)D3 level was 65.5 ± 27.3 nmol/l 
(Table 1). Haplotype 1 was found to be signifi cantly associated with increased 
serum level of 25(OH)D3 (p = 3 × 10
-4 by a linear regression test for trend) and 1, 
25(OH)2D3 (p = 4 × 10
-4 for trend). In contrast, haplotype 2 was found to be highly 
signifi cantly associated with decreased serum level of 25(OH)D3 (p = 3 × 10
-6) and 
1, 25(OH)2D3 (p = 5 × 10
-5). The difference in serum vitamin D level between the 
extreme genotype groups was 0.2 – 0.6 standard deviation. No signifi cant differ-
ence in serum vitamin D level by haplotype 3 genotype was found. The associations 
were independent of age and gender.
Fracture risk and bone phenotypes: No signifi cant difference of fracture inci-
dence was observed by DBP haplotypes (Table 2), although we found a small in-
creasing trend of fracture risk by the DBP haplotype 1. The baseline characteristics 
by haplotype 1 of the DBP gene are shown in Table 3. In our study population, we 
did not observe a relationship between DBP haplotype 1 genotype and age, gender, 
body height, weight, clinical fracture and BMD.
Infl uence of dietary calcium intake: In the subgroup with record of dietary 
calcium intake, we observed a similar trend (as seen in the whole study population) 
and borderline signifi cant association of the DBP haplotype 1 and fracture risk (p 
= 0.06, Table 4). We further investigated the relationship between DBP haplotype 
1 and clinical fracture risk after stratifi cation for low or high dietary calcium intake. 
In the low dietary calcium intake group, we found that subjects homozygous for 
haplotype 1 had 47% increased risk of clinical fracture compared to non-carriers (p 
= 0.02). The association remained when we adjusted for age and gender. In the high 
dietary calcium intake group, no association was found. The interaction p-value 
between the haplotype 1 genotype and dietary calcium intake for clinical fracture 
was 0.06 after adjustment for age and gender. No effect of the interaction between 
DBP genotype and calcium intake on BMD and serum vitamin D level was found. 
We also stratifi ed calcium intake as tertiles and quartiles, and similar patterns of 
increased fracture risk by DBP haplotype2 was observed in those with a relatively 
lower calcium intake (Fig. 3).
Interaction between DBP and VDR: We stratifi ed the study population as non-
DBP Haplotype on Vit D & Fracture
139
T
ab
le
 1
 S
er
um
 v
ita
m
in
 D
 le
ve
l b
y D
BP
 (G
c) 
ha
pl
ot
yp
es
 in
 1,
31
7 e
ld
er
ly 
m
en
 an
d 
wo
m
en
To
ta
l
By
 h
ap
lo
ty
pe
s o
f D
BP
 C
od
on
41
6-
42
0
N
on
-c
ar
rie
r v
s. 
p-
va
lue
#
N
on
-c
ar
rie
r
H
ete
rz
yg
ou
s
H
om
oz
yg
ou
s
H
om
oz
yg
ou
s (
SD
)
25
-O
H
-D
3 (
nm
ol/
l)
65
.5 
± 
27
.3 
(13
12
)
H
ap
 1 
(G
c1
s)
61
.1 
± 
26
.3 
(2
69
)
65
.4 
± 
26
.9 
(6
47
)
68
.5 
± 
28
.3 
(3
96
)
↑ 
0.3
3 ×
 10
-4
 *
H
ap
 2 
(G
c2
)
74
.2 
± 
28
.3 
(6
65
)
63
.0 
± 
25
.6 
(5
40
)
58
.5 
± 
27
.1 
(10
7)
↓ 0
.6
3 ×
 10
-6
 *
H
ap
 3 
(G
c1
f)
65
.0 
± 
27
.2 
(9
17
)
66
.7 
± 
27
.6 
(3
60
)
64
.9 
± 
27
.1 
(3
5)
↓ 0
.00
4
0.5
7
1,2
5-
(O
H
) 2-
D
3 (
pm
ol/
l)
10
9.3
 ±
 3
0.3
 (1
31
7)
H
ap
 1 
(G
c1
s)
10
3.7
 ±
 29
.1 
(2
70
)
10
9.8
 ±
 3
0.8
 (6
48
)
11
2.4
 ±
 29
.9 
(3
99
)
↑ 
0.3
4 ×
 10
-4
 *
H
ap
 2 
(G
c2
)
11
3.0
 ±
 3
0.9
 (6
68
)
10
5.6
 ±
 29
.2 
(5
41
)
10
5.7
 ±
 2
8.9
 (1
08
)
↓ 0
.2
5 ×
 10
-5
H
ap
 3 
(G
c1
f)
10
8.9
 ±
 29
.7 
(9
22
)
11
1.0
 ±
 31
.5 
(3
60
)
10
2.
0 ±
 32
.2 
(3
5)
↓ 0
.2
0.1
8
D
ata
 ar
e p
re
se
nt
ed
 as
 m
ea
n 
± 
SD
 (n
um
be
r o
f s
ub
jec
ts)
, V
ita
m
in
 D
 le
ve
l w
as
 ad
ju
ste
d 
fo
r a
ge
 an
d 
ge
nd
er
#:
 p
-v
alu
e f
or
 tr
en
d 
(*,
 es
tim
ate
d 
by
 li
ne
ar
 re
gr
es
sio
n 
an
aly
sis
) a
nd
 A
N
O
VA
Chapter 8
140
T
ab
le
 2
 R
isk
 o
f c
lin
ic
al
 fr
ac
tu
re
 b
y 
D
BP
 h
ap
lo
ty
pe
s i
n 
6,
18
1 
el
de
rly
 m
en
 a
nd
 w
om
en
To
ta
l
H
ap
lo
ty
pe
s o
f D
BP
 C
od
on
41
6-
42
0
p-
va
lu
e
N
on
-c
ar
rie
r
H
et
er
zy
go
us
H
om
oz
yg
ou
s
H
ap
 1
 (G
c1
s)  
Ca
se
/t
ot
al
 (%
)
90
5/
61
81
 (1
4.
6)
15
5/
11
83
 (1
3.
1)
45
6/
30
68
 (1
4.
9)
29
4/
19
30
 (1
5.
2)
0.1
3*
Cr
ud
e 
H
R 
(9
5%
 C
I)
1
1.1
6 
(0
.95
-1
.41
)
1.1
9 
(0
.9
7-
1.
41
)
0.
13
*
A
dj
us
te
d 
H
R 
(9
5%
 C
I)
#
1
1.1
3 
(0
.93
-1
.3
8)
1.
20
 (0
.9
7-
1.4
9)
0.1
3*
H
ap
 2
 (G
c2
) 
Ca
se
/t
ot
al
 (%
)
48
2/
32
21
 (1
5.
1)
34
8/
24
77
 (1
4.
0)
72
/4
83
 (1
4.
9)
0.
56
Cr
ud
e 
H
R 
(9
5%
 C
I)
1
0.
92
 (0
.8
0-
1.
07
)
0.
99
 (0
.76
-1
.2
9)
0.
56
A
dj
us
te
d 
H
R 
(9
5%
 C
I)
1
0.
89
 (0
.77
-1
.0
4)
0.
95
 (0
.72
-1
.2
5)
0.
35
H
ap
 3
 (G
c1
f)
 
Ca
se
/t
ot
al
 (%
)
64
9/
43
48
 (1
4.
9)
23
9/
16
86
 (1
4.
2)
17
/1
47
 (1
1.
6)
0.
24
*
Cr
ud
e 
H
R 
(9
5%
 C
I)
1
0.
94
 (0
.8
0-
1.1
0)
0.
74
 (0
.4
5-
1.
24
)
0.
24
*
A
dj
us
te
d 
H
R 
(9
5%
 C
I)
1
0.
95
 (0
.8
1-
1.1
2)
0.
84
 (0
.5
0-
1.4
2)
0.
42
*
#:
 H
az
ar
d 
R
at
io
 (H
R)
 w
as
 a
dj
us
te
d 
fo
r a
ge
 a
nd
 g
en
de
r
*:
  T
re
nd
 p
-v
al
ue
 e
st
im
at
ed
 b
y 
lin
ea
r r
eg
re
ss
io
n 
an
al
ys
is
DBP Haplotype on Vit D & Fracture
141
T
ab
le
 3
 C
ha
ra
ct
er
ist
ics
 o
f t
he
 st
ud
y 
po
pu
lat
io
n 
of
 6
,18
1 
el
de
rly
 m
en
 a
nd
 w
om
en
 b
y 
D
BP
 h
ap
lo
ty
pe
 1
 (G
c1
s)
Ch
ar
ac
te
ris
tic
*
To
ta
l C
oh
or
t
H
ap
lo
ty
pe
 1
 o
f D
BP
 C
od
on
41
6-
42
0
p-
va
lu
e
N
on
-c
ar
rie
r
H
et
er
oz
yg
ou
s
H
om
oz
yg
ou
s
N
um
be
r (
%
)
61
81
11
83
 (1
9.1
)
30
68
 (4
9.
6)
19
30
 (3
1.
2)
Fe
m
al
e 
(%
)
36
89
 (5
9.7
)
70
3 
(5
9.4
)
18
31
 (5
9.7
)
11
55
 (5
9.
8)
0.
97
A
ge
 (y
ea
rs
)#
69
.4
 ±
 9
.1
69
.3
 ±
 9
.1
69
.7
 ±
 9
.3
69
.1
 ±
 8
.9
0.
07
H
ei
gh
t (
cm
) #
16
6.
8 
±
 9
.5
16
6.
7 
±
 9
.4
16
6.
6 
±
 9
.5
16
7.0
 ±
 9
.7
0.
11
W
ei
gh
t (
kg
) #
73
.2
 ±
 1
2.
0
73
.2
 ±
 1
2.
3
73
.2
 ±
 1
2.
3
73
.0
 ±
 1
1.
5
0.
68
D
iet
ar
y 
Ca
lc
iu
m
 in
ta
ke
 (g
/d
ay
) #
1.1
3 
±
 0
.3
6
1.1
3 
±
 0
.3
7
1.1
3 
±
 0
.3
6
1.1
2 
±
 0
.3
5
0.
36
Fe
m
or
al
 n
ec
k 
BM
D
 (g
/c
m
2 ) 
#
0.
84
 ±
 0
.14
0.
84
 ±
 0
.13
0.
84
 ±
 0
.14
0.
84
 ±
 0
.14
0.
90
Lu
m
ba
r s
pi
ne
 B
M
D
 (g
/c
m
2 ) 
#
1.
09
 ±
 0
.2
0
1.1
0 
±
 0
.2
0
1.
09
 ±
 0
.2
0
1.
09
 ±
 0
.19
0.
82
*: 
T
he
 fo
llo
w
in
g 
ad
ju
st
m
en
ts
 w
er
e 
ap
pl
ie
d:
- A
ge
: a
dj
us
te
d 
fo
r g
en
de
r
- H
ei
gh
t: 
ad
ju
st
ed
 fo
r a
ge
 a
nd
 g
en
de
r
- W
ei
gh
t: 
ad
ju
st
ed
 fo
r a
ge
, g
en
de
r, 
an
d 
bo
dy
 h
ei
gh
t
- D
ie
ta
ry
 C
al
ci
um
 in
ta
ke
: s
ub
se
t n
 =
 4
74
7; 
ad
ju
st
ed
 fo
r a
ge
, g
en
de
r a
nd
 d
ie
ta
ry
 e
ne
rg
y 
in
ta
ke
- B
M
D
: s
ub
se
t n
 =
 5
02
7, 
ad
ju
st
ed
 fo
r a
ge
, g
en
de
r, 
he
ig
ht
, a
nd
 w
ei
gh
t
#:
 D
at
a 
ar
e 
pr
es
en
te
d 
as
 m
ea
n 
±
 S
D
 (n
um
be
r o
f s
ub
je
ct
s)
Chapter 8
142
carriers of DBP haplotype 1 and carriers of DBP haplotype 1 (Table 5). In the 
group of non-DBP haplotype 1 carriers, fracture risk was not different by the VDR 
haplotype 1 (p = 0.70). However, the subjects who carried DBP haplotype 1 and 
were homozygous for VDR block 5-haplotype 1, had a 33% increased fracture 
risk (p = 0.008 by the Cox model). This association was independent of age and 
gender. The p-value of interaction between the DBP genotype and VDR genotype 
in relation to fracture risk was p = 0.09.
No interaction between DBP or VDR genotypes in relation to vitamin D level 
or BMD was observed in the study population (data not shown).
DISCUSSION
In this study we fi rst compared the LD structure of the DBP gene according 
to different haplotype databases. The haplotype structure analysis may facilitate to 
identify functional SNPs (in both association and functionality studies) of the DBP 
gene for disorders such as osteoporosis. The spans and boundaries of haplotype 
blocks were found to be different between different datasets. The different selec-
tion of SNPs, determination of common SNPs for the LD analysis, defi nition of 
haplotype block (e.g., threshold of D’) and the size of the study population can 
contribute to the LD map differences. We observed the most common haplotypes 
(haplotype 1 and haplotype 2 constructed by rs7041 and rs4588), to reside in an LD 
block “C” and to correspond to the common protein isoforms of the Gc protein: 
Gc1s and Gc2. The LD block spans > 20 kb from exon 7 to the 3’ end of the gene, 
including the 3’-UTR. Thus, variants in this region and linked to the two SNPs we 
analysed, can contribute to explain any observed association.
The classical function of DBP is to store and prolong the half-life of circulat-
ing vitamin D metabolites. DBP binds 88% and 85% of serum 25(OH)D3 and 1, 
25(OH)2D3, respectively
20. In our study, haplotype 1 (corresponding to Gc1s) was 
positively correlated with both 25(OH)D3 and 1, 25(OH)2D3, while haplotype 2 
(Gc2) was negatively correlated and haplotype 3 (Gc1f) was not associated with 
vitamin D level. Lauridsen et al.40 demonstrated that Gc1 (consisting of 80% Gc1s 
and 20% Gc1f in our analysis) was associated with increased plasma vitamin D and 
DBP level, and the DBP Gc2 allele was negatively correlated to plasma vitamin D 
and DBP level. Thus, our fi nding of a relationship between haplotype 1 and vita-
min D level indeed refl ects the correlation between serum DBP level and vitamin 
D level, and this is in line with a previous report23.
A relationship of Gc1 (associated with increased serum vitamin D level) and 
increased fracture risk was reported by Lauridsen et al.25,40. We also observed a 
similar trend in the complete study population (Table 2) and borderline signifi -
cance in a sub-group population based on availability of dietary calcium intake 
data (Table 5). This relationship can not be explained by the effect of DBP on the 
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vitamin D endocrine system, since increased vitamin D level is not associated with 
increased fracture risk. Moreover, according to the “free hormone” hypothesis, the 
free hormone performs the biological activity rather than bound hormone41, and 
the free vitamin D level is only <12-15% of total vitamin D level we measured.
The genomic and protein structures also reveal at least two different functions 
of the DBP. The vitamin D-binding region of the DBP is located between residues 
35-49 in the N-terminal end of the DBP (domain I in Figure 1)20. The two non-
sysnonymous coding SNPs are located in the C-terminal end (domain III, from 
residue 375 to the end) with a single glycosylation site nearby. Our LD structure 
analysis showed that these two domains are in different haplotype blocks for all 
ethnic populations. These two domains have a different function: domain I can 
bind to sterols, domains II and III are responsible for non-sterol binding activities 
of DBP42. The macrophage/osteoclast activating activity is also related to domain 
III16,42. The glycosylation of DBP in domain III is important for macrophage and 
osteoclast activation, while it has been shown that binding of vitamin D does not 
infl uence this activity43. This indicates that domain III plays an independent role of 
domain I in the function of stimulating osteoclast.
DBP haplotype 1 is associated with increased serum DBP level40. We hypothesize 
that the association of DBP haplotype with increased DBP levels is caused by SNPs 
in this block that result in increased mRNA levels, and thereby in increased DBP 
protein levels. The most likely position of these SNPs is in the 4.3 kb large 3’-UTR 
area. About 17 SNPs have been identifi ed in this region and further functional 
studies will be necessary to determine if and which of these SNPs cause differential 
mRNA expression. We note that we have recently identifi ed a similar situation for 
SNPs in the 3’-UTR of the VDR gene28.
DBP-MAF is an activator of osteoclasts, while in vivo studies demonstrated that 
a calcium-defi cient diet in rat studies could signifi cantly increase the number of 
osteoclast in different sites of bone26,27. In our sub-group population of human 
subjects with record of dietary calcium intake, we found that dietary calcium intake 
infl uenced the strength of the association between DBP haplotype 1 (Gc1s) and 
fracture risk. The association between the DBP haplotype 1 and fracture risk was 
only seen in subjects with a relatively low dietary calcium intake (< 1.09 g/day). We 
note that Lauridsen et al.25 showed a similar relationship between Gc1 and fracture 
risk in a population of Danish Caucasian with a dietary calcium intake at 0.8 g/day 
level40. Another study in a Japanese population24 found the Glu-allele at codon 416 
(corresponding to our haplotype 1) to be associated with decreased radial BMD. 
The dietary calcium intake of Japanese populations is considered to be lower [0.6 
g/day44] than ours and the Danish study populations. Although this seems to be 
in line with our observations, the association between the DBP haplotype 1 (or 
Gc1) and fracture risk in ours and the Danish studies was independent of BMD. 
We therefore also analysed subjects with dietary calcium intake < 0.6 g/day for 
DBP related differences in BMD. No association was observed. However, since we 
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had only 147 subjects in this category, we were not sure whether there is really no 
association, or we did not have suffi cient statistical power to detect the relationship 
between DBP haplotypes and BMD.
In this study we also demonstrated interaction of VDR and DBP polymor-
phisms on fracture risk. This gene-gene interaction on fracture risk is likely to 
involve two aspects of bone modelling and remodelling, which are active during 
the whole lifespan, and includes bone formation (by osteoblasts) and bone resorp-
tion (by osteoclasts) to maintain serum calcium homeostasis and bone metabolism. 
The block 5-haplotype 1, fracture risk allele, of the VDR gene results in a lower 
expression of VDR mRNA in osteoblasts28. This indicates that the osteoblast of 
block 5-haplotype 1 carriers could give a compromised response to vitamin D since 
lower numbers of VDR protein are present in the cells. Thus, this is likely to result 
in lower bone formation for the VDR block 5-haplotype 1 carriers. As mentioned 
above, DBP haplotype 1 is associated with increased DBP level, and this might 
result in increased osteoclast activity, and thus increased bone resorption. Taken 
together, carriers of both risk alleles might have a lower bone formation and higher 
bone resorption resulting in increased bone turnover which negatively infl uences 
bone quality and strength45. Thus, bone of both risk-allele carriers becomes weaker 
with time, and thus fracture risk consequently increases. This hypothesis needs to 
be confi rmed by functionality studies.
In conclusion, we summarised the haplotype structure of the DBP gene accord-
ing to three major haplotype datasets. The most commonly used haplotypes (or 
protein isoforms) of the DBP gene were found to be associated with serum vitamin 
D level, while an additive effect of VDR block 5-hap 1 and DBP haplotype 1 (Gc1s) 
on fracture risk was observed, and DBP haplotype 1 was found to be associated with 
fracture risk especially in a low calcium intake group. Further functional analysis of 
DBP 3’-UTR variants is necessary to investigate the underlying mechanism, while 
the relationship between DBP haplotypes in other LD blocks and osteoporosis 
remains to be studied.
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In this thesis, we investigate the relationship between polymorphisms in the vitamin D endocrine pathway and bone phenotypes. The thesis consists of three 
major consecutive portions: molecular genetic studies, genetic association studies 
and functionality studies.
First, we integrated all resources from web databases and publications to de-
termine the most accurate genomic structure of the VDR gene. This complete 
genomic sequence of the human VDR gene was compared with the mouse VDR 
sequence to identify high homology regions between these two species as potentially 
functional regions and as targets for sequencing. 62 polymorphisms were detected 
by re-sequencing those potentially functional regions, and used to determine the 
LD structure and tagging SNPs across the VDR gene for different ethnic groups. 
We then investigated the association between VDR haplotypes (defi ned by tagging 
SNPs) and bone phenotypes, including fracture, body height and bone geometry 
parameters in a large population-based study population and in an independent 
sample: the LASA population. Potentially functional haplotypes were found ac-
cording to association and functionality studies. Gene-gene and gene-environment 
interactions in relation to fracture risk were briefl y described in the study. Finally, 
we performed functionality studies to provide possible molecular mechanism that 
could explain the association results.
9.1 Usage of bioinformatics in our study
9.1.1 Structure and polymorphisms of VDR gene: Baker et al.1 reported the 
DNA sequence of human VDR cDNA in 1988, while Miyomoto et al.2 and Croft et 
al.3 simultaneously described the major genomic structure and four tissue-specifi c 
exons at 5’-end of the VDR gene after 10 years. However, the genomic structure 
of the VDR gene as is reported in the NCBI database4 so far does not include the 
results of the Croft study, and the size of the VDR gene is only about 65 kb. In 
our study, we integrated all published data and data from the Celera database, and 
described the genomic structure of the VDR gene with a size of > 105 kb (up to 
exon 1f). Our study and Nejentsev et al.5 re-sequenced the VDR gene in 30 and 16 
chromosomes, respectively, and thus polymorphisms with a minor allele frequency 
(MAF) of > 3% and 6% could be detected, respectively. Therefore, both studies 
described a higher quantity and quality of polymorphism data than the Celera6 and 
NCBI7 database (before these studies submitted their data to the dbSNP database). 
40% of the polymorphisms we found were not in those databases or in any publica-
tions.
9.1.2 Haplotype structures from different resources: Our study and the 
study of Nejentsev5 focused on analysing the haplotype structure of and around 
one single gene, e.g. the VDR gene. The initiatives of Perlegen8, HapMap9 and 
SNPbrowser10 create a genome-wide haplotype map of SNPs. The studies on single 
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gene LD structure so far have high densities of selected SNPs. For example in our 
study we determined an LD map used on average one SNP per 0.54 kilo-basepairs 
(kb), as compared to one SNP per 1.7 kb by Nejentsev et al.5. The three databases 
generated LD maps of the VDR gene with a density of one SNP per 2.2 – 9.5 
kb (including SNPs with MAF < 10%). With a high density of SNPs, a similar 
haplotype block defi nition and the same program (PHASE11), both our study and 
the study by Nejentsev et al. identifi ed a similar and higher resolution LD map 
compared to the three databases. The consensus LD map of the VDR gene accord-
ing to all studies and databases shows differences in haplotype block size. The LD 
block sizes determined in our study and Nejentsev et al. (< 17 kb) are smaller than 
that of the three databases (see Figure 2 in chapter 3).
These three databases analyse LD structure of the whole genome. Large num-
bers of SNPs are included to be analysed: Perlegen included 1.6 million SNPs in 
February 2005, HapMap have 2.25 million in its database (until August 2005), 
SNPbrowser contains 5 million till August 2005. The data of Perlegen and HapMap 
have been merged together, and by the end of 2005 Perlegen plans to test another 
4.6 million SNPs in public databases and add them to the map. Although more 
and more SNPs have and will be included in those databases, the selected SNPs 
are not based on the gene structure, or based on functional domains of the gene. 
This contrasts somewhat with our approach as is shown in the Figure 2 of chapter 
3 for the VDR gene and the Figure 1 of chapter 8 for the DBP gene. Reasons why 
these databases do not show consistent LD structures are not only because of the 
lack of common SNPs in all three databases (see selected SNPs in the Figure 2 of 
chapter 3 and Figure 1 of chapter 8), but also because of different defi nitions of 
haplotype blocks that were used. For example, Perlegen selects MAF of SNPs > 
10% and uses the Hap algorithm12 to infer haplotypes from their diploid genotype 
data13. HapMap and SNPbrowser use the PHASE algorithm14 to estimate pair-wise 
LD of SNPs and keep the selection of MAF and haplotype block cutoff value open 
for users. MAF is known to affect LD structure and determination of tagging SNP, 
and MAF depends on sample size. Small sample size requires high MAF cutoff 
value for the LD analysis. Another pitfall of these databases is that they mostly use 
computational constraints on SNP selection, and ignore common variations and the 
functional aspect in the SNP selection criteria. For example, two non-anonymous 
SNPs, rs7041 and rs4588 SNPs, are close to each other and in exon 11 of the DBP 
gene. They defi ne the most common DBP phenotypes, and two phenotypes were 
found to be signifi cantly correlated with serum vitamin D level in our and other 
studies, and also have interaction with VDR haplotype for fracture risk. They are 
functional SNPs of the DBP gene. However, SNP rs7041 was not included in the 
LD analyses of all three databases, and was not determined as haplotype tagging 
SNP. Unlike most genome-wide studies, databases and DNA-array design, we pro-
vide a way to determine haplotype tagging SNPs (htSNPs) not only according to 
computer programs based LD analysis but also taking SNP that are frequently used 
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in other studies and taking functional aspects into account. For the LD analysis of 
a gene, we suggest to combine information from Perlegen, HapMap, SNPbrowser 
and other publications, and to use the same haplotype defi nition and program to 
achieve a relatively accurate haplotype structure of the gene.
9.2 Genetic studies
9.2.1  Linkage or candidate gene association study: The initial genetic study 
design for inherited disease dominantly focused on linkage analysis in pedigrees. 
This design is very powerful to identify rare high-risk disease alleles, such as in 
single-gene Mendelian diseases. The linkage design searches for the disease-causal 
alleles in relative large regions of the genome. Because of low frequent recombina-
tion events within most families, it is mostly diffi cult to narrow the interesting 
region below several megabases. Inversely, association design is more powerful to 
detect  common alleles with modest disease risks15. For the association design it 
is easier to recruit large numbers of unrelated affected individuals than to collect 
large numbers of families, especially for diseases in the elderly, and it can investi-
gate the relationship between single variations and disease. However, association 
analysis requires markedly higher density of genetic markers than linkage analysis. 
The combined study design, candidate gene analyses within linked regions, which 
have been greatly accelerated by the availability of the complete sequence of the 
human genome, provides a reasonable strategy to identify fi ne disease genes in 
suggestive-linkage regions16. SNPs are the most frequent sequence variations of the 
genome by now, more than eleven million SNPs have been identifi ed in the human 
genome. Since SNPs are relatively easy to be analysed compared to multi-allele 
polymorphisms, they are commonly used in genetic association studies.
We can distinguish direct and indirect association studies, which are based on 
functional polymorphisms and “marker” polymorphisms respectively. A direct 
association study can be carried out for the putatively functional SNPs based on 
the evidence of functionality studies, e.g., the Cdx-2 polymorphism of the VDR 
gene. Alternatively, an indirect association between unknown functional SNPs and 
a disease requires to test a dense map of marker SNPs and to identify the LD 
map across the gene, e.g., other analysed SNPs across the VDR gene. Both direct 
and indirect association studies have proven to be effective methods to identify 
association of candidate genes that have been implicated in disease pathogenesis 
in our study.
9.2.2 Whole genome association (WGA) study: WGA study, a non-hypoth-
esis study design and analysing association between sequence variations in whole 
genome and one phenotype, can theoretically analyse the entire genome at once in 
an unbiased fashion. This design intends to investigate highly dense polymorphic 
markers across the whole genome for diseases, and is a promising research direction 
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to identify the genetic basis of complex disorders. For WGA, high-density SNP 
genotyping assays (gene chips) are required to be used in a case-control design. 
For example, Perlegen offers a set of 1.6 million validated SNP assays to genotype 
pooled case or control DNAs, and Affymetrix is developing a 500,000 SNP-chip17. 
However, SNP selection strategies (like those based on haplotype tagging, or on 
potential function) differ for the different platforms, e.g., Affymetrix selects equi-
distant SNPs, Perlegen focuses on tagging SNPs and Illumina selects coding and 
tagging SNPs.
9.2.3 Genetic meta-analysis: A retrospective meta-analysis (for instance, 
Mann et al.18 for COLIA1 Sp1 SNP and our study in chapter 8) of the VDR Bsm 
I RFLP can systematically summarize and obtain suffi cient statistical power to 
detect an overall modest genetic effect according to published association studies 
(with different study sizes). However, publication bias (positive results are likely 
to be published) and heterogeneity between studies (e.g. the meta-analysis of Bsm 
I genotype and fracture risk in chapter 5.1) are remarkably infl uencing the reli-
ability of the conclusion from meta-analyses. The GENOMOS (Genetic Markers 
for Osteoporosis) project provides an example of another design of meta-analysis 
of genetic association studies: prospective meta-analysis. This design involves the 
study of several candidate gene polymorphisms in relation to osteoporosis-related 
outcomes in approximately 20,000 individuals drawn from eight European centers. 
Genotype data is obtained prospectively from all centers and all are included in the 
analyses to avoid the publication bias. Standardization of genotyping and analysing 
can avoid attributing to genuine genetic variability difference between study teams 
that might be simply due to analytical inconsistencies. This design detected the 
genetic effect of ESR1 gene polymorphisms on osteoporosis19.
9.3 Individual polymorphism or haplotypes in association study
Initially most genetic association studies investigated relationships between in-
dividual polymorphisms and clinical endpoints. Nowadays, more and more studies 
are focusing on studies of haplotypes, as haplotypes combine genetic information 
of individual polymorphisms. Haplotype-based methods offer a powerful approach 
to disease gene mapping20, and the Human Genome Project, the SNP project and 
the HapMap project make great efforts to provide haplotype data for association 
studies. In a study, we identifi ed the VDR Cdx-2 polymorphism to be associated 
with fracture risk in the Rotterdam Study population, especially for non-vertebral 
fracture in women (chapter 4). In our more recent and more comprehensive study 
(1st section of chapter 5), we used the Cdx-2 and GATA polymorphisms as haplotype 
tagging SNPs (htSNPs) of the VDR LD block 2, and demonstrated that haplotype 
1 defi ned by these two SNPs and containing the risk allele of the Cdx-2 SNP 
was associated with any fracture in the complete study population. Furthermore, 
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functionality studies (chapter 8) showed that GATA is another potential functional 
polymorphism (in addition to Cdx-2) in the haplotype block. This suggests that 
several functional SNPs in a haplotype block can “collaborate” to confer risk for a 
certain disease.
In the 3’-end of the VDR gene, most previous studies performed association 
studies for individual RFLPs: Bsm I, Apa I and Taq I which are in the same haplo-
type block as 3’-UTR SNPs. Bsm I and Apa I RFLPs are in intron 8, and although 
Taq I is in exon 9, it does not change the amino acid sequence of the VDR, so they 
are all anonymous (not functional) RFLPs. In our study (1st section of chapter 5), 
haplotype 1 defi ned by 3’-UTR SNPs was found to be associated with fracture 
risk, and similar associations were detected for haplotype 1 of Bsm-Apa-Taq and 
the “b-allele” of Bsm I RFLP. The function of 3’-UTR of a gene likely involves 
infl uencing the gene expression by regulating the stability of mRNA. Thus, we hy-
pothesized that the causal polymorphisms to potentially explain those associations 
in the haplotype block were in the 3’-UTR. In the functional study (chapter 7), 
when we transfected the same coding sequence, as well as complete VDR 3’-UTR 
sequences of haplotype 1 and 2 (excluding Bsm I and Apa I RFLPs) into different 
cell lines, the 3’-UTR in haplotype 1 was indeed found to have 15% lower mRNA 
level compared to haplotype 2. The differences between haplotype 1 and haplotype 
2 are limited to 25 sequence variations across 17 kb (LD block 5) in Caucasian 
population. When we assume the causal nucleotide variants to reside in the 3’-UTR, 
this is further limited to fi ve polymorphisms. The question arises whether it is one 
of these variants that “drives” the association, or perhaps the combination of > 2 
polymorphisms. This has to be investigated in further studies by analysing 3’-UTR 
constructs of different combination of nucleotide variants. As a parallel alterna-
tive study, one could also perform a similar association study, but now in African 
Americans. The LD blocks there are smaller, thus, we could “zoom in” on smaller 
region/haplotype blocks that show association. In any case, we can conclude from 
this study that VDR haplotypes represent the genetic effect of VDR variations on 
fracture risk in our population.
Polymorphisms within a gene are interacting with each other (intragenic 
interaction) to determine the gene functions in a give cell and/or subject. The 
promoter area regulates production of mRNA while the 3’-UTR is involved in 
stability/degradation of mRNA and their interaction/combined effects regulates 
the net availability of the mRNA for translation into the VDR protein. In our 
study we detected not only haplotypes in separate LD blocks that are related to 
bone phenotypes, but we also further investigated the combined genetic effect of 
haplotypes in the promoter region and in the 3’-UTR. Indeed, we observed additive 
effects of haplotypes in both regions on fracture risk and body height. 
In addition to our study, Nejentsev et al.5 also similarly re-sequenced the com-
plete VDR gene, performed LD analysis, determined haplotype structure across 
the VDR gene for three major ethnic populations. However, in their subsequent as-
Chapter 9
158
sociation study21, they analysed 98 individual SNPs instead of haplotypes for type 1 
diabetes risk in 3,763 families. They found two intronic SNPs and one 3’-UTR SNP 
with p = 0.02 – 0.05 (which no longer are signifi cant when p-values are adjusted 
for multiple testing by the Bonferroni correction). When they tested those three 
SNPs in an independent case-control (n = 1,587 and 1,827, respectively) study, 
no signifi cant p-value was found. Finally, they conclude that sequence variation 
in the VDR gene had no major effect on type 1 diabetes in their populations. 
Although the conclusion might be true, some questions and discussions remain 
after this study. First, the authors had LD structure and race-specifi c tagging SNPs 
of the whole VDR gene, but did not report the association of VDR haplotypes 
and diabetes. Although they did not fi nd individual SNPs to be associated with 
type 1 diabetes, the relationship between VDR haplotypes and diabetes remains 
to be further investigated. Secondly, since there might be less than 20 common 
haplotype alleles (frequency > 5%) across the whole VDR gene (according to our 
study), the number of the analyses using haplotypes is much lower than the number 
of the analyses using 98 individual SNPs. Thus using haplotypes in the study will 
reduce the number of analyses thereby diminishing multiple testing. Thirdly, the 
MAF of one “signifi cant” SNP for diabetes in the family study was 1%. Even in 
3,763 subjects, the authors have not suffi cient statistical power to detect the subtle 
genetic effect of the SNP on diabetes. Therefore, it is important to determine the 
cut off value of allele frequencies for selected SNPs or haplotypes according to the 
statistical power of the study population before carrying out the association study 
or LD analysis.
9.4 VDR polymorphisms and bone phenotypes
VDR mediates the endocrine function of vitamin D for calcium and phosphate 
homeostasis and bone metabolism. Over 1,000 of studies have investigated the 
relationship between VDR polymorphisms with osteoporosis (especially focusing 
on the most important clinical endpoints: BMD change and fracture risk), adult 
stature and bone geometry variables.
9.4.1  Association studies of VDR polymorphisms and BMD: Low BMD is 
an important risk factor of osteoporosis. As mentioned in chapter 1, many associa-
tion studies have been performed to test the relationship of VDR polymorphisms 
and BMD. Furthermore, three studies22-24 summarized association studies between 
VDR polymorphisms and BMD. Cooper et al.22 reported that the BB genotype of 
the Bsm I was associated with decreased BMD only at the hip, and that younger 
women with BB genotype had border line signifi cantly lower BMD compared to 
women with the bb genotype. Nevertheless, such effect disappeared after omitting 
the data25 with genotyping error. The meta-analysis of Gong et al.23 summarized 
75 studies on the association between Bsm I, Apa I, Taq I and Fok I RFLPs of 
General Discussion
159
VDR gene with BMD as well as other related skeletal phenotypes. These authors 
grouped all studies as “positive” and “non-positive”, while the “positive” study was 
defi ned as studies with association between either one of the b, a, T, or F alleles and 
increased BMD or other phenotypes. However, this study has several drawbacks. 
Some phenotypes in the study were not always in line or even comparable with 
BMD, such as, bone geometry variables, response to vitamin D treatment, bone 
turnover and fracture, and they should not be counted together in the same pheno-
type group as BMD. Furthermore, according to what is known about linkage of the 
VDR gene polymorphisms, the Fok I RFLP is not linked to Bsm I, Apa I and Taq I 
polymorphisms, and can therefore not “explain” the association results of the Bsm 
I, Apa I and Taq I RFLPs. Studies on the Fok I RFLP should be analysed as a dif-
ferent genotype group in the meta-analysis. Thakkinstian et al.24 observed that the 
BB genotype had lower spine BMD than Bb + bb genotypes but only in studies of 
postmenopausal women with a big range of B-allele frequency (29 – 53%, possibly 
due to ethnic admixture) and heterogeneity was generally present in their analyses. 
All together, this indicates that there is also no evidence of a genetic effect of Bsm 
I and Taq I RFLPs on BMD, and the genetic effect of Fok I and Apa I RFLPs on 
BMD is unclear. 
A functional polymorphism, Cdx-2, in the promoter region of the VDR gene 
was implicated to infl uence vitamin D regulation of calcium absorption in the 
intestine26. Consequently, the A-allele of the Cdx-2 binding site was found to be as-
sociated with increased BMD in Japanese postmenopausal women27. However, we 
only see a borderline signifi cant BMD difference by Cdx-2 (or haplotype 1 of VDR 
LD block 2, containing the G-allele of the Cdx-2 SNP) genotype in the Rotterdam 
Study population, and no association was found in the LASA population. One 
interpretation might be a difference in dietary calcium intake between Japanese and 
Dutch populations. The mean of dietary calcium intake in the Rotterdam Caucasian 
population is 1,117g/day, but is only about 600g/day for the Japanese Asian popula-
tion28. We also analysed in the Dutch Caucasian the relationship between VDR 
Cdx-2 genotype and BMD in subjects with calcium intake < 600 or < 800 mg/day, 
but we did not have suffi cient statistical power to detect the association, since the 
A-allele frequency in Caucasian population (19%) is lower than in Asian population 
(44%).
9.4.2 VDR polymorphisms predict multiple bone phenotypes in the 
Rotterdam Study: The Rotterdam study has collected multiple phenotypes and 
in this respect is likely to help us to understand the contribution of genetic factors 
to components of disease by looking for biological consistency in associations. In 
association studies of the thesis we demonstrated a relationship between VDR 
polymorphisms with several related bone phenotypes, including fracture risk, body 
height, bone size.
We have described associations between VDR polymorphisms and osteoporosis 
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in our previous studies29-31. Recently we extended the study size and investigated 
most potentially functional polymorphisms across the VDR gene. Our current fi nd-
ings not only confi rmed the previous associations, but also presented an overview 
of genetic effects of VDR polymorphisms on osteoporosis. We fi rst found that 
three haplotype alleles in the promoter and 3’-UTR were associated with increased 
fracture risk, while an additive effect of these risk alleles across the VDR gene was 
observed. The haplotype alleles in the 3’-UTR show the strongest effect on the 
fracture risk (chapter 5.1). 
We secondly demonstrated the associations between two fracture-risk haplotypes 
and their combined genotype with decreased body height in the same population 
and another independent elderly population (the LASA study). These associations 
were further confi rmed by a meta-analysis of VDR genotype (defi ned by the Bsm 
I RFLP) and body height according to published data. The same haplotype alleles 
were observed to be associated with decreased bone size and strength (chapter 6). 
Another fracture-risk haplotype allele found in our population, block 2-hap1, was 
not found to be related to height difference in our elder and high calcium intake 
(1,117 mg/day) populations: the Rotterdam Study and the LASA. However, this 
haplotype was found to be associated with decreased body height in young and 
low calcium-intake (< 865 mg/day) French adolescent girls32. This haplotype also 
associated with decreased serum 25(OH)D3 and decreased serum IGF-1 level in the 
same French population. Since Cdx-2 polymorphism is one of the htSNPs which are 
related to calcium absorption through the intestine, the interaction between block 
2-hap 1 with calcium-intake and/or serum vitamin D level on bone phenotype is 
interesting to be further investigated in other young and old populations. 
We then described an interaction effect between VDR 3’-UTR haplotype and 
DBP haplotype on fracture risk (chapter 8). All those associations are independent 
of BMD. With the evidence of functionality study of VDR haplotypes (chapter 7), 
the underlying mechanism of the association studies seems to be that VDR frac-
ture-risk allele carriers have a lower sensitivity to the vitamin D ligand because of 
lower expression of VDR. Perhaps this is due to lower osteoblast activity compared 
to non risk allele carriers. Thus, the bone gain decreases because of decreasing bone 
formation, consequently the bone loss is relatively increased, which is refl ected in 
decrease of the bone size and strength, and bone shape change, fi nally height loss 
increases and fracture risk increases. On the other hand, DBP-macrophage activat-
ing factor (DBP-MAF) can mediate bone resorption by activating osteoclasts33, 
and the fracture-risk haplotype allele of the DBP gene (according to Lauridsen et 
al.34) is associated with increased plasma DBP level35. Thus, the fracture-risk allele 
of the DBP carriers is likely to have higher osteoclast activity, and thus higher bone 
resorption. When carrying both risk alleles of VDR and DBP genes, the subject has 
low bone formation because of low osteoblast activity and high bone resorption 
because of high osteoclast activity. Bone strength in these subjects could therefore 
decrease and fracture risk could increase. However, those hypotheses need to be 
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confi rmed by further studies.
9.4.3 Reason of confl icting association results: Many studies reported con-
fl icting associations between VDR polymorphisms and fracture risk. Our meta-
analysis does not show a genetic effect of Bsm I RFLP on fracture risk, and this 
seems to contradict our association results in the Rotterdam Study. Some factors 
could underlie the differences in association results. Our association study is based 
on a population-based and large-scale study design. All subjects of the study popu-
lation share similar environmental factors and have the same ethnical background, 
and haplotypes of each of the blocks were used for the association analysis. Many 
previous confl icting association studies on VDR and fracture, analysed usually 
(very) small study populations and used the Bsm I, Apa I or Taq I polymorphisms 
in the VDR LD block 5, but mostly analysed separately. We therefore suppose 
that this controversy can partly be explained by a lack of statistical power as a 
result of small sample size, and failure to use haplotypes. The meta-analysis of the 
association between Bsm I and fracture risk showed a signifi cant heterogeneity 
between different individual studies (I2 < 0.001). The direction and strength of 
association results from different studies is shown different in fi gure 1 of chapter 
5.2. The defi nition of phenotype, such as fracture, crucially affects the prospects 
of an association analysis, and it is diffi cult to standardize the defi nition of fracture 
among the individual published studies for the meta-analysis. The different type of 
study design is also another important source of heterogeneity (such as equal-size 
case-control, non equal-size case-control, hospital source case-control, population-
based and non population-based cohorts). Such settings will determine study size 
and different numbers of fracture, such as incidence and prevalence of fracture in 
the study population. In addition, population stratifi cation, such as mixed ethnic 
groups with different allele frequencies, population-specifi c differences of some 
environmental factors, such as (dietary) calcium intake, (dietary) vitamin D intake, 
sunlight-exposure, and other characteristics of the study population pertinent to 
bone metabolism and fracture risk could result in heterogeneity of associations ob-
served across different study populations. Therefore, non-standardized phenotype 
defi nition, poorly characterized and non-normal distributed study populations, 
unregulated environmental exposures can essentially infl uence (and/or cover up) to 
identify modest genetic effects of sequence variations, because those factors bring 
genetic and environmental noise in the meta-analysis. Especially, for supposedly 
small effects such as for the VDR (see below), this can mask their detection in 
meta-analysis.
9.5 Magnitude of genetic effect of gene variation
The genetic effect of VDR polymorphisms on bone phenotypes is generally 
modest in our study. In the association studies, we demonstrated that two haplotype 
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alleles (in block 3 and 5) increased fracture risk by 15 – 74 %, and decreased 0.09 
– 0.15 SD. of body height. Our results refl ect the common disease/common variant 
(CDCV) hypothesis36. In a public health context, few high-risk alleles may have a 
large population attributable ratio (PAR, >50%), which is thought of as the fraction 
of the disease that would be eliminated if the risk factor were removed. Common 
modest-risk alleles may account for a greater PAR in common disease than do rare 
high-risk alleles16. The haplotype 3 homozygous in VDR LD block 3 increases frac-
ture risk by 60%, but contributes only 1% PAR because of 2% genotype frequency 
in the population. With 68% genotype frequency, haplotype 1 carriers in block 5 
increases fracture by 20%, being associated with 12% PAR. In a previous study we 
showed the homozygous “s-allele (or T-allele)” of the COL1A1 Sp1 polymorphism 
to be associated with 50% increased fracture risk and 0.23 and 0.35 SD. decreased 
femoral neck and lumbar spine BMD37. We now demonstrated it has 1% PAR in 
our complete study population, and genotype frequency of TT homozygotes is 3%. 
These small risks are in line with small effects detected in functional studies. Our 
functionality study showed that the difference of VDR mRNA level by 3’-UTR 
haplotype was 15%, and Mann et al.18 presented the “Ss” (or GT) genotype of 
COL1A1 Sp1 was found to have a 21% increased COL1A1/COL1A2 protein ratio 
compared to “SS” (or GG) as measured in osteoblasts. Another functional study38 
of a 3’-UTR SNP [+1073C/T in the oxidised LDL receptor (OLR1) gene] that asso-
ciates with increased risk for Alzheimer’s disease (AD) demonstrated that C-allele 
carriers had 41% decreased OLR1 mRNA level compared to “TT” homozygotes. 
Therefore, common variants contribute modest genetic effect to common diseases, 
but they are the most interesting variations for genetic studies in the terms of public 
health. 
9.6 Suggestions of future studies
9.6.1 Identifi cation of functional variations of a candidate gene: Our stud-
ies in the thesis provide a study strategy, which combines bioinformatics, molecular 
genetics, genetic association and functionality aspects together, to identify func-
tional polymorphisms for candidate gene studies. A procedure of genetic study for 
a candidate gene is described in Figure 1. The study begins with bioinformatics 
aspects: a. view previous studies (association, functional experiments in vivo or in 
vitro) to make a hypothesis for the current study; b. fi nd genomic organization of 
the gene, collect all information of sequence variations of the gene (from genetic 
databases, e.g., NCBI, and publications); c. download genotype data from Perlegen, 
HapMap and SNPbrowser databases, compare LD maps of those resources (as 
well as published data) with the same haplotype defi nition criteria to generate a 
consensus LD map. If few common SNPs are present in all resources, and LD 
structures are much different among the resources, an assessment of an accurate 
LD pattern in a small set of control individuals (called the LD sample) is suggested 
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Figure 1. A procedure of genetic study for a candidate gene.
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to be carried out. The consensus LD pattern is then intended to determine com-
monly used and/or potentially functional variations as tagging SNPs across the 
gene for the association study. Genotyping all tagging SNPs in the association 
study population, generates haplotypes to test the hypothesis of the association 
between haplotypes of the gene and phenotype. Analysing an association in one 
study population is followed by replication studies in other populations, and retro-
spective or prospective meta-analysis to systematically summarize the association 
studies. Finally, functionality studies are carried out if the associated haplotypes 
are identifi ed.
9.6.2 WGA study: With the developing support of the SNP project and the 
HapMap project, high-throughput genotyping technology and statistics, WGA 
study becomes a critical tool for the identifi cation of susceptibility genes for complex 
traits15. The study design of a WGA might briefl y consist of following portions. The 
major study population of the WGA studies is the Rotterdam Study population, 
the replication of positive results will be tested in several independent populations, 
such as LASA, EPOS and so on. The phenotypes of the studies should be precisely 
defi ned, it will have greater chances of success and will increase the likelihood that 
the results will be replicated39. The tagging SNPs across the whole genome should 
be well selected according to systematical analysis of resources information on 
SNPs and LD maps from Perlegen, HapMap, SNPbrowser, other publications and 
LD-study samples. The selection criteria should consider allele frequencies of SNPs 
(following CDCV hypothesis), physical distance between SNPs, SNP distribution 
in the genome, potential function of SNPs and linkage status of SNPs. Common 
haplotypes in LD blocks are suggested to be used in the study to restrict multiple 
testing. The threshold of common haplotype frequency is determined by power 
calculation based on different type of study populations.
9.6.3 Pharmacogenetics: Complex genetic traits involve gene-environment 
and gene-gene interactions. Pharmacogenetics studies the role of DNA sequence 
variation in individual variation in drug response, and represents the fi eld of gene-
environment interactions. Functional variations in gene products that play essential 
roles in determining variability in drug responses are analysed for the correlations 
between the genetic variant and drug associated toxicity or therapeutic effect40,41. 
Difference in response to vitamin D supplementation for BMD change by VDR 
genotype was reported in a Caucasian population42. In this study, a placebo-con-
trolled clinical trial was carried out in elderly women (age > 70 years), and the effect 
of vitamin D supplementation on BMD and fracture was examined after one and 
two years follow-up. The increase of BMD in the vitamin D group relative to the 
placebo group was signifi cantly higher in BB and Bb genotypes of the VDR gene as 
compared to the bb genotype. This was the fi rst study to demonstrate that the ef-
fect of vitamin D supplementation on BMD depends on the VDR genotype. More 
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and more polymorphisms and mutations are identifi ed as prognostic markers, and 
fi rst phase of “personalized medicine” is already under way with the genotyping 
required to prescribe drug for patients, although there is still a long way to go43. 
Pharmacogenetic studies will be an attractive fi eld for scientists. 
WGA studies followed by candidate gene studies provide the opportunity to 
investigate the pathway and network of gene-gene and gene-environmental in-
teractions. Overall disease risk can be modeled as the product of risks at many 
independent genetic risk loci and environmental factors. It is interesting and a great 
challenge to determine the genetic contribution of variations of candidate genes 
and environmental contributions to a certain clinical endpoint, such as osteopo-
rosis, with statistic models. In osteoporosis, more than 20 candidate genes have 
been analysed in more or less detail so far to determine their contribution. Studies 
on the Rotterdam study30,37,44-46 and in particular the GENOMOS consortium19 
provide important research environments to dissect the genetics of osteoporosis 
and determine their contribution to the overall risk for this disabling disease.
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Genetic variations of the vitamin D receptor (VDR) gene have been found associated with several complex diseases, including osteoporosis, but with 
controversial results. This can be due to small sample size of the association studies 
and non-functional sequence variations analysed. We performed the current study 
to fi nd and characterize genetic variations across the whole VDR gene, investigate 
functionality of variations and determine association with bone phenotypes. This 
research involved several approaches including bioinformatics, molecular genetics, 
genetic epidemiology and cell biology.
In Chapter 2, we integrated information from different resources and updated 
the genomic organization of the human VDR gene. Homology analysis between 
human and mouse VDR genomic DNA sequences was used to determine the 
potentially functional regions of the human VDR gene for the re-sequencing study. 
We then sequenced those potentially functional regions (22 kb) across the VDR 
gene to fi nd sequence variations (polymorphisms) in 15 Caucasian individuals. 
We observed 62 polymorphisms, and compared the fi ndings with other genetic 
databases using bioinformatic methods and determined a more accurate genomic 
structure of the VDR gene.
In Chapter 3, we examined the linkage disequilibrium (LD) and haplotype 
structure across the VDR gene based on the sequencing results, defi ned the hap-
lotype maps and haplotype tagging SNPs for association studies in Caucasians, 
Asians and Africans. Four to eight haplotype blocks and nine to 28 tagging SNPs 
were determined in those three ethnic groups which can be used in association 
studies.
In Chapter 4, we investigated the relationship between a functional SNP in a 
VDR promoter region and fracture risk. The Cdx-2 SNP is a G to A substitution 
and was fi rst reported at a position in front of exon 1a by a Japanese group, but 
they only tested the relationship with BMD in a small Japanese female population. 
During our re-sequencing analysis, we also observed this SNP, and identifi ed the 
location of the SNP is at 1012 basepair in front of exon 1e, and we resolved that 
the distance between exon 1e and 1a is 2kb. We then developed a simple and quick 
genotype method to analyse DNA samples from 8 different ethnic groups and a 
large sample of the Rotterdam Study. We found a correlation between the Cdx-2 
genotype and prevalence of fracture in different ethnic populations, and identi-
fi ed a BMD-independent association between the G-allele and fracture risk in the 
Rotterdam Study population.
In Chapter 5, we focus on the analyses of VDR haplotypes and one 3’-end 
polymorphism in relation to fracture risk. An association study in the complete 
Rotterdam Study population and a meta-analysis of published data were carried 
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out.
In Chapter 5.1, we demonstrated a relationship between haplotypes defi ned by 
tagging SNPs across the VDR gene (in chapter 3), and fracture risk in > 6,500 
subjects from the Rotterdam Study population. We observed an association of frac-
ture risk with three haplotype alleles in the promoter region and the 3’-end of the 
VDR gene, and an additive effect of those haplotype alleles on fracture risk. These 
associations were observed for different kinds of fractures, such as wrist, hip, and 
vertebral fractures, and independent of age and gender. We also analyzed a pos-
sible relationship of VDR haplotypes with BMD and bone loss. One fracture risk 
haplotype allele in the promoter region was found to be associated with decreased 
BMD, and a risk allele at the 3’-end of the VDR gene was observed to be associated 
to bone loss. However, those effects were not explaining the relationship between 
VDR haplotypes and fracture risk.
In Chapter 5.2, we systematically reviewed all published association studies of 
VDR Bsm I RFLP and fracture risk and performed a meta-analysis. The Bsm I 
RFLP is the most widely studied polymorphism until now and so the meta-analsis 
had to be limited to this SNP. No evidence of a relationship between the VDR BsmI 
RFLP and fracture risk was observed. However, Bsm I RFLP is not a good marker 
of haplotype diversity in the 3’ area of the VDR gene. Therefore, the meta-analysis 
result might not completely represent the genetic effect of other polymorphisms 
across the VDR gene on fracture risk.
In Chapter 6, we fi rst demonstrated a relationship between VDR fracture-risk 
haplotype alleles and combined genotypes with body height in the Rotterdam Study 
and the LASA population. This association was found to be independent of age, 
gender and vertebral fracture. In addition, the combined promoter and 3’-UTR 
VDR genotype was found to be associated with decreased lumbar spine area and 
narrow neck width of the femoral neck in the Rotterdam population. We then car-
ried out a meta-analysis according to published data, and found that the VDR Bsm 
I RFLP was associated with differences in body height in adult elderly populations, 
which is in line with results from our association analysis in the Rotterdam Study.
In Chapter 7, we performed functionality studies by EMSA and transactivation 
experiments for SNPs in the 1e-1a promoter region, and measured VDR mRNA 
level and stability at the two major 3’-UTR haplotypes in different cell lines. We 
found that fracture risk alleles in the promoter region that associate with increased 
fracture risk, had low binding affi nity to transcriptional factors and resulted in 
lower expression of the VDR gene. The fracture risk haplotype allele of the 3’-
UTR resulted in decreased VDR mRNA level, and had lower mRNA stability. The 
functionality results are in line with our association results on fracture and body 
height.
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In Chapter 8, we described an LD map across the DBP gene by integrating DBP 
LD data from different resources. In a subset of the Rotterdam Study population 
we observed a signifi cant correlation of common haplotypes of the DBP and serum 
vitamin D level. In the complete Rotterdam Study population, we also observed 
interactions between DBP haplotype with dietary calcium intake and VDR haplo-
types in relation to fracture risk.
In Chapter 9, basing on the results of the thesis, we discuss the usage of bioin-
formatics in genetic studies, the comparison of linkage studies and candidate gene 
association studies, whole genome association studies, genetic meta-analysis and the 
use of single polymorphisms or haplotypes for association studies. We also discuss 
an overview of association of VDR polymorphisms and bone phenotypes, possible 
reasons of confl icting association results, the magnitude of genetic effects of com-
mon gene variation. Finally we provide suggestions for future studies following 
the conclusions of the thesis, including identifi cation f functional variations in a 
candidate gene and applications of genetic association study in Pharmacogenetics.

Chapter 10.2
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Genetische variaties in het vitamine D receptor gen zijn in het verleden geassocieerd gevonden met verschillende complexe ziekten, waar osteoporose 
(botontkalking) er één van is. Deze associaties worden echter niet consistent 
gevonden en zijn daarom controversieel. Deze inconsistente bevindingen kunnen 
zowel door te kleine studiegrootte worden veroorzaakt als door de niet-functionele 
DNA-variaties die meestal in het VDR gen worden onderzocht. 
Het hier beschreven onderzoek had tot doel om alle relevante variaties in het 
VDR gen te vinden en te karakteriseren, en de functionele gevolgen van deze varia-
ties te onderzoeken. Tevens was het doel om de relatie te bestuderen tussen deze 
variaties en osteoporose. Tijdens het beschreven onderzoek is er gebruik gemaakt 
van verschillende soorten benaderingen, waaronder bio-informatica, moleculaire 
genetica, genetische epidemiologie en celbiologie.
In hoofdstuk 2 hebben we de genomische organisatie van het VDR gen op-
gehelderd en verbeterd ten opzichte van eerder gepubliceerde gegevens, waarbij 
gebruik is gemaakt van verschillende informatiebronnen. Om de potentieel 
functionele gedeeltes van het VDR-gen te bepalen, werd er een homologie analyse 
uitgevoerd, waarbij het muizen VDR-gen werd vergeleken met het mensen VDR-
gen. De gedeelten van het gen die grote gelijkenis vertonen (hoge homologie) 
werden vervolgens in detail bestudeerd in een aantal verschillende mensen. De 
basenpaarvolgorde (sequentie) van het VDR gen werd bepaald in 15 verschillende 
mensen, zodat alle veelvoorkomende DNA variaties (polymorfi smen) in het VDR 
gen gevonden werden; dit waren er 62 in totaal.
In hoofdstuk 3 is de correlatie tussen de verschillende variaties in het VDR-gen 
onderzocht. In het gen werden blokken van polymorfi smen met hoge onderlinge 
correlatie gevonden, deze blokken worden ook wel “linkage disequilibrium” (LD) 
blokken genoemd. Binnen een dergelijk blok voorspellen de variaties elkaar goed, 
zodat niet alle polymorfi smen bepaald dienen te worden om toch alle genetische 
variatie te kunnen voorspellen. Binnen elk LD-blok werden de variaties bepaald 
die nodig waren om alle andere variaties te kunnen voorspellen, de zogenaamde 
“tagging” polymorfi smen. De correlatie van de DNA polymorfi smen in het VDR-
gen werd bestudeerd in 3 verschillende rassen: het Kaukasische, Aziatische, en 
Afrikaanse ras. Daarbij zagen we dat in de individuen van Afrikaanse afkomst meer 
en beduidend kleinere blokken van SNPs met hoge correlatie gevonden werden.
In hoofdstuk 4 is de relatie tussen een functionele variant in het VDR gen 
en het risico op het krijgen van een botbreuk onderzocht. De variant die werd 
onderzocht zit in het gedeelte dat het VDR gen bestuurt, de zogenaamde promoter. 
De promoter bepaald hoe hard het gen “aan” staat. Variaties in dit gedeelte kunnen 
er dus voor zorgen dat er meer of minder VDR mRNA gemaakt wordt. De variatie 
die in dit hoofdstuk is onderzocht, het Cdx2-polymorfi sme, werd voor het eerst 
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onderzocht door een Japanse groep in een kleine populatie van Japanse vrouwen. 
Tijdens onze eerdere sequentie-bepaling (hoofdstuk 2), zagen we dat dit polymor-
fi sme ook in onze populatie voorkwam en konden we de exacte positie van deze 
variant bepalen. Vervolgens vonden we, in onze grote Rotterdam-populatie van 
ongeveer 7000 mensen, een correlatie tussen dit polymorfi sme en het risico op het 
krijgen van een botbreuk. Deze correlatie was onafhankelijk van de botdichtheid.
In hoofdstuk 5 wordt de relatie beschreven tussen de polymorfi smen in het 
VDR gen en het risico op het krijgen van een botbreuk. In hoofdstuk 5.1 laten we 
zien dat er een relatie bestaat tussen bepaalde variaties in het VDR-gen en botbreu-
krisico. De beschreven studie werd uitgevoerd in meer dan 6500 individuen van de 
Rotterdam studie. Bepaalde polymorfi smen in de promoter en in het uiteinde (het 
zogenaamde 3’einde) van het gen voorspelde samen een verhoogd risico voor het 
krijgen van een botbreuk. Deze relatie bleek heel consistent aanwezig te zijn en was 
onafhankelijk van geslacht, leeftijd en type botbreuk.
Er werd ook een relatie gevonden tussen de promoter variant en botdichtheid, 
daarnaast vonden we een relatie tussen de variatie in het uiteinde van het gen en 
botverlies. Beide relatie konden echter niet het verhoogde risico op botbreuken 
verklaren dat eerder was gevonden.
In hoofdstuk 5.2 is een analyse beschreven van alle eerder gepubliceerde artikel-
en (een meta-analyse) over een VDR polymorfi sme en botbreuk risico: het BsmI 
polymorfi sme. Deze DNA variant is gesitueerd in het 3’-uiteinde van het gen en is 
al door vele groepen onderzocht. Alle gepubliceerde artikelen met als onderwerp 
de relatie tussen dit BsmI polymorfi sme en het risico van een botbreuk werden 
gebruikt voor de meta-analyse. Er werd geen relatie tussen dit polymorfi sme en 
botbreuken gevonden. Onze eerder beschreven studies (hoofdstuk 2 en 3) laten 
echter zien dat het BsmI polymorfi sme de totale genetische variabiliteit van het 
3’uiteinde van het VDR-gen niet goed voorspelt. Dit zou kunnen verklaren waarom 
er geen relatie gevonden werd tussen het BsmI polymorfi sme en botbreuken in alle 
verschillende studies tot nu toe.
In hoofdstuk 6 laten we zien dat de variaties die eerder gerelateerd waren gevon-
den met botbreuken (hoofdstuk 5) ook samen hangen met verschillen in lengte van 
de individuen. Dit werd gevonden in zowel de Rotterdamse ERGO populatie als de 
Amsterdamse LASA Studie.
Vervolgens is er een meta-analyse uitgevoerd van alle gepubliceerde data voor 
het BsmI polymorfi sme in relatie tot lengte. Deze meta-analyse had als conclusie 
dat het BsmI polymorfi sme gerelateerd is met verschillen in lengte in volwassen 
populaties. Dit ondersteunt de eerder gevonden relatie in de Rotterdam studie en 
de LASA Studie.
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In hoofdstuk 7 is de mogelijke functionaliteit van een aantal polymorfi smen 
in het promoter gedeelte van het VDR-gen onderzocht. Dit werd gedaan door het 
onderzoeken van de capaciteit van (verschillende varianten van) de promoter om 
een gen tot expressie te brengen (“aan” te zetten) . We vonden dat de variaties die 
eerder (hoofdstuk 5) gerelateerd waren gevonden met fractuurrisico, ook minder 
capaciteit hadden om een gen tot expressie te brengen. Waarschijnlijk leiden deze 
varianten dus tot een lagere expressie van het VDR-gen.
In dit hoofdstuk werden ook de polymorfi smen in het 3’uiteinde van het gen 
onderzocht. Deze polymorfi smen zijn gelegen in een gedeelte van het gen dat wordt 
gedacht de stabiliteit van het mRNA te beïnvloeden. Het bleek dat deze polymor-
fi smen, welke al eerder bleken te relateren met botbreukrisico (hoofdstuk 5), ook 
samen hingen met een verlaagde stabiliteit van het mRNA. Dit leidt uiteindelijk tot 
minder mRNA van het VDR gen in de cel.
Beide resultaten van de functionaliteit experimenten zijn in lijn met de eerder 
gevonden relaties van de DNA varianten met verhoogd botbreuk risico. 
In hoofdstuk 8 wordt data van verschillende databanken gebruikt om de LD 
blokken van het vitamine D bindings eiwit (DBP) gen te bepalen. Het DBP is erg 
belangrijk voor het Vitamin D endocrien systeem, het zorgt voor transport van het 
Vitamine D naar de doelcellen toe. Daarnaast kan het DBP ook een rechtstreeks 
effect uitoefenen op de botafbrekende cellen, de osteoclasten. In hoofdstuk 8 zijn 
er een tweetal polymorfi smen in het DBP-gen onderzocht in de Rotterdam studie. 
Er werd gevonden dat deze polymorfi smen samenhangen met de vitamine D spie-
gel in het bloed. Bovendien zagen we een interactie van deze polymorfi smen met 
calcium-inname en met de eerder beschreven VDR-polymorfi smen in relatie tot 
botbreukrisico.
Gebaseerd op de beschreven resultaten in dit proefschrift, worden in hoofd-
stuk 9 een 5-tal onderwerpen bediscussieerd: 1. het gebruik van bioinformatica in 
genetische studies, 2. de voor- en nadelen van linkage studies en associatie studies, 
3. associatie studies van het hele genoom, 4. meta-analyse van genetische stud-
ies, 5. het gebruik van aparte polymorfi smen of combinaties van polymorfi smen 
(haplotypes). Daarnaast wordt er in dit hoofdstuk ook een overzicht gegeven van 
alle studies die zijn verschenen op het gebied van VDR polymorfi smen in relatie 
tot osteoporose en worden mogelijke verklaringen gegeven voor de tegenstrijdig 
resultaten die in eerdere studies zijn gevonden. Geconcludeerd kan worden dat 
VDR polymorfi smen een effect op botbreuk risico kunnen hebben in sommige 
populaties, maar niet noodzakelijkerwijs in alle populaties. Als laatste worden 
enkele suggesties voor vervolgstudies gedaan.
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通过以前的研究人们发现维生素Ｄ受体（ＶＤＲ）基因的变异与某些具有遗传背景的综合性疾病（其中包括骨质疏松）的发病相关，但研究结果并不
一致。其原因可能是由于过小的样本研究数量不能提供可靠的结果，以及非功
能性遗传变异被用于研究。通过本研究，我们着眼于发现并描述整个ＶＤＲ基
因的遗传变异，通过研究基因变异对骨质疏松和人体身高等骨代谢特征的影响，
确定ＶＤＲ基因的功能性变异。为将来研究ＶＤＲ基因和其它疾病（如心血管疾
病、肿瘤、糖尿病、脱发和一些免疫性疾病）的遗传易感性提供可靠的研究线索
和研究模式，并可为临床诊断以上疾病提供科学依据，该结果还可用于药物遗
传学领域，着眼于今后开发具有高效、特异、付作用小的治疗药物，实现“个体治
疗”，即根据个体的遗传特征选择不同种类、不同计量的药物进行治疗。本研究
涉及到多方面的研究方法：生物信息学、分子遗传学、遗传流行病学和细胞生物
学。
第一章为论文集的前言部分，其中主要描述了相关背景知识、当前对骨代谢
和ＶＤＲ基因变异研究的现状和主要存在的问题，其中包括：维生素Ｄ内分泌系
统的功能、当前对ＶＤＲ基因结构的了解、ＶＤＲ基因多肽性变异、ＶＤＲ基因变
异的联系不平衡和单倍型、骨质疏松和ＶＤＲ基因多肽性变异、ＶＤＲ基因多肽
性变异的功能性。同时本章也引出了本课题研究的目的、方法和该论文集各章节
的内容。
第二章，利用生物信息学手段，我们综合多方面的信息资源，更新了人类ＶＤ
Ｒ基因的物理结构。通过比较人类和鼠类ＶＤＲ基因的基因组序列，我们确定了
具有潜在功能的区域作为下一步脱氧核苷酸（ＤＮＡ）序列区域。我们接下来用
了两年半的时间对那些潜在功能区（２，２０００碱基对）进行了ＤＮＡ测序分析
以发现序列变异（多肽性），在３０条白种人的染色体中我们检测了３９个大小在
２９７到２，２０１碱基对的ＤＮＡ序列，发现了６２个多肽性变异，填补了５００碱
基对的序列空白区。通过运用生物信息方法将我们发现的序列变异和其它遗传
学数据库进行了比较，确定了更为精确的ＶＤＲ基因的基因组结构，将ＶＤＲ基
因的长度从以前描述的８，５００碱基对更正为１０，５００碱基对。
第三章，根据序列分析的结果，我们创立了一套新颖方法用于研究整个ＶＤＲ
基因的连锁不均衡（ＬＤ）和单倍型结构，确认了白种人、亚洲人和非洲人所特异
的单倍型图谱和单倍型标记单核苷酸多肽性（ＳＮＰ），在以上三个人种中我们
确定了四到八个单倍型区和九到２８个标记ＳＮＰ，这些结果将用于流行病学的
相关性研究。
第四章，我们对一个ＳＮＰ（它位于ＶＤＲ基因启动区，并具有功能性）和骨折
的危险关系进行了调查。这个被称作Cdx-2的ＳＮＰ是一个Ｇ对Ａ的变异，一个日
本研究小组曾经报道它位于外显子1a的前方，但他们只在小范围的日本女性人
群中调查了该ＳＮＰ与骨密度（ＢＭＤ）的关系。通过对ＤＮＡ的测序分析，我们
也发现了该ＳＮＰ，并确认它定位于外显子1e前方１，０１２碱基对处，而且我们还
确定外显子1a和1e之间的距离为２，０００碱基对。我们进而研发出一种简单快速
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的基因分型方法，对八个不同人种和“鹿特丹研究”人群的ＤＮＡ样品进行了基因
分型。我们发现Cdx-2的基因型别和不同人群的股骨骨折发病具有相关性，同时
在“鹿特丹研究”的人群中我们也发现该变异的Ｇ－等位基因和骨折的发生有
联系，ＢＭＤ不影响这种联系。
第五章，我们着重研究了整个ＶＤＲ基因的单倍型和一个位于３’端的多肽性
变异同骨折的危险性关系。本章描述了一个基于整个“鹿特丹研究”人群的流行
病学相关性研究和一个基于文献的荟萃分析（Meta-analysis）。
在５.１章节，根据对鹿特丹人群的６，５００对象的研究，我们揭示了由特征性
ＳＮＰ定义并含盖整个ＶＤＲ基因的单倍型（基于第三章的结果）与骨折发病具
有相互关联。我们发现发生骨折的危险性与两个位于ＶＤＲ基因启动区和一个位
于３’端的单倍型有明显相关，并且这三个单倍型对骨折的危险性有相加效应。
这种联系还见于不同类型的骨折，例如：手腕、股骨和脊椎骨折，并不受性别和
年龄的影响。我们也分析了ＶＤＲ单倍型与ＢＭＤ或骨量减少的可能联系，一个
位于启动区的骨折相关性单倍型被发现与ＢＭＤ的下降有关，另一个位于３’端
的骨折相关性单倍型与骨量减少有关。但是这些ＢＭＤ或骨量减少并不能影响Ｖ
ＤＲ单倍型与发生骨折的危险性，这提示我们可能存在别的病理机制。
在５.２章节，我们系统地回顾了所有已发表的关于ＶＤＲ基因Bsm I 限制性
内切酶多肽性（RFLP）和骨折危险性的流行病学研究，并进行了荟萃分析。到目
前为止Bsm I RFLP是被研究得最多的ＶＤＲ多肽性变异点，因此我们的荟萃分析
着眼于该ＲＦＬＰ。我们的分析发现没有证据显示ＶＤＲ基因的Bsm I RFLP与骨
折的发病相关。然而，Bsm I RFLP并不是一个好的遗传标志代表ＶＤＲ３’端的
单倍型。因此，荟萃分析的结果并不能完全代表ＶＤＲ其它多肽性变异，特别是单
倍型对骨折发生的遗传学作用。
第六章，根据对鹿特丹人群和另一个人群（LASA）研究，我们揭示了以上ＶＤ
Ｒ骨折相关性单倍型等位基因及其联合基因型与身高的联系，该联系不受年龄、
性别和脊椎骨折地影响。另外在鹿特丹人群，该启动区和３’端的联合基因型同
时被发现与腰椎的纵向骨面积及股骨颈狭窄处的宽度的减少相关。在接下来的
荟萃分析中我们还发现ＶＤＲ的Bsm I RFLP与成人的身高差异有关联，这一结果
和我们的流行病学发现相吻合。
第七章，我们运用电泳迁移率变动分析（EMSA）和转录活性试验对ＶＤＲ基因
1e-1a启动区的ＳＮＰ进行了功能性研究，同时也在不同的细胞系里对位于ＶＤＲ
基因３’端非转录区（3’-UTR）的主要单倍型等位基因，进行了ＶＤＲ信息核糖核
酸（mRNA）水平及其稳定性的检测。我们发现位于启动区的与骨折相关的等位基
因和转录因子的结合力低，以至于ＶＤＲ基因的表达水平较低。在3’-UTR的与骨
折相关的等位基因也表现出低的ＶＤＲ的mRNA表达水平及较低的mRNA稳定性。
这些功能性实验的结果与我们关于骨折和身高的流行病学结论相符。
第八章，通过整合不同来源的有关维生素Ｄ结合蛋白（ＤＢＰ）基因的ＬＤ数据
资料，我们描绘出关于整个ＤＢＰ基因的ＬＤ图谱。在部分鹿特丹人群中我们观
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察到ＤＢＰ基因的单倍型与血清中的维生素Ｄ水平有显著性关联。我们同时在整
个鹿特丹研究人群中发现，ＤＢＰ基因的单倍型与饮食中的钙摄入量的互相作用
以及ＤＢＰ和ＶＤＲ基因的单倍型之间的互相作用对骨折的发生有显著影响。本
研究也提示，ＤＢＰ对骨折的影响基理可能是通过对破骨细胞的直接活化作用，
而不是通过维生素Ｄ内分泌系统发挥作用。
第九章，基于整个论文集的结果，我们讨论了生物信息学在遗传学研究上的
应用，遗传学上连锁分析、相关性研究的比较，全基因组相关性分析，遗传流行
病的荟萃分析，以及基因单独的多肽性变异点或单倍型分析在遗传流行病学上
的应用。我们还总的评述了ＶＤＲ多肽性变异与不同的骨代谢表型的相互关系，
造成不同相关性研究结果的可能原因，普通基因变异所表现的遗传性作用的强
度。最后我们也提供了一些对今后研究工作的建议，包括：如何确定被选基因的
功能性变异和遗传流行病学研究在药物遗传学上的应用。
第十章，论文集的英文、荷兰文和中文总结。
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